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ABSTRACT 
Carnitine plays a key role in the regulation of skeletal muscle metabolism during 
intense exercise and increasing muscle carnitine content enhances PDC flux during 
30 minutes of continuous intense exercise at 80% Wmax, reducing reliance on non-
mitochondrial ATP production and improving work output. The studies in this thesis 
evaluated a carnitine feeding strategy that did not rely on the high carbohydrate load 
previously used to increase muscle carnitine; then further investigated the role of 
carnitine during intense exercise in healthy volunteers and whether increasing 
skeletal muscle carnitine content could augment the adaptations to a chronic period 
of submaximal high-intensity intermittent training (HIT).  
 
Following acute 
2
H3-L-carnitine feeding, the rate of carnitine uptake into skeletal 
muscle was directly quantified for the first time in vivo in humans and shown to be 
increased up to 5-fold by the ingestion of an 80 g carbohydrate formulation. This 
promoted a positive forearm carnitine balance, an effect that was entirely blunted 
when the carbohydrate load was supplemented with 40 g of whey protein, suggesting 
a novel antagonisation of insulin-stimulated muscle carnitine transport by amino 
acids.  
 
Skeletal muscle biopsy sampling found acetylcarnitine accumulation and non-
mitochondrial ATP production during single-leg knee extension at 85% Wmax to be 
minimal, suggesting that PDC flux is probably not limiting to oxidative ATP 
production under these exercise conditions. Conversely, PDC flux appeared to 
decline over repeated bouts of intense cycling exercise at 100% Wmax, as evidenced 
by greater non-mitochondrial ATP production in the face of similar acetylcarnitine 
iii 
 
accumulation. This identified submaximal HIT as an exercise paradigm during 
which muscle carnitine availability would be expected to influence oxidative ATP 
delivery and exercise performance. 
 
Manipulation of muscle carnitine content by daily carnitine and carbohydrate feeding 
resulted in the elevation of free carnitine availability and maintenance of PDC flux 
during repeated bouts of intense exercise. However, profound improvements in 
oxidative ATP delivery in response to submaximal HIT during the second bout 
eclipsed any effect of this carnitine-mediated increase in PDC flux on non-
mitochondrial ATP production and indeed, carnitine supplementation did not 
potentiate any of the increases in maximal workload, oxygen consumption or 
exercise capacity above submaximal HIT alone. 
 
Collectively, these novel data further advance our understanding of skeletal muscle 
carnitine transport and the interplay between carnitine metabolism, PDC flux and 
non-mitochondrial ATP production during intense exercise. These findings have 
important implications for the development of nutritional and exercise prescription 
strategies to enhance human performance and health in both athletic and clinical 
populations. 
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CHAPTER 1: GENERAL INTRODUCTION 
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1.1 Regulation of fuel metabolism during exercise 
1.1.1 Overview 
History 
Skeletal muscle contractile activity is a prerequisite for all locomotive tasks and 
relies exclusively on the chemical energy derivable from the hydrolysis of adenosine 
triphosphate (ATP). At the start of the 20
th
 century and prior to the discovery of 
ATP, it was widely believed that muscle contraction was supported solely by the 
direct combustion of oxygen. Following the identification of ATP in 1950, Cain and 
Davies (1962) were able to demonstrate that the energy required to perform a single 
muscle contraction was identical to that lost through the decrease in ATP content 
when resynthesis was inhibited using fluoro-dinitrobenzene, thus proving that ATP 
was explicitly responsible for the energy necessary to fuel muscle contraction. 
Experiments in amphibian muscle by Fletcher and Hopkins (1907) established that 
lactate accumulated during contraction in the absence of oxygen and it was 
acknowledged at this time that this could be associated with contraction-induced 
fatigue. Work from the pioneering exercise physiologist AV Hill led to the view that 
“lacticacidogen” (now known as fructose-1-6-diphosphate), an intermediate in the 
conversion of glycogen to lactate, was responsible for the energy derivable from 
anaerobic glycolysis. The discovery of phosphocreatine in skeletal muscle (Eggleton 
and Eggleton, 1927), together with a series of experiments from Hartree and Hill 
(1928) and Lundsgaard (1938) reconciled the existence of two distinct oxygen-
independent pathways of energy production. In 1933, Margaria and colleagues 
investigated the relationship between oxygen consumption and blood lactate 
concentrations during exercise and recovery in human volunteers. They proposed 
that the difference between the oxygen consumption and the total energy demand of 
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the work done (the so-called oxygen deficit) must indeed be dependent on both a 
lactic and an “alactic” component, but were unable to measure any indication of 
intramuscular phosphocreatine breakdown at this time. The advent of muscle biopsy 
sampling in human volunteers, largely facilitated by the introduction of Bergstrom’s 
percutaneous needle technique (Bergstrom & Hultman, 1966), allowed for the direct 
measurement of skeletal muscle metabolism during exercise. Muscle glycogen 
availability was identified as a crucial and manipulable determinant of exercise 
capacity and fatigue development during submaximal exercise (Bergström et al., 
1967; Bergström & Hultman, 1967). During more intense exercise, studies from 
Karlson and Saltin (Karlsson et al., 1970; Karlsson & Saltin, 1970) assessed the role 
of intramuscular ATP, PCr and lactate concentrations in the development of fatigue. 
They also related the magnitude of change in these metabolites to the oxygen deficit, 
i.e. the shortfall between total ATP demand and mitochondrial ATP production.   
 
Routes of ATP Resynthesis  
The primary ATP dependent processes in contracting skeletal muscle involve the 
myosin, Ca
2+
 and Na
+
/K
+ 
ATPase enzymes, which are responsible for approximately 
70, 25 and <5%, respectively, of total ATP consumption. During high-intensity 
exercise, ATP demand can increase over 100-fold above resting turnover rates and as 
such, requires a dynamic and highly regulated matching from ATP resynthesis 
pathways to defend the limited intramuscular ATP store (20-25 mmol·kg dw
-1
). 
Illustrated in Figure 1.1, the principle routes for the resynthesis of ATP within 
skeletal muscle are the hydrolysis of phosphocreatine, the glycolytic conversion of 
glucose-6-phosphate to pyruvate and the mitochondrial oxidation of acetyl-CoA. 
Glucose-6-phopshate is derivable from the phosphorylation of either blood-borne 
 4 
 
glucose or intramuscular glycogen, whilst mitochondrial acetyl-CoA is generated 
mainly from the decarboxylation of pyruvate and from the β-oxidation of fatty acids. 
The generation of acetyl-CoA from both carbohydrate and lipid precursors relies on 
the availability of skeletal muscle carnitine which, through the carnitine 
acyltransferase class of enzymes is able to reversibly bind coenzyme-A esters of 
various chain lengths. This reversible binding facilitates the translocation of long-
chain fatty acyl groups into the mitochondrial matrix for subsequent β-oxidation and 
independently promotes the conversion of pyruvate to acetyl-CoA by buffering intra-
mitochondrial acetyl-group production. The importance of these roles during 
exercise will be discussed further in section 1.2. 
 
The main substrates that fuel skeletal muscle contraction are listed in Table 1.1. 
Mitochondrial ATP resynthesis is by far the most efficient pathway for the 
maintenance of intramuscular ATP concentrations, yielding 38 or 39 mmols of ATP 
for every one mmol of glucose or glycogen phosphorylated, respectively. Lipid 
substrates provide an even greater energy yield, with 106 mmols ATP obtained from 
the mitochondrial oxidation of one mmol palmitate. Adipose tissue triacylglycerides 
also represent the most abundant substrate for ATP resynthesis in the body, with the 
average lean male having approximately 10 kg adipose tissue, compared to whole 
body carbohydrate stores (mainly muscle and liver glycogen) of only 0.5 kg 
(Maughan, 1997). Given the greater ATP mole yield associated with fatty acid 
oxidation, this equates to an almost 50-fold larger energy store of lipids than 
carbohydrates. In contrast to mitochondrial oxidation, glycolysis provides only three 
mmol ATP per mmol glucose, whilst the degradation of PCr resynthesizes ATP with 
a 1:1 ratio. 
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Figure 1.1 Schematic showing pathways of ATP resynthesis in skeletal muscle.  
 6 
 
Reciprocally, the maximal rate of mitochondrial ATP production is about half that 
which can be achieved from glycolysis and approximately one sixth that which can 
be obtained from the combined non-mitochondrial reactions (glycolysis plus PCr; 
see Table 1.1). These differences in the total energy yield and rate of ATP delivery 
from a given substrate mean that fuel selection within skeletal muscle is largely 
dictated by the intensity and duration of muscle activation. It is also important to 
consider that different sub-populations of muscle fibres exist within skeletal muscle, 
which can broadly be classified as type I (slow) or type II (fast). These two fibre 
types possess distinct biochemical characteristics (see Table 1.2) and their pattern of 
recruitment, again largely determined by the exercise intensity, will influence the 
metabolic responses to an exercise challenge.  Under most exercise scenarios, 
mitochondrial oxidation predominates as the major route of ATP resynthesis. 
However, when the rate of ATP hydrolysis exceeds the capacity of mitochondrial 
ATP delivery, as can occur during high-intensity exercise, reliance on non-
mitochondrial ATP production must increase. In the next sections, the governance of 
fuel selection by exercise intensity is described in more detail, with reference given 
to how this determines the likely limitations to exercise performance. Although 
theoretically represented as a continuum, exercise intensities will be categorised into 
prolonged submaximal exercise, high-intensity submaximal exercise and maximal 
(i.e. requiring maximal effort) exercise, including repeated bouts. 
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Table 1.1 Maximal rates and capacity for ATP resynthesis from different substrates 
 
Values are expressed in mmol of ATP per kg dry muscle mass and are based on Bangsbo et al. (1990), Hultman et al. (1991) and Maughan 
(1997). 
Pathway 
Maximal Rate 
(mmol·kg dw
-1
·s
-1
) 
Capacity for ATP delivery 
(mmol·kg dw
-1
) 
PCr hydrolysis 9
 
80 
Glycolysis 5.3 300 
Glycogen oxidation 2.5 10000 
Lipid oxidation 1 >500,000 
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Table 1.2 Biochemical characteristics of type I and type II muscle fibres  
 
a [mmol·kg dw
-1
] from Soderlund et al. (1992); b [mmol·min
-1
·kg ww
-1
] from (Maughan and Gleeson, 2004), values of type II fibres represent 
the average of values for type IIa and type IIx. 
 
 
  
Fibre type characteristic Type I Type II 
Glycogen content
a
 400 480 
PCr content
a
 80 90 
PFK activity
b
 7.5 15.6 
Glycogen phosphorylase activity
b
 2.8 7.3 
Citrate synthase activity
b
 10.8 7.6 
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1.1.2 Prolonged submaximal exercise 
Submaximal exercise intensities refer to workloads where the rate of ATP 
resynthesis required to sustain muscle contraction is lower than the maximal rate that 
can be supported by mitochondrial ATP delivery alone. Strictly speaking, this 
equates to any workload that requires steady-state oxygen consumption rates below 
the maximal obtainable rate (100% VO2max). However, as will be discussed, beyond 
exercise intensities of ~85% VO2max (or even lower for untrained persons), a steady-
state oxygen consumption rate is rarely attained (Hill et al., 2002) and exercise time 
is often restricted by factors different to those which limit exercise performance at 
lower intensities. Therefore, prolonged submaximal exercise generally refers to 
steady-state exercise intensities below 85% VO2max. As mentioned above, 
mitochondrial ATP resynthesis is sustained utilising acetyl-CoA derived primarily 
from lipid or carbohydrate substrates. The relative proportions of these substrates 
contributing to total ATP delivery is principally an acute function of exercise 
intensity, but is also altered by other factors including exercise duration (Edwards et 
al., 1934), diet (Roepstorff et al., 2005), gender (Venables et al., 2005) and training 
status (Bergman & Brooks, 1999). 
 
Lipid availability to skeletal muscle is dependent upon the appropriate lipolysis of 
adipose tissue TAG stores, release of these liberated fatty acids into the circulation 
and effective uptake of the fatty acids across the sarcolemma. In addition, 
intramyocellular lipid droplets (IMCL) provide a viable pool of fatty acids to the 
mitochondria and represent an important substrate during exercise (van Loon et al., 
2003). As will be discussed, under most exercise conditions the rate of ATP 
resynthesis attributable to lipid oxidation is regulated at the level of the 
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mitochondrion and limited by the entry of long-chain fatty acids into the organelle 
matrix. In line with the lower maximal rate of ATP resynthesis that can be supported 
by lipids compared to carbohydrate, it has long been known from respiratory 
exchange measurements made on expired gases that muscle contraction relies more 
heavily on lipid oxidation during low-intensity exercise than during high-intensity 
exercise (Krogh & Lindhard, 1920). More recent studies investigating whole-body 
fat oxidation rates over a number of exercise increments suggest that the absolute 
rate of lipid oxidation during low to moderate intensity exercise increases linearly 
with ATP demand, with maximal rates of lipid oxidation occurring at an exercise 
intensity between 50 – 65% VO2max (Achten et al., 2002; Achten & Jeukendrup, 
2003; Achten et al., 2003; Achten & Jeukendrup, 2004). When the exercise intensity 
is increased beyond that which elicits maximal fatty acid oxidation rates, reliance on 
lipid substrates drops sharply and, when measured at the whole-body level, can be 
almost negligible beyond approximately 80% VO2max in untrained volunteers.  
 
The development of stable isotope tracer methodology has enabled a more detailed 
evaluation of the effects of exercise intensity on skeletal muscle substrate selection. 
For example, based on the plasma disappearance of [6,6-
2
H2]glucose and 
[
2
H2]palmitate, combined with indirect calorimetry measurements,  Romijn and 
colleagues (1993) determined total fat and carbohydrate oxidation rates in volunteers 
exercising for 30 minutes each at 25, 65 and 85% VO2max. Whilst estimated rates of 
carbohydrate oxidation increased linearly with exercise intensity, lipid oxidation 
only increased
 
between the initial two workloads, from 27 to 43 µmol·kg
-1
·min
-1
, 
before declining at 85% VO2max to 30 µmol·kg
-1
·min
-1
.  A subsequent study from 
van Loon et al. (2001) further illustrated that at rest and during low (40% VO2max) to 
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moderate (57% VO2max) intensity exercise, the relative contribution of lipid 
oxidation to total energy expenditure was reasonably consistent at approximately 
50%. However, when the exercise intensity was increased to 72% VO2max, [U-
13
C]palmitate oxidation declined, reflecting a reduction in both the absolute and 
relative rate of total fat oxidation. The additional employment of muscle biopsy 
sampling in this latter study confirmed that the reduction in whole-body lipid 
oxidation coincided with an increased reliance on muscle glycogen stores, such that 
the glycogenolytic rate increased from 0.9 mmol·kg dw
-1
·min
-1
 at 57% VO2max to 6.2 
mmol·kg dw
-1
·min
-1
 at 72% VO2max. Moreover, lactate accumulation at the highest 
workload (29.5 mmol·kg dw
-1
) was also double that of the moderate intensity 
workload (15.6 mmol·kg dw
-1
). This accelerated glycolytic rate is likely responsible 
for the restriction of lipid oxidation at higher exercise intensities, although the 
mechanisms behind this are not fully understood. The authors of the aforementioned 
study proposed that, under these conditions, free carnitine availability could become 
limiting to mitochondrial fatty acid oxidation (van Loon et al., 2001), a discussion 
point that will be developed in section 1.2. 
 
The greater rate of muscle gylcogenolysis seen with increasing exercise intensities is 
likely related, at least in part, to the progressive recruitment of type II muscle fibres 
during more intense exercise. Indeed, single fibre staining for glycogen revealed 
significantly more glycogen remaining in type II fibres compared to type I, which 
were mostly glycogen depleted, following three hours of cycling exercise at 31% 
VO2max (Gollnick et al., 1974).  In the same study, the proportion of both fibre types 
staining negative for glycogen increased progressively during exercise at 64% (two 
hours) and 83% VO2max (one hour), which was consistent with the greater rates of 
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whole-muscle glycogenolysis 
 
as intensity increased (0.7, 2.2 and 5.0 mmol·kg     
dw
-1
·min
-1
, respectively). Biochemical measurement of fibre type-specific 
glycogenolysis confirms these findings, with over twice the glycogen utilisation seen  
in type I (195 mmol·kg dw
-1
) compared to type II fibres (90 mmol·kg dw
-1
) over the 
first 15 minutes of one-legged exercise at 61% VO2max (Ball-Burnett et al., 1991). In 
both fibre types, the rate of muscle glycogen utilisation was greater over the first 15 
minutes of exercise compared to the remainder of the bout (~two hours in total). 
Similarly, muscle lactate increased from a resting value of 9.3 mmol·kg dw
-1
, to 50.4 
mmol·kg dw
-1
 after 15 minutes of exercise before declining to 25.5 mmol·kg dw
-1
 
after one hour. This increased reliance on anaerobic glycolysis during the initial 
several minutes of exercise likely reflects the delay in mitochondrial carbohydrate 
oxidation in reaching the required rate of ATP resynthesis. This point will be 
considered further in the section 1.1.3. Above exercise intensities of ~65% VO2max, 
where muscle glycogen becomes the predominant substrate, it is intuitive that muscle 
glycogen reserves might become the limiting factor in exercise capacity. This was 
classically demonstrated by a series of studies from Bergstrom and Hultman in the 
1960s. By manipulating the pre-exercise muscle glycogen levels they were able to 
demonstrate a close relationship between resting glycogen availability and the time 
to exhaustion during exercise at 75% VO2max, which coincided with the near 
complete depletion of muscle glycogen stores (Bergström & Hultman, 1967). They 
further observed that consuming a carbohydrate-rich diet following glycogen 
depleting one-legged cycling exercise increased resting muscle glycogen of the 
exercised leg (normally about 300-400 mmol·kg dw
-1
) to approximately 900 
mmol·kg dw
-1
, with no change in the non-exercised leg (Bergstrom & Hultman, 
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1966). This illustrates one of the most robust adaptations to exercise training in 
skeletal muscle, that is, an increase in substrate availability.  
 
1.1.3 High-intensity submaximal exercise 
High-intensity submaximal exercise refers to exercise workloads above 
approximately 85% VO2max, which generally represent non-steady state conditions 
whereby oxygen consumption will trend towards the maximal attainable rate (Poole 
et al., 1988; Hill et al., 2002), but can be sustained at a fixed workload for more than 
a few seconds. Theoretically, exercise at 100% VO2max could be sustained by the 
maximal capacity of mitochondrial respiration using muscle glycogen as the sole 
fuel. However, glycogen oxidation takes several minutes to reach its maximal rate 
and thus during this “lag” period, non-mitochondrial sources of ATP resynthesis 
must cover the energy deficit. High-intensity exercise is thus characterised not only 
by the eventual requirement for a near-maximal mitochondrial respiration, but also 
the immediate mismatch in mitochondrial ATP delivery and total ATP demand. The 
intramuscular ATP store (25 mmol·kg dw
-1
), in isolation, could sustain intense 
muscle contraction for less than one second and thus alternative pathways for ATP 
resynthesis must be rapidly activated.  
 
One of the earliest studies to investigate the time-course of non-mitochondrial ATP 
delivery during high-intensity exercise was that by Karlsson and Saltin in 1970. 
They demonstrated that during exhaustive constant load exercise bouts at 90 - 125% 
VO2max, skeletal muscle PCr was degraded to ~20 mmol·kg dw
-1
, approximately 
25% of resting values, within the first two minutes of exercise for each workload. 
Lactate also accumulated most rapidly over this initial period, reaching values of ~80 
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mmol·kg dw
-1
 within two minutes and continuing to increase until exhaustion. 
Furthermore, the ATP resynthesis from these two pathways was closely related to 
the oxygen deficit during exercise, particularly at the highest workloads. The 
products of ATP hydrolysis (ADP and AMP) are powerful allosteric activators of 
creatine kinase and phosphofructokinase, the rate-limiting enzymes in PCr 
degradation and glycolysis, respectively, and signal to accelerate the rate of ATP 
delivery to match ATP demand. During a ten minute bout of cycling at 90% VO2max, 
AMP and ADP concentrations in skeletal muscle were found to increase 
approximately 10-fold and 3-fold, respectively, over the first minute of exercise 
(Howlett et al., 1998). Together with the rapid degradation of phosphocreatine (PCr 
was less than 50% of resting values within one minute of exercise) and the reciprocal 
elevation of inorganic phosphate, accumulation of these metabolites was associated 
with the activation of glycolytic and mitochondrial ATP production. Despite the 
latter, substantial lactate accumulation occurred throughout the exercise bout, 
reaching values in excess of 100 mmol·kg dw
-1
 by 10 minutes. This reflects an 
imbalance between pyruvate production from glycolysis and pyruvate oxidation, 
particularly during the initial minute of exercise, when the rate of lactate 
accumulation was greatest (31 mmol·kg dw
-1
·min
-1
). As will be discussed below, the 
metabolic events occurring during the early seconds/minutes of high-intensity 
exercise may be crucial in the development of fatigue later in the bout.  
 
Unlike prolonged, submaximal exercise, fatigue during high-intensity exercise is less 
easily explained by substrate availability. Indeed, in the study by Karlson and Saltin 
(1970), muscle glycogen content at exhaustion was above 100 mmol·kg dw
-1
 and 
thus, presumably not limiting, for all workloads. Furthermore, the constancy of PCr 
 15 
 
concentrations (~20 mmol·kg dw
-1
) from two minutes until exhaustion at 90% and 
100% VO2max (approximately 16 minutes and 6 minutes, respectively) would suggest 
that the continued  rate of PCr hydrolysis equalled its resynthesis from mitochondrial 
ADP phosphorylation (Perry et al., 2012) for the remainder of the exercise. Thus, 
neither muscle glycogen nor PCr depletion could be considered as limiting to 
exercise performance at these workloads. Instead, fatigue is commonly cited as 
resulting from substantial lactate production, the accompanying accumulation of 
hydrogen ions and the reciprocal decline in muscle pH that occur during high-
intensity exercise. Allosteric inhibition of the key glycolytic enzymes glycogen 
phosphorylase (Chasiotis et al., 1983) and phosphofructokinase (Trivedi & Danforth, 
1966) by muscle acidosis has been proposed to limit ATP turnover during high-
intensity exercise. However, Bangsbo et al. (1996) have reported that following the 
elevation of systemic lactate concentrations by prior intense arm exercise, 
glycogenolysis (~35 mmol·kg dw
-1
·min
-1
) was unchanged during a subsequent bout 
of exhaustive leg-extension exercise, despite a lower muscle pH and a 25% reduction 
in exercise time. Thus it would appear that the acidosis-induced inhibition of 
glycolytic enzymes can be overcome in contracting human muscle. This of course 
does not rule out any negative effects on hydrogen ion accumulation or acidosis on 
other aspects of the contractile cascade (Gladden, 2004), some of which will be 
discussed in the subsequent section (see section 1.14). In support of this, 
interventions to increase the hydrogen ion buffering capacity of skeletal muscle by 
β-alanine supplementation (Hill et al., 2007), sodium bicarbonate (Bird et al., 1995) 
or sodium citrate (McNaughton & Cedaro, 1992) ingestion have all been shown to 
increase high-intensity exercise performance. Consistent with the likely role of 
accelerated lactate production in the development of fatigue, the oxidation of 
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pyruvate, or its reciprocal conversion to lactate, represents a key branch-point in 
skeletal muscle metabolism. Moreover, the rapid activation of non-mitochondrial 
pathways of ATP delivery at the onset of high-intensity and maximal exercise is vital 
to compensate for the comparatively slow activation of mitochondrial ATP 
resynthesis. The reason that carbohydrate oxidation is more slowly activated than 
non-mitochondrial ATP resynthesis may be related to the proximity of the 
phosphocreatine stores to the site of ATP utilisation or the greater number of 
enzymatic reactions involved. In particular, substrate flux through the pyruvate 
dehydrogenase complex (PDC), the rate-limiting enzyme in the conversion of 
pyruvate to acetyl-CoA, has been studied with regard to its regulatory role in 
mitochondrial ATP production.  
 
The pyruvate dehydrogenase complex 
Carbohydrate oxidation initiates with the glycolysis of skeletal muscle glycogen or 
glucose to pyruvate in the cytosol. Depending on the redox state of the cell, pyruvate 
can either be reduced to lactate via the lactate dehydrogenase reaction or converted 
to acetyl-CoA by the PDC. Pyruvate can also enter a number of other pathways, 
including the anaplerotic/gluconeogenic reactions catalysed by alanine 
aminotransferase and pyruvate carboxykinase, but these are quantitatively less 
important in energy metabolism. The PDC is a mitochondrial membrane-bound 
multi-enzyme complex that catalyses the irreversible decarboxylation of pyruvate to 
acetyl-CoA and is considered one of the rate-controlling reactions in carbohydrate 
oxidation. The catalytic activity of the PDC is regulated by covalent transformation 
between its active and inactive forms (Linn et al., 1969), as well as by end-product 
inhibition. Transformation of the PDC to its active form (PDCa) is determined by the 
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competing activities of the PDC phosphatases (activators) and kinases (deactivators), 
whilst in-vitro observations suggest end-product inhibition to be principally 
regulated by the ratios of acetyl-CoA to CoASH and NADH to NAD
+ 
(Pettit et al., 
1975). However, measurements of PDCa in human skeletal muscle biopsies would 
suggest that exercise is able to override the inhibition by acetyl-CoA accumulation 
on PDC transformation to its active form, possibly via calcium-stimulated 
phosphatase activation (Constantin-Teodosiu et al., 2004). Flux through the PDC 
ultimately determines the fate of pyruvate and is thus considered a branch-point 
between mitochondrial and non-mitochondrial ATP resynthesis.  
 
The Acetyl-group Deficit 
As previously discussed, the deficit between total ATP demand and mitochondrial 
ATP delivery is most expansive under non-steady state conditions. These occur at 
the onset of exercise or during the transition to a higher exercise increment and were 
classically thought to result from a delay in the oxygen transport pathway (Margaria 
et al., 1933). However, a series of studies from Timmons and colleagues indicated 
that the delay in mitochondrial ATP delivery could be due to a lag in the rate of PDC 
activation at the onset of contraction (Timmons et al., 1996; Timmons et al., 1997; 
Timmons et al., 1998a; Timmons et al., 1998b). Using a perfused hind-limb 
contraction model in canine gracilis muscle, with which blood-flow and oxygen 
delivery can be kept constant, it was demonstrated that maximal activation of the 
PDC (using the pharmacological PDK antagonist dichloroacetate; [DCA]) reduced 
reliance on non-mitochondrial ATP production during 20 minutes of subsequent 
contraction (Timmons et al., 1996). Consistent with the suspected role of inorganic 
phosphate and hydrogen ion accumulation in the impairment of contractile function, 
DCA administration also attenuated the decline in force production by 40%.  A 
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parallel study using the same model demonstrated that this reduction in PCr 
hydrolysis and lactate accumulation was most prominent over the first minute of 
contraction (Timmons et al., 1997), findings that were later reproduced in humans 
performing eight minutes of single leg extension exercise (Timmons et al., 1998a; 
Timmons et al., 1998b). 
 
One apparent paradox of the studies from Timmons and colleagues is the observation 
that acetylcarnitine accumulation, an indication of excessive PDC flux relative to the 
TCA cycle, is greatest during the initial minutes of exercise (Figure 1.5), when PDC 
flux is proposed to be limiting mitochondrial ATP production. However, using the 
same canine contraction model as previously employed, Roberts et al. (2002, 2005) 
sampled multiple muscle biopsies over the first minute of contraction, affording a 
much greater temporal resolution than previous studies. This approach demonstrated 
that during the first 20 seconds of contraction, acetylcarnitine and acetyl-CoA 
concentrations tended to decrease from baseline values, providing unequivocal 
evidence of the existence of a mitochondrial inertia at the level of the PDC. 
Moreover, DCA administration prior to the start of muscle contraction reduced PCr 
hydrolysis and lactate accumulation, with the majority of this effect attributable to 
the first 20 seconds of contraction (Roberts et al., 2002). Similar results were 
obtained when acetyl-group availability was increased independently of changes in 
PDC activation, by the infusion of sodium acetate (Roberts et al., 2005). The authors 
concluded that the pre-contraction accumulation of acetylcarnitine and acetyl-CoA 
facilitated a greater acetyl-group flux into the TCA cycle, thus increasing the 
contribution from mitochondrial respiration to total ATP resynthesis. In this respect, 
any intervention that can accelerate the delivery of acetyl-CoA to the TCA cycle has 
potential to reduce reliance on non-mitochondrial ATP production. It is of note that 
 19 
 
manipulation of the muscle carnitine pool has been demonstrated to influence PDC 
flux and acetyl-group availability to the TCA cycle (Wall et al., 2011), a facet that 
will be explored further in section 1.2. 
 
Not all studies have demonstrated an effect of DCA administration on mitochondrial 
ATP delivery. For example, (Savasi et al., 2002) reported that whilst maximal 
activation of the PDC with DCA prior to a 90 second exercise bout at 90% Vo2max 
was sufficient to elevate acetyl-group availability (increasing acetyl-CoA 4-fold and 
acetylcarnitine 5-fold compared to a control condition), no differences were 
observed in PCr degradation or lactate accumulation at either 30 seconds or 90 
seconds of exercise. It has been argued that increasing acetyl-group availability is 
unlikely to enhance mitochondrial ATP delivery when the initial rate of PCr 
degradation is greater than ~1 mmol·kg
-1
·s
-1
 (Timmons et al., 2004), as was the rate 
in the study by Savasi and colleagues.  It is also important to consider that under 
certain conditions PDC activation may be uncoupled from PDC flux (Putman et al., 
1993) and, theoretically, the pharmacologically-induced stockpiling of acetyl-groups 
at rest may actually serve to dampen further increases in PDC flux during subsequent 
exercise.  
 
1.1.4 Maximal exercise  
Maximal exercise efforts, i.e. not constant load, place the greatest demand possible 
on ATP resynthesis pathways and ATP delivery declines in parallel with work 
output. By means of example, the average rate of skeletal muscle PCr degradation 
during the first six seconds of a 30 second maximal cycle sprint was found to 
approximately 4.9 mmol·kg dw
-1
·s
-1
 (Boobis, 1983). Over the subsequent 24 s the 
average rate of PCr degradation had fallen to approximately 1.1 mmol·kg dw
-1
·s
-1
. 
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During the same exercise bout, ATP production derived from muscle lactate 
accumulation averaged 4.8 mmol·kg dw
-1
·s
-1
 over the initial six seconds and was 3.8 
mmol·kg dw
-1
·s
-1
 over the subsequent 24 seconds. The progressively lower rates of 
PCr hydrolysis and lactate accumulation over the 30 seconds was associated with a 
corresponding decline in work output, such that the average power during the first 
six seconds was 847 watts, compared to 649 watts when averaged over the entire 30 
second bout. Similar rates of PCr degradation and glycolytic ATP delivery have been 
observed over comparable time periods of electrical stimulation, which can be 
refined to elicit near-maximal intensity involuntary contractions (Hultman et al., 
1991). Using this model in combination with single muscle fibre analysis, Soderlund 
et al. (1992) demonstrated that the rate of total ATP turnover was substantially 
greater in type II fibres (13.4 mmol·kg dw
-1
·s
-1
) compared to type I fibres (4.9 
mmol·kg dw
-1
·s
-1
), over 20 seconds of intermittent (1.6:1.6 seconds; 50Hz) 
stimulation. This was attributable to a greater rate of PCr degradation in type II 
fibres, particularly during the first 10 seconds of contraction (5.3 vs 3.3 mmol·kg 
dw
-1
·s
-1
), as well as a high glycogenolytic rate in these fibres (6.3 mmol·kg dw
-1
·s
-1
) 
compared to a negligible rate in type I fibres (0.6 mmol·kg dw
-1
·s
-1
). Using similar 
electrical stimulation protocols, epinephrine infusion (Greenhaff et al., 1991) and 
blood flow occlusion (Greenhaff et al., 1993) have independently been shown to 
accelerate the glycogenolytic rate in type I fibres (6 and 11-fold, respectively) but 
not type II fibres over 64 seconds of contraction. These data suggest that glycolytic 
ATP delivery from type II fibres is near-maximal under these conditions and are 
consistent with the maximal reported activity of glycogen phosphorylase in each 
fibre type (Table 1.2)  
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During maximal exercise, glycolytic rates begin to decline within 10-20 seconds of 
contraction, whilst the rate of PCr hydrolysis declines almost immediately following 
the onset of contraction (Hultman et al., 1991). Fatigue during maximal effort 
exercise ultimately results from this inability to maintain the extremely high rates of 
ATP delivery required at these workloads. Furthermore, the reduction in the overall 
rate of non-mitochondrial ATP delivery would appear to be primarily related to the 
capacity of the type II muscle fibres. For example, the rate of PCr degradation in 
type II fibres declined by more than half between 10 and 20 seconds of maximal 
contraction, whilst it remained relatively constant in type I fibres (Soderlund et al., 
1992). Similarly, the fall in the glycolytic rate in mixed-muscle from 20-30 seconds 
could be almost entirely accounted for by a 45% reduction in type II fibre 
glycogenolysis. The authors proposed that the high oxidative capacity of the type I 
muscle fibres enables continued resynthesis of ATP at a rate sufficient to match PCr 
hydrolysis in these fibres. Conversely, the low oxidative capacity of the type II 
muscle fibres prohibits the matching of mitochondrial ATP resynthesis to the high 
rate of PCr hydrolysis, resulting in a rapid decline in type II fibre PCr availability.  
Coupled with the concomitant decline in type II fibre glycolysis, this precludes the 
further production of non-mitochondrial ATP delivery at the rate necessary to sustain 
maximal muscle contraction. Aside from the possible direct effects of myofibrillar 
PCr depletion, the impairment of contractile function during high-intensity or 
maximal exercise may also be related to the disruption of sarcoplasmic reticulum 
calcium cycling, secondary to local reductions in phosphocreatine availability (Duke 
& Steele, 2001). Furthermore, the reciprocal accumulation of inorganic phosphate 
that accompanies PCr hydrolysis has also been implicated in the development of 
fatigue under these conditions. For example, it was shown that force production in 
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intact skeletal muscle was enhanced in the presence of pyruvate compared to glucose 
or lactate, an effect apparently mediated by a concurrent lowering of myocellular 
inorganic phosphate concentrations (Phillips et al., 1993). A number of specific 
detrimental effects of inorganic phosphate accumulation on contractile function have 
been proposed, including the direct or indirect (reduced calcium sensitivity) 
interference with cross-bridge formation and the possible impairment of 
sarcoplasmic reticulum calcium release or uptake (Westerblad et al., 2002). Finally, 
it has been speculated that muscle potassium efflux during high-intensity exercise 
may result in the accumulation of extracellular potassium and subsequently 
contribute to the development of fatigue (Bangsbo et al., 1996). This is supported by 
the finding that the enhancement of fatigue-resistance gained following exercise 
training was associated with lower interstitial potassium accumulation during high-
intensity one-legged exercise (Nielsen et al., 2004).  
 
Repeated bouts of exercise 
Exercise paradigms that involve repeated bouts of high-intensity exercise are a 
useful tool for the study of metabolic regulation during skeletal muscle contraction, 
demanding substantial ATP delivery from both mitochondrial and non-mitochondrial 
pathways. For example, Gaitanos et al. (1993) demonstrated that across a series of 
six-second maximal bicycle sprints separated by 10 seconds of recovery, the rate of 
glycolytic ATP production fell markedly from 6.6 mmol·kg dw-1·s-1 during the first 
sprint, to 0.9 mmol·kg dw-1·s-1 during the tenth bout, whilst PCr degradation also 
declined, from 7.4 to 4.2 mmol·kg dw-1·s-1. Similarly, the reported contributions 
from anaerobic glycolysis, PCr degradation and mitochondrial oxidation to total 
ATP production during an initial 30 second bout of maximal sprint exercise (300-
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400% VO2max) range between 50-55, 23-28 and 16-28%, respectively (Bogdanis et 
al., 1996; Trump et al., 1996; Parolin et al., 1999). However, during a third bout, 
following four minutes recovery between bouts, the absolute rate of non-
mitochondrial ATP production declines such that anaerobic glycolysis and PCr 
degradation each provide at most 15% of the total ATP resynthesis, with the relative 
contribution from mitochondrial ATP delivery increasing to approximately 70%. 
Given the lower rates of ATP production that can be sustained by mitochondrial 
oxidation compared to anaerobic glycolysis and PCr degradation, this shift in 
substrate metabolism is associated with a reduction in the overall rate of ATP 
production. Moreover, when repeated bouts of maximal effort exercise are 
performed, work output declines in parallel with total ATP production over 
successive bouts (McCartney et al., 1986; Spriet et al., 1989; Trump et al., 1996; 
Parolin et al., 1999).   
 
Given the near-equilibrium rate constant of the creatine kinase reaction during 
recovery from high-intensity exercise (Sahlin et al., 1979), the reduction in PCr 
degradation over repeated bouts of exercise is likely related to an incomplete 
resynthesis of PCr between bouts. Trump et al. (1996) investigated the influence of 
PCr recovery on skeletal muscle metabolism during three 30 second maximal bicycle 
sprints by occluding blood flow to one leg between bouts two and three. Occlusion 
prevented PCr resynthesis such that prior to the start of bout three, the PCr 
concentration in the occluded leg (21 mmol·kg dw
-1
) was one third that of the non-
occluded leg (63 mmol·kg dw
-1
). The blunted ability to resynthesize ATP from PCr 
hydrolysis in the following bout was associated with a 15% reduction in work output 
compared to the non-occluded leg (5.8 vs 6.8 kJ, respectively). Positive correlations 
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have been reported between the extent of PCr resynthesis during recovery and the 
work output attained in a subsequent bout, whilst the recovery of muscle pH does not 
seem to influence subsequent power output (Bogdanis et al., 1995; Bogdanis et al., 
1996). This supports the notion that PCr availability per se, rather than muscle 
acidosis, is responsible for the progressive decline in ATP production over repeated 
bouts of maximal exercise. In particular, and consistent with the lower oxidative 
capacity of type II muscle fibres (Table 1.2), it has been suggested that lower rates 
of PCr resynthesis in these muscle fibres during recovery may be a primary 
determinant of the decline in work output during repeated bouts of high-intensity 
exercise (Casey et al., 1996).  
 
The mechanisms that govern the reduction in glycolytic rate with successive high-
intensity exercise bouts are less clear though have been proposed to be related to the 
inhibitory effect of hydrogen ion accumulation on glycogen phosphorylase activity 
(Spriet et al., 1989). However, given the accumulation of other key glycolytic 
activators during high-intensity exercise (ADP, AMP, Pi, IMP), it would seem 
unlikely that allosteric modulation of phosphorylase can wholly explain the 
reduction in lactate accumulation during repeated bouts. Putman et al. (1995) 
calculated that the ATP delivered from PDC flux increased progressively over three 
maximal 30 second cycle sprints, such that it equalled 220 mmol in bout 1, 255 
mmol in bout 2 and 357 mmol in bout 3. This was attributed to the maintenance of a 
sequentially greater (2.2 and 2.8-fold) pre-bout PDC activation above resting levels 
(0.45 mmol·kg ww
-1
·min
-1
), as PDCa was maximal (~3.0 mmol·kg ww
-1
·min
-1
) by 
the completion of each bout. As the overall work output decreased with each sprint 
(19.3, 16.3 and 14.2 kJ, respectively), PDC flux accounted for a progressively 
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greater proportion of total ATP production (29, 33 and 63%, respectively) and thus 
may partially explain the lower lactate accumulation during latter bouts. Relatively 
little is known about the metabolic responses to repeated bouts of high-intensity non-
maximal exercise, where the workload can be fixed and thus total ATP demand 
maintained constant over successive bouts. Manipulation of PDC flux by carnitine 
under these conditions, where PDC is likely to be activated more slowly than during 
maximal exercise, may represent a possible strategy to enhance mitochondrial ATP 
delivery and improve exercise performance.  
 
1.2 Carnitine metabolism during exercise 
The increase in ATP turnover during exercise requires the integration of greatly 
accelerated rates of fat and carbohydrate oxidation. As mentioned previously, both 
these pathways depend upon adequate carnitine availability and changes in the free 
carnitine pool during exercise are closely linked with changes in substrate utilisation 
in skeletal muscle. Carnitine (3-hydroxy-4-N-trimethylaminobutyric acid) is a 
naturally occurring quaternary amine compound, synthesised from the amino acids 
lysine and methionine. Being a zwitterionic molecule, carnitine contains a positively 
charged amine and a negatively charged carboxyl group, as well as a centrally 
positioned hydroxyl group (Figure 1.2). This hydroxyl group functions as a binding 
site for acyl residues and is fundamental to the two primary biochemical roles of 
carnitine in skeletal muscle, where around 95% of whole body carnitine stores are 
sequestered (Brass, 1995).  
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Figure 1.2 Structure of carnitine and the acyltransferase reaction 
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1.2.1 Carnitine regulates fat oxidation during exercise 
Translocation of long chain fatty acids 
Mitochondrial combustion of lipids is one of the most vital pathways for energy 
production in humans. In skeletal muscle, the primary substrates for mitochondrial 
lipid oxidation are cytosolic long-chain fatty acids, derived either from plasma-borne 
free fatty acids, or the lipolysis of plasma lipoprotein- or intramuscular-triglyceride 
depots. Once activated to their respective CoA esters via acyl-CoA synthetase, long-
chain fatty acyl-CoAs must be converted to acylcarnitine esters before they are able 
to permeate the mitochondrial membranes and access the matrix enzymes of the β-
oxidation pathway (Fritz & Yue, 1963). This reversible trans-esterification is 
facilitated by carnitine palmitoyltransferase 1 (CPT1) and is illustrated schematically 
in Figure 1.3. Owing to the close association between ACS and CPT1 within the 
contact sites of the outer mitochondrial membrane (Hoppel et al., 1998; Hoppel et 
al., 2002), activated long-chain acyl-CoAs would appear to be preferentially 
trafficked towards the mitochondrial matrix for subsequent oxidation. Once formed, 
acylcarnitines are translocated from CPT1, on its cytosolic-facing site of the outer 
mitochondrial membrane (Murthy & Pande, 1987; Fraser et al., 1997), to CPT2 on 
the inner mitochondrial membrane (Woeltje et al., 1987). This process necessitates a 
stoichiometric 1:1 exchange of the cytosolic acylcarnitine with intra-mitochondrial 
free carnitine by the enzyme carnitine acylcarnitine translocase (CACT). Upon 
exposure to CPT2 acylcarnitine is trans-esterified back to free carnitine and LCFA-
CoA, which can then be sequentially cleaved of two-carbon acetyl-CoA units by the 
enzymes of the β-oxidation cycle. The free carnitine product of CPT2 is 
subsequently available to participate in the CACT reaction and as such, under 
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normal resting conditions mitochondrial fatty acid flux can be sustained with 
minimal disturbance to the free carnitine pool. 
 
Carnitine deficiencies impair fat metabolism 
The paramount involvement of carnitine and its associated enzymes in fat oxidation 
is highlighted by multiple pathophysiological scenarios in humans. For example, 
systemic carnitine deficiency (Engel & Angelini, 1973); chronic haemodialysis, 
which results in secondary carnitine deficiency (Calvani et al., 2004; Evans et al., 
2004); or genetic mutations in CPT2 (Orngreen et al., 2005) all result in marked 
suppression of whole-body lipid oxidation, increased intramuscular lipid storage and 
impairments in exercise performance. Furthermore, pharmacological partial 
blockade of CPT1 via Etomoxir administration acutely recapitulates these 
perturbations of lipid metabolism in healthy volunteers (Hinderling et al., 2002). The 
absence of reports concerning human genetic defects in CPT1 would suggest that 
these are incompatible with life and indeed homozygous knockout of the skeletal 
muscle isoform of CPT1 is embryonically lethal in mice (Ji et al., 2008).  
Interestingly, genetic variants in the skeletal muscle CTP1 gene, particularly the 
E531K variant, have recently been linked with lower rates of post-exercise fat 
oxidation (Gomez-Gomez et al., 2014) and an increased prevalence of obesity and 
the metabolic syndrome in humans (Robitaille et al., 2007; Auinger et al., 2013). 
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Figure 1.3 Schematic illustrating the role carnitine in fatty acid oxidation. PM 
plasma membrane, OMM outer mitochondrial membrance, IMM inner mitochondrial 
membrane. 
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Carnitine acetylation limits CPT1 flux 
As previously discussed, above exercise intensities of approximately 65% VO2max, 
there is a sharp decline in the absolute rate of whole body fat oxidation. Concurrent 
with an acceleration of glycolytic rate, PDC flux is also increased at higher exercise 
intensities and is associated with the formation of acetylcarnitine (see Acetyl Group 
Buffering). Studies in human volunteers confirm that the increase in acetylcarnitine 
concentrations within skeletal muscle during exercise of increasing intensity is 
paralleled by a reciprocal decline in free carnitine content (Constantin-Teodosiu et 
al., 1991). The first evidence that this acetylation of the free carnitine pool was 
mechanistically responsible for the decline in lipid oxidation was provided by van 
Loon et al. (2001), who observed a 35% reduction in [
13
C]-palmitate oxidation 
during cycling exercise at 72% VO2max compared to 57% VO2max. This coincided 
with a lowering of intramuscular free carnitine concentrations to 5.6 mmol·kg dw
-1
, 
or approximately 30% of the total carnitine pool (excluding long-chain 
acylcarnitine), which was argued could possibly limit CPT1 flux and led to the 
hypothesis that increasing skeletal muscle free carnitine availability could alleviate 
this inhibition of fat oxidation. It has since been demonstrated that increasing the 
skeletal muscle carnitine pool via a chronic nutritional strategy, such that the free 
carnitine concentration during a 30 minute bout of cycling exercise at 80% VO2max 
was 8.8 mmol·kg dw
-1
, was unable to prevent the decline in whole-body lipid 
oxidation (Wall et al., 2011). Although free carnitine availability in this study was 
likely increased above the intracellular concentration expected to limit CPT1 flux 
(0.5 mM; McGarry et al., 1989) it still only represented ~30% of the total carnitine 
pool.  Thus, the marked decline in lipid oxidation during exercise at intensities above 
~65% VO2max is paralleled by a rapid acetylation of the free carnitine pool, whereas 
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acetylcarnitine accumulation is far more moderate at lower exercise intensities, when 
lipid oxidation is still increasing (see Figure 1.5). As a consequence of these (and 
other) findings, it has recently been proposed that the absolute rate of lipid oxidation 
will decline when carnitine acetylation reaches 50% of the total carnitine pool 
(Stephens & Galloway, 2013). This hypothesis predicts that at such exercise 
intensities, the intra-mitochondrial free carnitine concentration will become limiting 
to the CACT reaction flux, which will in turn restrict the delivery of free carnitine to 
the cytosolic site of CPT1 and inhibit fatty acid entry into the mitochondria. This 
acknowledges that an elevation of the total muscle carnitine pool will not only 
increase free carnitine availability to CPT1, but also to the CAT reaction. As such, 
this intervention might only be expected to increase the rate of lipid oxidation under 
conditions of low glycolytic flux.  
 
An additional implication of this working model is that free carnitine availability 
will be limiting to CPT1 flux at any exercise intensity, even when lipid oxidation is 
increasing. This is consistent with the observation that acetylcarnitine concentrations 
generally decline with progressive exercise durations at these intensities (Figure 
1.5).  For example, Watt et al. (2002) found that the increase in plasma fatty acid 
oxidation with prolonged (four hours), moderate intensity (57% VO2max) exercise 
coincided with a reduction in PDC activation and a return in acetylcarnitine 
concentrations to resting values. This also aligns with the finding that increasing 
muscle total carnitine content by 21%, such that free carnitine availability was 
increased from 14.5 to 19.6 mmol·kg dw
-1
, resulted in a 31% suppression of PDCa 
during 30 minutes of exercise at 50% VO2max (Wall et al., 2011). This was 
associated with a near-halving of glycogen utilisation (from 49.9 to 26.9 mmol·kg
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dw
-1
) and has subsequently been shown to concomitantly increase whole body fat 
oxidation rates by about 10%, from 0.61 to 0.67 mg min
-1
·kg
-1
 lean mass (Stephens 
et al., 2013). Interestingly, the latter study found that this carnitine-mediated increase 
in fat oxidation was able to prevent the 1.8 kg gain in fat mass observed in the 
control group  (attributed to chronic carbohydrate overfeeding), and was reflected in 
the modulation of related metabolic gene networks. These findings were consistent 
with earlier work from this group, demonstrating that acute elevation of the muscle 
carnitine compartment was associated with a blunting of resting PDCa and glycogen 
utilisation (Stephens et al., 2006a). The authors concluded that the increase in free 
carnitine availability had promoted a greater CPT1-mediated oxidation of lipids, as 
supported by increased long-chain acyl-CoA content, leading to an elevation of 
mitochondrial acetyl-CoA availability and thus driving the suppression of PDC and 
glycogenolytic fluxes (Garland & Randle, 1964). 
 
1.2.2 Carnitine maintains PDC flux during exercise 
Acetyl group buffering 
As previously discussed, at rest and during steady-state low intensity exercise (<50% 
VO2max) the contribution from fat oxidation to total energy expenditure is 55-80%, 
with the remaining portion fulfilled almost entirely by carbohydrate oxidation 
(Romijn et al., 1993; van Loon et al., 2001). Reciprocally, non-mitochondrial ATP 
generation (and thus glycolytic flux) proceeds at a relatively low rate. Specifically, 
pyruvate-derived acetyl group production through the PDC is well matched to 
acetyl-CoA flux through the tricarboxcylic acid cycle. However, during times of 
accelerated glycolytic flux, as occurs at higher exercise intensities (>70% VO2max), 
acetyl-CoA production from the decarboxylation of pyruvate would appear to exceed 
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its rate of condensation with oxaloacetate. The resting muscle CoASH pool is 
approximately 15 µmol∙kg wm-1 which, in isolation, would be sufficient to support 
maximal PDC flux of 20-25 µmol∙s-1∙kg wm-1 (Constantin-Teodosiu et al., 1991) for 
less than one second of intense muscular contraction. If acetyl-group delivery was 
supported solely by the formation of acetyl-CoA, this rapid acetylation of the 
mitochondrial CoASH pool would prevent succinyl-CoA formation via the α-
ketogluturate dehydrogenase reaction, resulting in the complete inhibition of TCA 
cycle flux.  By reversibly binding to mitochondrial acetyl-groups, carnitine prevents 
this depletion of the CoA pool, facilitating an increase in the catalytic activity of the 
PDC (Figure 1.4). Experiments on blowfly flight muscle by Childress and Sacktor 
(1966) demonstrated that the tissue had a carnitine content comparable to human 
skeletal muscle (~4 mmol·kg ww), despite lacking the capacity to oxidise fatty acids. 
The findings that carnitine enhanced the conversion of pyruvate to acetyl-CoA and 
that acetylcarnitine accumulated during flight (4-fold increase) led to the hypothesis 
that free carnitine buffers excess acetyl-CoA. The formation of acetylcarnitine from 
carnitine and acetyl-CoA is catalysed by the mitochondrial matrix enzyme carnitine 
acetyltransferase (CAT). Compared to relatively small pool of CoASH in skeletal 
muscle (~90 µmol·kg dw
-1
), free carnitine (~20 mmol·kg dw
-1
) provides a far greater 
capacity for acetyl-group transfer during conditions of accelerated mitochondrial 
acetyl-group delivery. Indeed, the extent of acetylcarnitine accumulation in muscle 
during exercise can be an order of magnitude higher than any increase in acetyl-CoA 
concentration (Constantin-Teodosiu et al., 1992). The observations of Childress and 
colleagues were subsequently confirmed in contracting frog (Alkonyi et al., 1975), 
rat (Carter et al., 1981), and human (Constantin-Teodosiu et al., 1991; Constantin-
Teodosiu et al., 1992, 1993) skeletal muscle and it was proposed that this acetyl-  
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Figure 1.4 Schematic showing role of carnitine in acetyl-group buffering. PM 
plasma membrane, IMM inner mitochondrial membrane. 
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buffering role of carnitine and the CAT reaction was tightly coupled to the activity of 
the PDC. 
 
Acetylcarnitine formation during exercise 
The formation of acetylcarnitine by CAT is crucial to the maintenance of the high 
rates of carbohydrate oxidation evoked by high-intensity exercise. A comparison of 
25 published studies that have measured acetylcarnitine formation during exercise of 
various intensities and durations demonstrates that acetylcarnitine accumulates most 
rapidly during the initial minutes of exercise, suggesting that the CAT reaction is 
particularly important over this period (Figure 1.5). Consistent with the greater 
dependence on non-mitochondrial ATP delivery during the first few minutes of 
exercise, acetylcarnitine accumulation would also appear to suggest that PDC flux is 
accelerated more rapidly than TCA cycle flux over this period. During exercise at 
75% VO2max and above, most studies report that acetylcarnitine remains elevated or 
continues to accumulate, albeit at a lesser rate, for the remainder of exercise (Sahlin, 
1990; Constantin-Teodosiu et al., 1992; Leblanc et al., 2004).  Thus, once the initial 
mitochondrial inertia has been overcome (see Acetyl-group Deficit) and oxidative 
ATP delivery begins to approach the total ATP demand, PDC flux and hence acetyl-
group availability would appear to become better matched to the demands of the 
TCA cycle. However, estimates of in vivo TCA cycle flux have challenged this 
concept. 
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Figure 1.5 Acetylcarnitine formation at different exercise intensities. 
Open circles <50% VO2max, closed circles 65% VO2max, closed triangles 75% 
VO2max, open triangles 90% VO2max. Values are averaged from studies that have 
determined acetylcarnitine content in skeletal muscle before and after voluntary 
exercise of various intensities and durations (Harris et al., 1987; Hiatt et al., 1989; 
Sahlin, 1990; Constantin-Teodosiu et al., 1991; Constantin-Teodosiu et al., 1992; 
Spencer et al., 1992; Putman et al., 1993; Putman et al., 1995; Howlett et al., 1998; 
Howlett et al., 1999a; Parolin et al., 2000; St Amand et al., 2000; Tsintzas et al., 
2000; van Loon et al., 2001; Campbell-O'Sullivan et al., 2002; Gibala et al., 2002a; 
Gibala et al., 2002b; Savasi et al., 2002; Leblanc et al., 2004; Roepstorff et al., 2005; 
Sahlin et al., 2005; Vollaard et al., 2009; Marwood et al., 2010; Wall et al., 2011). 
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Gibala et al. (1998) found that during five minutes of leg extension exercise at 60% 
maximal exercise capacity, in-vitro determination of PDCa accounted for only 77% 
of the estimated TCA cycle flux (calculated from leg O2 uptake). In this exercise 
model it is quite likely that lipid oxidation provides a substantial portion of the 
acetyl-groups entering the TCA cycle (Helge et al., 2007), even during more intense 
workloads. Moreover, the relatively low muscle mass recruited during single-leg 
knee extension lessens the restrictions imposed by circulating catecholamine 
concentrations and local vasoconstriction on the active muscle oxygen uptake, 
compared to two-legged cycling exercise (Helge et al., 2007; Boushel & Saltin, 
2013). With these considerations, it might be expected that total TCA cycle flux be 
greater than flux through the PDC under the exercise conditions employed by Gibala 
and colleagues. Indeed, the maximal activity of citrate synthase, the enzyme 
regulating acetyl-group entry into the TCA cycle, is approximately 10-fold greater 
than that of the PDC (Rasmussen et al., 2001). It is also interesting to note that the 
reported Km of the CAT reaction for acetyl-CoA (40 µM;Childress & Sacktor, 1966) 
is substantially lower than that of the condensation of acetyl-CoA with oxaloacetate 
(500 µM; Newsholme & Leech, 1983), raising the possibility that under certain 
conditions acetyl-CoA could be preferentially converted to acetylcarnitine over entry 
to the TCA cycle. Consistent with the finding that acetylcarnitine concentrations tend 
to decline during 20 seconds of electrical stimulation (Roberts et al., 2002), 
acetylcarnitine accumulation is negligible during a single bout of maximal cycling 
exercise, lasting either ten (Howlett et al., 1999b) or 30 seconds (Parolin et al., 
1999). Under these conditions, mitochondrial (oxidative) ATP delivery cannot 
approach the required rate of ATP hydrolysis and the duration of exercise is 
probably insufficient for an acetyl-group excess to develop. Indeed, whole body 
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oxygen uptake reaches at most 60% and 85% of VO2max within 15 and 30 seconds of 
maximal cycle sprinting (Putman et al., 1995), reflecting a submaximal 
mitochondrial respiration.  
 
Carnitine matches glycolytic and TCA cycle fluxes 
As discussed, acetylation of the free carnitine pool indicates that acetyl-group 
delivery from the PDC exceeds acetyl-CoA entry into the TCA cycle. Similarly, 
lactate accumulation during exercise largely reflects an imbalance between pyruvate 
formation (i.e. glycolytic rate) and disposal through the PDC. Thus during high-
intensity exercise, the simultaneous accumulation of both lactate and acetylcarnitine 
can be considered to reflect an overall imbalance between glycolytic and TCA cycle 
fluxes.  It has been proposed that the availability of free carnitine, if limiting to PDC 
flux, could in part regulate the matching of substrate fluxes in skeletal muscle during 
high-intensity exercise (Siliprandi et al., 1990). However, the study by Siliprandi and 
colleagues made no attempt to measure skeletal muscle metabolism and was unlikely 
to have successfully manipulated muscle carnitine availability (Stephens et al., 
2006b). To date, only one study has addressed the impact of manipulating skeletal 
muscle carnitine content on fuel metabolism during high-intensity exercise (Wall et 
al., 2011).  Elevating muscle total carnitine content by 21% was associated with a 
50% increase in PDCa following a 30 minute exercise bout at 80% VO2max. 
Acetylcarnitine accumulation also appeared to be greater, suggesting that flux 
through the PDC had indeed been augmented during the exercise bout.  Moreover, 
the post-exercise PCr/ATP ratio was higher following carnitine loading, implying 
reduced reliance on PCr degradation during exercise. Glycolytic flux was accelerated 
following the intervention period, probably as a result of the daily carbohydrate load 
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needed to increase muscle carnitine uptake, but lactate accumulation was 
significantly lower in the carnitine fed group than in the control group (carbohydrate 
only). Altogether, the findings from Wall and colleagues demonstrated that 
increasing free carnitine availability during high-intensity exercise enabled a greater 
flux through the PDC, facilitating a better matching of glycolytic and TCA cycle 
fluxes and thus reducing reliance on non-mitochondrial ATP resynthesis. 
Importantly, the metabolic impact of muscle carnitine loading translated into an 11% 
improvement in work output during a subsequent 30 minute performance trial.  
 
Disease states under which skeletal muscle mitochondrial ATP production is 
impaired are often reflected in perturbed carnitine metabolism. For example, patients 
suffering from unilateral peripheral arterial disease have reduced resting muscle free 
carnitine content compared to their non-symptomatic leg (Hiatt et al., 1992). These 
patients commonly experience exercise-induced claudication which severely limits 
exercise tolerance and thus any physical task can represent an intense exercise 
challenge. Hiatt and colleagues also reported that those patients who were able to 
exercise for longer accumulated greater amounts of acetylcarnitine, whilst resting 
acetylcarnitine content was a negative predictor of exercise tolerance. Although 
derangements in carnitine metabolism are perhaps secondary to other features of this 
disease (e.g. tissue perfusion, mitochondrial volume), these findings demonstrate the 
importance of acetyl-group buffering in reflecting the metabolic state of skeletal 
muscle. Indeed, evidence suggests that mitochondrial oxidative capacity is impaired 
in peripheral arterial disease patients (Hands et al., 1986; Bauer et al., 1999). 
Furthermore, targeting of the PDC to reduce reliance on non-mitochondrial ATP 
production may represent a means to increase the efficacy of exercise prescription in 
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this population (Calvert et al., 2008), or indeed in any clinical population in which 
mitochondrial ATP production appears impaired (e.g. chronic obstructive pulmonary 
disease, mitochondrial myopathy). 
 
1.2.3 Novel areas of carnitine metabolism during exercise 
The data from the study by Wall et al. (2011), described above, suggest that 
increasing skeletal muscle carnitine content could facilitate the enhancement of 
oxidative ATP provision during continuous high-intensity exercise, as reflected by 
the lower rate of PCr degradation and diversion of glycogenolysis away from lactate 
production. These findings could potentially have a wide applicability, not only as an 
ergogenic tool to improve athletic performance, but also with respect to the efficacy 
of exercise prescription in pathologies where mitochondrial ATP production and 
hence, exercise capacity, may be impaired. However, whether the metabolic 
alterations observed during 30 minutes of exercise at 80% VO2max (Wall et al., 2011) 
are transferable to other exercise paradigms is unclear and requires further 
investigation.  In order to fully exploit the utility of skeletal muscle carnitine loading, 
further clarification is needed as to the roles of carnitine metabolism and PDC flux in 
the facilitation of oxidative ATP production under various exercise conditions.    
 
Carnitine metabolism during single leg exercise 
As already discussed, during the initial few minutes of high-intensity exercise, non-
mitochondrial ATP-producing pathways are rapidly activated to compensate for the 
deficit in ATP turnover associated with the more gradual rise in oxidative ATP 
delivery towards the required ATP demand. Similarly, the formation of 
acetylcarnitine in skeletal muscle during the first 5-10 minutes of high-intensity 
 41 
 
exercise is generally considered to reflect a rate of PDC flux that is in excess of 
acetyl-group entry to the TCA cycle (Figure 1.5). Wall et al. (2011) reported that 
acetylcarnitine accumulation during 30 minutes two-legged cycling exercise at 80% 
VO2max was more than double that observed during an equivalent bout at 50% 
VO2max. This demonstrates how the proposed imbalance between PDC and TCA 
cycle fluxes becomes more exaggerated as the exercise intensity, and thus the 
demand for non-mitochondrial ATP production, is increased. However, a study from 
Gibala and co-workers (1998) has challenged this concept, estimating TCA cycle 
flux to be 10-30% greater than PDC flux over five minute periods of single-legged 
knee extension exercise. Should acetylcarnitine formation indeed reflect the balance 
between PDC and TCA cycle fluxes, under these conditions acetylcarnitine 
accumulation might be considered somewhat paradoxical. As acetylcarnitine 
metabolism was not determined in the study by Gibala and colleagues, definitive 
conclusions cannot be drawn on the relevance of acetylcarnitine accumulation during 
the single-leg knee extension model, when oxidative ATP delivery may not be 
impeded by the same limitations as during two-legged cycling (Boushel & Saltin, 
2013).  
 
Repeated bouts of high-intensity exercise 
The progressive increase in the relative contribution from mitochondrial ATP 
resynthesis to total ATP production is well characterised during repeated sprint 
(maximal effort) exercise, with a concurrent decline in non-mitochondrial ATP 
delivery. A confounding factor concerning the investigation of skeletal muscle 
metabolism during repeated sprints is the inherent reduction in work output over 
successive bouts. The implementation of a slightly lower exercise intensity (e.g. 
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100% VO2max), where the workload can be fixed and sustained over repeated bouts 
provides an exercise paradigm that relies on a rapid and near-maximal activation of 
mitochondrial ATP production and yet still demands a substantial non-mitochondrial 
component. Using this type of paradigm, Bangsbo et al. (2001) reported that 
oxidative ATP delivery increased in a second three minute bout of single-leg knee 
extension exercise at 100% Wmax, whilst reliance on non-mitochondrial ATP 
production declined, relative to the first bout. In line with the aforementioned 
relationship between PDC flux, oxidative ATP production and acetylcarnitine 
accumulation, it might be expected that under these conditions, where TCA cycle 
flux is apparently accelerated during a second exercise bout at a fixed workload, 
acetylcarnitine accumulation would decline. Acetylcarnitine was not determined in 
the study by Bangsbo and colleagues and indeed, relatively little is known about 
skeletal muscle carnitine metabolism during repeated-bout exercise, or during the 
recovery between exercise bouts and how this might influence subsequent bout 
performance.  
 
Effects of training on carnitine metabolism during exercise  
A limited number of studies have reported data on skeletal muscle carnitine 
metabolism during exercise in response to training. For example, Leblanc et al. 
(2004) observed a training-induced reduction in PDC activation and acetylcarnitine 
accumulation during 15 minutes of constant-load cycling exercise at 80% VO2max. 
Taken together with the calculation that absolute rates of pyruvate oxidation were 
lower following training, this would indicate that flux through the PDC was 
suppressed post-training. Whilst this might initially appear counterintuitive to a 
training adaptation, the relative proportion of pyruvate production that was diverted 
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towards oxidation actually increased and was accompanied by lesser reliance on 
non-mitochondrial ATP delivery, as evidenced by lower PCr degradation, lactate 
accumulation and glycogenolytic flux. The latter were probably related to a better 
preservation of resting ADP and AMP concentrations, a finding consistent with the 
reported increase in maximal citrate synthase activity (an enzymatic marker of 
mitochondrial content). Finally, a reduction in pyruvate oxidation with a concomitant 
decrease in non-mitochondrial ATP production would imply that the contribution 
from lipid oxidation to energy provision was increased. This is certainly plausible 
given the increased availability of free carnitine, in the face of a lower glycolytic 
flux. In agreement with this, a second study that observed comparable training 
adaptations with respect to acetylcarnitine accumulation and non-mitochondrial ATP 
production, also reported a lower post-training respiratory exchange ratio during 
exercise (70% pre-training VO2max), suggesting that fat oxidation was indeed 
enhanced by training at this workload (Vollaard et al., 2009). If alterations in 
carnitine metabolism during exercise are an important aspect of the metabolic 
responses to training in skeletal muscle, it would be pertinent to investigate whether 
increasing muscle carnitine during training could influence these adaptations. As will 
be discussed below, the current strategy to increase muscle carnitine availability is 
not without limitations and could benefit from further empirical optimisation. 
 
1.3 Increasing skeletal muscle carnitine content 
1.3.1 Carnitine homeostasis  
Although the regulation of muscle carnitine stores is poorly understood, muscle 
carnitine uptake would appear to be primarily driven by the sodium-dependent 
organic cation transporter OCTN2 (Tamai et al., 1998) and relies on a tightly-
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controlled plasma carnitine availability. Plasma carnitine is in turn regulated by 
intestinal dietary absorption, renal reabsorption and endogenous biosynthesis (see 
Chapter 3). The difficulties in increasing muscle carnitine content are multifaceted 
and are addressed in greater detail in Chapter 3. Briefly, the bioavailability of orally 
ingested boluses of L-carnitine is less than 20% and declines further as dose size 
increases (Harper et al., 1988). Secondly, the renal reabsorption of carnitine is near-
saturated at normal plasma carnitine concentrations, meaning that any elevation of 
plasma carnitine concentration is matched by rapid urinary carnitine elimination 
(Brass et al., 1994). Consequently, a sustainable increase in systemic carnitine 
availability would require constant oral dosing. Finally, the active transport of 
carnitine into muscle by OCTN2 must occur against a considerable (>100-fold) 
concentration gradient and would appear to be saturated by normal plasma carnitine 
concentrations under basal conditions (Stephens et al., 2006b). These features of 
carnitine homeostasis are reflected in the results from multiple studies demonstrating 
the failure of L-carnitine administration to measurably impact the muscle carnitine 
stores. For example, Vukovich and colleagues (1994) found no difference in muscle 
carnitine following two weeks of oral L-carnitine supplementation (6 g per day) 
despite maintaining elevated serum carnitine concentrations throughout the 
intervention period. Similar results were found following three months of 
supplementation (2 x 2g per day; Wachter et al., 2002). Moreover, Brass et al. 
(1994) found no impact of acute intravenous administration of carnitine upon muscle 
carnitine content. A further common finding from the three studies described above 
is the absence of any effect of carnitine supplementation on muscle metabolism or 
performance during exercise. Indeed, these findings cast doubt on a number of 
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studies that report the ergogenic effects of acute oral dosing of L-carnitine, as it is 
difficult to understand how such a strategy could alter skeletal muscle metabolism.  
 
Insulin stimulates muscle carnitine accretion 
The coupling of OCTN2 carnitine transport with the Na
+
 gradient makes it an 
electrogenic process, and reduction of the membrane potential via vanilomycin-
induced potassium diffusion has been shown to transiently increase OCTN2 activity 
(Tamai et al., 1998). This feature was the basis for the hypothesis that manipulating 
the sarcolemma membrane potential via non-specific targeting of the Na
+
/K
+
-
ATPase pumps with insulin could enhance OCTN2-mediated skeletal muscle 
carnitine transport. A series of novel studies from Stephens and colleagues (2006a, b, 
2007a; 2007b)  were able to demonstrate that insulin can indeed augment muscle 
carnitine transport and have led to the development of a dietary regime to 
successfully and sustainably increase muscle carnitine content by a physiologically 
relevant amount (Wall et al., 2011). The mechanism by which insulin stimulates 
Na
+
/K
+
 ATPase activity is not entirely clear, but is likely tissue specific and 
multifaceted (Sweeney & Klip, 1998). Insulin-signalled translocation of α2 and β1 
subunits from an intracellular storage depot, to the plasma membrane, has been 
demonstrated in skeletal rat muscle (Hundal et al., 1992). Other potential 
mechanisms include an insulin-induced increase in intracellular K
+
 concentrations, 
or in ATPase sensitivity to Na
+ 
(Ewart & Klip, 1995).  
 
Initially it was shown that maintaining serum insulin at a supraphysiological level 
(~150 mU·L
-1
) during a five hour carnitine infusion resulted in a significant 13% 
increase in skeletal muscle carnitine content (Stephens et al., 2006b). This was 
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associated with the induction of a 2.3-fold increase in skeletal muscle OCTN2 
mRNA expression. Importantly, no change in muscle carnitine content or OCTN2 
expression was observed when carnitine was infused with circulating insulin 
clamped at fasting levels. This is likely due to the considerable concentration 
gradient that carnitine must be transported against, from plasma into muscle (~40 
µM and 4 mM in plasma and muscle, respectively). The reported muscle specific Km 
of OCTN2 for carnitine is around 3.6 µM (Tamai et al., 1998), suggesting that basal 
muscle carnitine uptake is saturated at normal plasma concentrations. Subsequent 
studies clarified that this insulin-mediated increase in muscle carnitine content 
required a threshold serum insulin concentration of somewhere between 50 and 75 
mU·L
-1
 (Stephens et al., 2007a) and necessitates an elevation of plasma carnitine 
(Stephens et al., 2006a) most likely because the basal plasma carnitine compartment 
was insufficient to measurably increase muscle stores. In an attempt to make the 
manipulation of muscle carnitine more practically appealing, a subsequent study 
investigated whether carbohydrate feeding (to stimulate insulin secretion) with an 
oral bolus of L-carnitine could acutely increase muscle carnitine uptake (Stephens et 
al., 2007b). The anticipated effect of short-term L-carnitine feeding on muscle 
carnitine content is so low as to be undetectable in muscle biopsy samples, so urinary 
carnitine excretion was used as a surrogate marker of whole body carnitine retention. 
Over a two week period of daily L-carnitine feeding, the average 24 hour urinary 
carnitine excretion was reduced by 29% with carbohydrate co-ingestion, compared 
to L-carnitine alone (188 vs 252 mg per day, respectively).  Furthermore, plasma 
carnitine concentrations following a single oral bolus of L-carnitine were lower with 
carbohydrate ingestion and were negatively related to the seven hour area under the 
serum insulin x time curve (Stephens et al., 2007b), supporting the notion of insulin-
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stimulated plasma carnitine clearance into skeletal muscle.  Utilising a similar 
feeding strategy, Wall et al. (2011) subsequently demonstrated that chronic (24 
weeks) twice-daily L-carnitine feeding (3 g per day) in a carbohydrate beverage 
resulted in a 21% increase in total muscle carnitine stores. This was the first study to 
confirm the efficacy of carbohydrate-L-carnitine feeding to measurably increase 
muscle carnitine and provided a critical tool for investigating the impact of 
manipulation of the muscle carnitine pool on exercise metabolism. 
 
1.3.2 Current limitations  
Chronic carbohydrate intake 
The feeding strategy used to increase muscle carnitine content by Wall and 
colleagues (160g daily carbohydrate load; ~650 kcal) is perhaps not appropriate for 
long-term, mass implementation. The control group, who consumed the same 
amount of carbohydrate in absence of L-carnitine, gained an average of 3% body 
weight (P<0.01) over the first 12 weeks of the study. It is interesting to note that L-
carnitine appeared to protect against this weight gain, through a coordinated up-
regulation of fat oxidation at both a physiological and genomic level (Stephens et al., 
2013). Nevertheless, there is concern that high carbohydrate diets adversely affect 
triacylglycerol and high-density lipoprotein (HDL) concentrations (Petersen et al., 
2007). Indeed, increased dietary carbohydrate intake is associated with reduced 
clearance of very low density lipoproteins (Parks et al., 1999), particles which have 
been implicated in the progression of atherogenesis (Zilversmit, 1995).  It is also 
possible that some of the negative effects of carbohydrate feeding observed in the 
control group could have supressed the adaptations to skeletal muscle carnitine 
loading, thus masking the true magnitude of the response. A supplemental protocol 
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that could have dyslipidemic properties would be unsuitable for chronic use, 
particularly in populations who might already be at risk of metabolic syndrome. It is 
therefore necessary to devise oral nutritional formulations which produce a 
physiologically high insulinaemic response, but with a relatively low caloric and 
carbohydrate load. It is well known that other macronutrients, namely proteins and 
amino acids, can stimulate insulin secretion in vivo, and are therefore potential 
candidates to achieve this.  
 
Urinary carnitine as a measure of muscle carnitine retention 
The most decisive way to determine the effectiveness of a feeding strategy in 
elevating muscle carnitine stores is to obtain a muscle biopsy sample following a 
chronic period (at least 12 weeks) of the feeding intervention. Clearly, this is a very 
time-consuming and invasive approach and is the reason less direct, more acute 
measures have been performed previously (Stephens et al., 2007b). The main 
limitation with previous investigations into the manipulation of whole body carnitine 
stores is the reliance on urinary measures of carnitine retention. The lower plasma 
and urinary carnitine concentrations following carbohydrate ingestion during the 
acute carnitine feeding study by Stephens and colleagues could equally have been 
attributed to a lower intestinal absorption. Given that a negative correlation was 
found between the area under the time curves for plasma carnitine and serum insulin 
concentrations, it seems highly likely that the suppression of plasma carnitine was 
indeed due to increased muscle uptake. Nevertheless, a more direct acute measure of 
muscle carnitine accretion would be a valuable tool in the investigation of novel 
ways to improve the efficacy of muscle carnitine loading.   
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1.4 Aims and hypotheses 
The general aim of these studies was to investigate whether skeletal muscle carnitine 
loading could alter the metabolic adaptations to high-intensity exercise training. 
Initially this involved the generation of experimental data to ascertain the most 
appropriate feeding strategy to elevate muscle carnitine. Secondly, an exercise 
paradigm was identified under which the manipulation of muscle carnitine stores 
could be most beneficial to the expected metabolic adaptations. Finally, the 
identified feeding strategy and exercise paradigm were implemented into a chronic 
exercise training study.  
 
Study one 
Given the disadvantages of a high carbohydrate intake, the principle aim of study 1 
(Chapter 3) was to investigate whether the carbohydrate load used to increase whole 
body L-carnitine retention in previous studies could be reduced using a carbohydrate 
and whey protein combination. Initially, the impact of this oral formulation upon 
whole-body carnitine retention was assessed using urinary and plasma carnitine 
measurements (part A). A second aim of study one was to obtain a more direct 
estimate of muscle carnitine uptake and accretion rates, and to determine the efficacy 
of the chosen oral formulations in acutely enhancing these rates (part B). The latter 
approach utilised the forearm arterio-venous balance model of net substrate uptake 
and circumvented any confounding influence of the possible inconsistencies in 
intestinal absorption.  It was hypothesised that following acute L-carnitine feeding, 
an orally administered carbohydrate and protein (PRO) solution would reduce 
urinary carnitine retention, relative to a flavoured water control (CON) and to the 
same extent as a carbohydrate only beverage (CHO). These were secondary to the 
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hypothesis that PRO and CHO would stimulate similar physiologically high insulin 
responses. In part B it was subsequently hypothesised that PRO and CHO would 
promote similar rates of insulin-stimulated net muscle carnitine balance, above that 
observed with CON.   
 
Study two 
In Chapter 4, two studies were conducted to investigate the concept that skeletal 
muscle acetylcarnitine accumulation can reflect the balance between PDC flux and 
TCA cycle flux, thus further informing on the balance between oxidative and non-
mitochondrial ATP production, during different exercise paradigms.  In study 2A, 
carnitine acetylation and non-mitochondrial ATP production were determined in a 
single-leg knee extension exercise model, using comparable workloads to those 
previously characterised for two-legged cycling (Wall et al., 2011). It was 
hypothesised that, consistent with the apparent excess of TCA cycle flux relative to 
PDC flux during this modality of exercise (Gibala et al., 1998), acetylcarnitine 
accumulation and non-mitochondrial ATP production would be negligible during 
work at both 55% and 85% Wmax. In study 2B, we investigated acetylcarnitine 
accumulation, PDC activation and non-mitochondrial ATP delivery during two 
successive bouts of high-intensity bicycle exercise, where the ATP demand could be 
fixed and sustained across both bouts, but oxidative ATP provision is apparently 
increased in the second bout (Bangsbo et al., 2001). This also provided the 
opportunity to study the recovery of these parameters during a five minute passive 
rest period between the two exercise bouts. It was rationalised that a five minute 
recovery period would allow PCr to return to basal values between bouts and thus 
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hypothesised that acetylcarnitine accumulation and non-mitochondrial ATP 
production would decline during the second bout relative to the first.  
 
Study three 
Study three (Chapter 5) investigated the impact of increasing skeletal muscle 
carnitine content on the metabolic adaptations to high-intensity bicycle exercise 
training. Based on previous data on the responses at 80% VO2max to muscle carnitine 
loading, and on data from the previous studies of this thesis, it was proposed that 
increasing muscle carnitine would maintain PDC flux during a second bout of 
exercise and thus alter the training adaptations to this type of exercise. Specifically, 
it was hypothesised that carnitine loading would reduce PCr degradation and 
glycolytic flux during repeated bouts of exercise, secondary to increasing activation 
and flux through the PDC and compared to a control group. It was further 
hypothesised that this could alter the functional adaptations to the training 
intervention, including divergent gains in VO2max and work output.   
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CHAPTER 2: GENERAL METHODS 
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2.1 Human Volunteers 
Volunteer recruitment 
For all of the studies described in this thesis, with the exception of Chapter 4 Study 
A, young (18-35 years), healthy, male volunteers were recruited from the University 
of Nottingham and surrounding area through responses to posters, social media and 
local newspaper advertisements. All recruitment strategies were approved by the 
University of Nottingham Ethics Committee. For Chapter 4 Study A, young healthy 
volunteers were recruited in accordance with the Ethics Committee for Medical 
Research in Copenhagen (Stallknecht et al., 2007). 
 
Volunteer Screening 
Prior to study participation, all volunteers attended a preliminary visit to give 
informed consent and complete a general health screening. Volunteers received a 
study information sheet in advance of the screening and were asked to read it 
thoroughly. During the preliminary visit the study timeline, protocol and procedures 
were explained explicitly before written consent was obtained. Volunteers were 
informed that they were free to withdraw from the study at any point. The 
subsequent general health screening consisted of a heath questionnaire (see 
Appendix 1.2), measurements of height, weight and blood pressure and a 12-lead 
electrocardiogram (Schiller, Altgasse, Switzerland) and small (<10 ml) blood sample 
from an antecubital vein. The blood sample was screened for blood cell count and 
serum indices of hepatic and renal function by the Departments of Haematology and 
Clinical Chemistry, Queen’s Medical Centre, Nottingham, UK. Screening results 
were overseen by the study medic before volunteers were recruited onto the study. 
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Determination of maximal oxygen consumption 
For Chapters 4 and 5, volunteers completed a continuous incremental exercise test to 
exhaustion to determine their individual maximal oxygen consumption (VO2max) and 
the workload that would elicit this under these exercise conditions (Wmax), on an 
electronically-braked cycle ergometer (Lode Excalibur; Lode, Groningen, The 
Netherlands). Following a five minute warm-up period cycling against a workload of 
50-100 watts (~1W/kg), the first stage commenced at the same workload and was 
increased by a 30W increment every three minutes in a step-wise fashion until 
volitional exhaustion. Heart rate (3-lead electrocardiogram; GE Medical Systems 
Technology Inc. Buckinghamshire, UK), oxygen consumption and carbon dioxide 
production (mixing chamber mode, Vmax; SensorMedics corporation, California, 
USA) were measured continuously throughout the test. In addition, the rating of 
perceived exertion (RPE) was determined on the Borg Scale (Borg, 1970) in the last 
30 seconds of each incremental stage. Upon cessation of exercise and following a 
short rest, volunteers cycled again at a workload 20-30 watts greater than the 
maximal increment achieved in the previous test. This confirmation procedure was 
also repeated on a separate occasion, within one week of the initial test. Oxygen 
consumption values were averaged over 20 second intervals and VO2max was taken 
as the highest value obtained across all three occasions. Wmax was calculated as: 
 
W𝑚𝑎𝑥 = W𝐹 + 30 ∙ (
T𝐹
180
)  
 
where WF is the workload of the final complete stage and TF is the time attained in 
the final stage.  
 55 
 
Calculation of mechanical efficiency 
Mechanical cycling gross efficiency, herein referred to as mechanical efficiency, is a 
whole-body measure of the fraction of total energy expenditure that can be ascribed 
to the actual work done relevant to the exercise task. It is calculated by the equation: 
 
GE% =
𝑊
𝑉𝑂2 × 𝑐 × 0.06
× 100 
 
where GE is the gross mechanical efficiency, W is the power output in watts, VO2 is 
the oxygen consumption at that power output in ml·min-1 and c is the energy 
equivalent of one litre of oxygen in kJ. When the whole-body respiratory exchange 
ratio exceeds 1.0, as was always the case for the calculation of mechanical efficiency 
at Wmax, the value used for c is 21.13 kJ·L
-1
.   
 
Determination of body composition 
For Chapter 5, volunteers received a dual energy X-ray absorptiometry (DEXA) 
scan (Lunar Prodigy DEXA; GE Medical Systems, Bedford, UK) at three time-
points throughout the study to determine fat mass and fat free mass. A questionnaire 
was completed prior to each scan to confirm volunteer suitability for the scan (see 
Appendix 1.3) and any metallic accessories that could interfere with the image were 
removed. Volunteers lay supine on the scanning platform, remaining motionless for 
the duration of the scan (approximately seven minutes), which involves two low-
dose X-ray beams (40 – 70  keV) passing through the body incurring a total radiation 
dose of less than 1 µSv. Estimations of fat and fat-free tissue masses are 
subsequently automated from the attenuation ratio of the two X-ray beams and 
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separated into leg, trunk and arm specific masses using the standardised regions 
specified in the software package (enCORE 2005 version 9.1; GE Medical Systems, 
U.K). All scans were analysed during a single session by an experienced operator. 
 
Blood Sampling 
For Chapter 3, volunteers were cannulated to enable regular (up to every ten 
minutes) arterialised-venous blood sampling. A sterile 12G cannula was placed 
retrograde into a dorsal vein on the back of the hand. Lidocaine (1%) was injected 
(approximately 1 ml) subcutaneously prior to cannula insertion to minimise 
discomfort.  The cannula was kept patent by a slow running 0.9% saline infusion. To 
arterialise the blood, this hand was then placed in an air-warming unit set to heat the 
hand to 55°C and kept there for the remainder of the visit. This method has been 
demonstrated to produce venous concentrations of the molecules of interest that are 
close to the arterial concentrations, without altering core body temperature (Gallen & 
Macdonald, 1990). For Chapter 3, it was necessary to sample venous blood draining 
directly (or as close as possible) from the forearm tissue. An ultrasound probe was 
used to locate the deep-lying branch of an antecubital vein of the contralateral 
forearm and a sterile cannula was inserted as above. Accurate placement of the 
cannula was verified using ultrasound.  
 
Muscle biopsy sampling 
Muscle biopsies were obtained from the vastus lateralis muscle using the 
percutaneous needle method as described by Bergstrom (1975). Briefly, a small area 
of the thigh was shaved and cleaned using iodine solution. Following local 
anaesthetic of the skin and proximal tissue (Lidocaine; 2 %) a small incision (<1cm) 
 57 
 
was made through the fascia using a sterile scalpel blade. A five millimetre 
Bergstrom needle (Bignell Surgical Instruments Ltd, West Sussex, UK) was used 
(with suction) to obtain 100 – 200 mg (wet weight) muscle tissue which was rapidly 
frozen in liquid nitrogen-cooled isopentane. Post-exercise muscle biopsies were 
obtained and frozen within 15 seconds of the cessation of exercise. For Study 2A 
(Chapter 4), two muscle biopsies were obtained from a single incision, in opposite 
directions (distal-proximal) to one another, from each leg. 
 
2.2 Plasma and serum analysis 
Serum Insulin 
For the studies in Chapter 3, two millilitres of freshly drawn blood was allowed to 
clot and following centrifugation (3,000 G for ten minutes), the serum was removed 
and stored at -80°C for analysis using a radioenzymatic kit (Coat-A-Count RIA; 
Seimens Healthcare, Erlangen, Germany). This assay involves a 24 hour incubation 
period during which endogenous insulin from the sample competes with [
125
I]-
insulin for binding sites on an insulin antibody lining the test tube. The tubes were 
then decanted, blotted thoroughly and counted in a gamma radiation scintillation 
counter (COBRA II Auto Gamma; Canberra-Packard, Melbourne, Australia). Counts 
per minute were used to interpolate serum insulin values from a [logconc] standard 
curve of known insulin concentrations, normalised to the blank which represented 
100% [
125
I]-insulin binding (Figure 2.1). The insulin assay kit had an intra-assay 
coefficient of variation (CV) of 2.8% and an inter-assay CV of 7.1%.  
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Figure 2.1 Serum insulin assay standard curve. Representative example of the 
response of the serum insulin assay to increasing concentrations (0-350 mU·L
-1
) of 
exogenous insulin standard.  
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Plasma and urine total, free and acylcarnitine  
Plasma was separated from two millilitres of freshly drawn blood (lithium 
heparinized vaccutainer), centrifuged (3,000G for 10 min) and immediately frozen at 
-80°C for the subsequent analysis of carnitine based on the original method of 
Cederblad and Lindstedt (1972). Thirty microlitres of plasma or urine (1:9 dilution) 
was deproteinized in one millilitre chloroform:methanol (3:2) and vigorously 
vortexed for two minutes. After centrifugation (7,000G for 10 min) the supernatant 
was decanted into glass test tubes and dried to residue under oxygen-free nitrogen. 
The residue was resuspended in 120 µl of distilled water and assayed directly for 
free carnitine. One hundred microliters of potassium phosphate buffer (pH 6.2; 250 
mM) containing both [
14
C]-acetyl-CoA (1.6 µM) and unlabelled acetyl-CoA (75 
µM) was added to each sample. The acetylation reaction was initiated by the 
addition of 20 µl CAT (0.4 U) and allowed to proceed for 20 minutes at room 
temperature (final reaction volume was 240 µl). NEM was included in the reaction 
mixture (4 mM) to remove any liberated coenzyme A and quench the reaction as 
follows: 
free carnitine + [ C14 ]-acetyl-CoA
        CAT          
→        [ C14 ]-acetylcarnitine +CoA-NEM 
 
The positively charged [
14
C]-acetylcarnitine product was separated from the 
unreacted [
14
C]-acetyl-CoA (negatively charged) by passing the sample through a 
positive ion exchange column (DOWEX chloride counter ion resin, 100-200 mesh) 
and then washing the columns with H2O. The flow-through was collected in 
scintillation vials to which 10 ml scintillation fluid was added, vortexed vigorously 
and subsequently counted for [
14C] β-radiation using a scintillation counter (TriCarb, 
2100TR, Canberra-Packard, Melbourne, Australia). Counts per minute were used to  
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interpolate carnitine values from a linear standard curve of known carnitine 
concentrations (0-3600 pmol) with a typical R
2 
>0.999 (Figure 2.2). The intra-assay 
coefficient of variation (CV) was less than 2%, whilst the inter-assay CV was less 
than 5%. For the determination of total carnitine, the dried residue was incubated (2 
hours @ 50°C) in 100 µl potassium hydroxide (KOH; 0.1 M) to ensure complete 
hydrolysis of the acylcarnitine ester bonds. Total carnitine was then assayed as above 
in the neutralised (20 µl 0.5 M HCl) samples. The difference between total 
(hydrolysed) carnitine and free carnitine was assumed to equal plasma (or urine) 
acylcarnitine concentration. 
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Figure 2.2 Free carnitine assay standard curve. Representative example of the linear 
response of the carnitine assay to increasing amounts (0-3600 pmols) of exogenous 
L-carnitine standard. 
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Plasma [methyl-
2
H3]-L-carnitine enrichment 
Solid phase extraction 
The molar percent excess (MPE) tracer enrichment, used to calculate the rate of 
plasma carnitine disappearance in Chapter 3, was determined by the parallel 
quantification of L-carnitine (m/z 162) and 
2
H3-L-carnitine (m/z 165) in each sample 
using high performance liquid chromatography mass spectrometry. Plasma samples 
were prepared for LCMS with prior solid phase extraction using strong cation 
exchange. Two hundred microliters of plasma was mixed with an acetyl-lysine 
internal standard (20 µM) and acidified in 800 µl formic acid (2%), vortexed briefly 
and centrifuged at 13,000G for two minutes. Strong cation exchange columns (30 
mg Oasis MCX 33 µm, 80Å; Waters) were prepared with 1 ml methanol (70%) and 
equilibrated with 1 ml formic acid (2%). Samples were then loaded and a flow rate 
of approximately 1 ml/min was set. Columns were subsequently washed, 
sequentially, with 1 ml formic acid (2%) and 1 ml methanol (70%), allowed to 
vacuum dry for 1-2 minutes and the flow-through discarded. Columns were eluted 
with 1 ml ammonium hydroxide (35%) in methanol (50%) and the eluate retained in 
low-bind microtubes. Sample eluates were dried to residue overnight in a vacuum 
centrifuge, resuspended in formic acid (0.1%) and centrifuged at 13,000G for two 
minutes. Two hundred microliters of the supernatant was decanted into an auto-
sampler vial for subsequent LCMS quantification.  
 
Liquid chromatography mass spectrometry 
All chromatographic experiments were performed on a Waters 2700 auto-sampler 
module using a C18 Brownlee column (2.1 x 300 mm, 5 µm) with a 50 µl injection 
volume and a single mobile phase  of 5% acetonitrile / 0.1% formic acid in HPLC 
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grade water (isocratic mode). Flow rate throughout separation was 0.3 ml/min. Mass 
spectrometry experiments were performed on a Micromass Quattro Ultima triple 
quadrupole mass spectrometer (Waters, MA, USA) in positive ion mode with 
nitrogen as the collision gas. The collision voltage (30 V), capillary voltage (3.6 kV), 
cone voltage (100 V), source temperature (96 °C) and desolvation temperature (250 
°C) were kept constant for experiments. Molecules of interest were quantified in 
MSMS ion monitoring mode with transitions of (m/z 162 → 60) for L-carnitine and 
(m/z 165 → 63) for 2H3-L-carnitine.  
 
2.3 Muscle metabolite, substrate and enzyme analysis 
Muscle metabolite extraction 
Muscle biopsy samples were cut (10-50 mg ww) and freeze-dried for 24 hours.  
Visible blood, fat and connective tissue were removed before powdering using sterile 
forceps and separate portions were weighed out for metabolite extraction (3-10 mg 
dw) and the determination of glycogen (1-3 mg dw). Eighty volumes of ice-cold 
perchloric acid (0.5 M with 1 mM EDTA) was added to the muscle powder before 
gentle vortexing (5 RPM) for ten minutes at 6°C to precipitate acid-soluble 
metabolites (Harris et al., 1974). After centrifugation (2,000G for 3 mins) the 
decanted supernatant was neutralised with 0.25 volumes of potassium bicarbonate 
(2.2 M), re-centrifuged and the neutralised supernatant stored at -80°C for 
subsequent metabolite analysis. The acid-insoluble muscle pellet from the initial 
centrifugation was blotted and digested in 500 µl KOH ( 0.2 M) for two hours at 
50°C, neutralised with 20 µl PCA (5M) and the supernatant (12,000G for 3 min) 
decanted and stored at -80°C for the analysis of long-chain acylcarnitine and the 
acid-insoluble glycogen fraction. 
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Muscle free, long-chain acyl and total carnitine  
Muscle free carnitine and long-chain acylcarnitine was determined in 10 µl PCA 
extract (made up to 120 µl with distilled water) or 120 µl long-chain extract, 
respectively, as described above for plasma and urine free carnitine. Total carnitine 
was calculated as the sum of free carnitine, long chain acylcarnitine and 
acetylcarnitine (see below). 
 
Muscle acetylcarnitine  
Muscle acetylcarnitine content was determined as described by Pande and 
Caramancion (1981) and modified by Cooper et al. (1988). Fifty microliters of 
diluted PCA extract (1:49 – 1:99) or standard (0-125 pmol) was incubated in 200 µl 
HEPES buffer (pH 7.4; 125 mM) containing EDTA (1 mM) and freshly reduced (1 
mM DTT) coenzyme A (25 µM). The acetyltransferase reaction was initiated by the 
addition of 20 µl CAT (0.4 U): 
acetylcarnitine + CoA
        CAT          
→        acetyl-CoA +free carnitine 
 
Following a 30 minute incubation at room temperature the reaction was terminated 
by heating the samples at 95°C for three minutes to denature the CAT and 30 µl 
NEM (40 mM) was subsequently added to remove any excess CoA. The acetyl-CoA 
formed, proportional to the initial acetylcarnitine concentration, was condensed with 
20 µl [
14
C]-oxaloacetate (freshly prepared from [
14
C]-aspartate; see Appendix 2.1) 
by the addition of 20 µl citrate synthase (0.4 U): 
 
acetyl-CoA + [ C14 ]-oxaloacetate
        CS          
→       [ C14 ]-citrate +CoA-NEM 
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Following a 20 minute incubation at room temperature, the excess [
14
C]-oxaloacetate 
(negatively charged) was removed by transamination back to [
14
C]-aspartate  via the 
addition of glutamate-oxaloacetate transaminase in the presence of excess potassium 
glutamate (133 mM). Following a final 20 minute incubation at room temperature 
the [
14
C]-citrate (negatively charged), proportional to the initial acetylcarnitine 
concentration, was separated from the [
14
C]-aspartate (positively charged) by the 
addition of one millilitre of negative ion exchange resin (DOWEX, hydrogen 
counter-ion resin, 50-100 mesh). Samples were vortexed vigorously and allowed to 
sediment, before 500 µl was decanted and mixed with 5 ml scintillation fluid. After 
vigorous vortexing, samples were counted for [
14C] β-radiation using a scintillation 
counter (TriCarb, 2100TR, Canberra-Packard, Melbourne, Australia). Counts per 
minute were used to interpolate acetylcarnitine values from a linear standard curve of 
known acetylcarnitine concentrations (0-125 pmol) with a typical R
2 
>0.999 (Figure 
2.3). 
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Figure 2.3 Acetylcarnitine assay standard curve. Representative example of the 
linear response of the acetylcarnitine assay to increasing concentrations (0-125 
pmols) of exogenous L-acetylcarnitine standard.  
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Muscle adenosine triphosphate and phosphocreatine 
Adenosine triphosphate (ATP) and phosphocreatine (PCr) were assayed sequentially 
using the method of Harris et al. (1974) in which NADPH production is coupled to 
three reactions and can be followed spectrophotometrically. Twenty microlitres of 
PCA extract was aliquoted in duplicate into a 96-well plate and mixed with 225 µl 
triethanolamine buffer (pH 7.5) containing NADP (1 mM), ADP (0.04 mM), glucose 
(5 mM) and EDTA (1 mM). Baseline light absorbance was read at a wavelength of 
340 nm before the sequential addition of four microlitres (1.5 U) of glucose-6-
phosphate dehydrogenase, hexokinase and creatine phosphokinase. After the 
addition of each enzyme, the plate was mixed and incubated for 20 minutes at 25°C 
and the absorbance was again recorded. The sequential reactions were as follows: 
 
G6P + NADP+
        G6PDH          
→           6-P-gluconolactone +NADPH + H+ 
 
ATP + glucose
        HK          
→        ADP +G6P  
 
PCr + ADP
        CPK          
→        Cr +ATP 
 
Muscle creatine  
Free creatine was assayed spectrophoptometrically (Harris et al., 1974) as the 
disappearance of NADH. Twenty microlitres of PCA extract was added in duplicate 
to each well and mixed with 300 µl glycine buffer (pH 9.0) containing ATP (1.5 
mM), phophoenolpyruvate (1 mM), NADH (0.15 mM) and the coupling enzymes 
lactate dehydrogenase (LDH) and pyruvate kinase (PK). Baseline light absorbance 
was read at a wavelength of 340 nm before the addition of four microlitres (1.5 U) of 
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creatine phosphokinase. After the enzyme was added, the plate was mixed and 
incubated for 35 minutes at 25°C before again reading absorbance. The coupled 
reactions were as follows: 
 
pyruvate + NADH + H+
        LDH          
→         lactate +NAD+ 
 
ADP + PEP
        PK          
→       ATP +pyruvate  
 
Cr + ATP
        CPK          
→        PCr +ADP 
 
Muscle lactate 
Lactate was assayed spectrophotometrically based on the method of Lundholm et al. 
(1963). Twenty microlitres of PCA extract was aliquoted in duplicate and mixed 
with 200 µl of glycine buffer (pH 9.2; 100 mM) containing NAD
+
 (3 mM) and 
hydrazine (260 mM) to quench the reaction in favour of pyruvate production.  After 
a baseline absorbance reading at 340 nm, four microlitres of lactate dehydrogenase 
(5.5 U) was added. The plate was mixed, incubated for 30 minutes at 25° and read a 
second time.  
 
lactate + NAD+
        LDH          
→         pyruvate-hydrazine + NADH + H+ 
 
Muscle Glycogen 
Muscle glycogen was determined by a modified version of the method employed by 
Harris et al. (1974). Glycogen was extracted from 1-3 mg freeze-dried muscle 
powder by hot alkaline digest (10 minutes at 80°C in 100 mM sodium hydroxide). 
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Following neutralisation with HCl (100 mM), the glycogen was enzymatically 
hydrolysed in a sodium phosphate/citrate buffer (200 mM) using amyloglucosidase. 
Samples were incubated with the enzyme for one hour at room temperature and then 
centrifuged for three minutes at 20,000 G. The liberated glucose was measured 
spectrophotometrically; twenty-five microlitres of extract was aliquoted to each well 
and mixed with 250 µl TEA buffer (pH 8.2) containing NAD
+
 (1 mM), ATP (0.75 
mM), EDTA (1 mM), DTT (1 mM) and glucose-6-phosphate dehydrogenase. After 
baseline absorbance measurement at 366 nm, 1.5 U hexokinase was added to each 
well and the plate was incubated at 25°C for 15 minutes. The change in absorbance 
after 15 minutes was corrected for a distilled-water blank and used to calculate 
glycosyl-units.  
 
G6P + NAD+
        G6PDH          
→           6-P-gluconolactone + NADH + H+ 
 
glucose + ATP
        HK          
→        ADP +G6P  
 
Calculation of metabolite concentrations 
For all spectrophotometric assays, absorbance values were automatically normalised 
to a one centimetre path-length using pre-programmed path-length correction values 
for the software (Spectra Max 190, Molecular Devices Ltd; Wokingham, UK) and 
changes in absorbance were corrected for the background change in absorbance of a 
distilled-water blank. Metabolite concentrations were then calculated from the 
following equation: 
 
Concmet =
{[Vol2 × (Abs2 − Bl2 )] − [Vol1 × (Abs1 − Bl1 )]} · EF
Vols × ε
  
 70 
 
 
Where Concmet is the concentration of the metabolite given in millimoles per 
kilogram of dry muscle mass; Vol is the pre- or post-enzyme well volume or sample 
volume given by the suffices 1,2 or S, respectively; Abs is the sample absorbance, Bl 
is the blank absorbance, EF is the PCA extraction factor (~100) and ε is the 
extinction coefficient for NADPH at 340 nm (6.22 cm
-1
·mmol
-1
) or NADH at 366 
nm (3.4 cm
-1
mmol
-1
). A one or two point standard was always included with each 
assay to confirm reactions had run to completion.  
 
Pyruvate dehydrogenase activation status  
The activation status of the pyruvate dehydrogenase complex (PDCa) is a 
measurement of the phosphorylation state of the enzyme, and in most situations 
where blood flow is not restricted, will be an indication of the actual activity or flux 
of the enzyme (Constantin-Teodosiu et al., 1991). 3-20 mg wet muscle was 
homogenised (50 seconds at 400 RPM) in 30 volumes ice-cold Tris buffer (pH 7.8; 
50 mM; see Appendix 2.2), which contained sucrose (200 mM); sodium fluoride (50 
mM) and dichloroacetate (5 mM), to inhibit PDC phosphatase and kinase activity, 
respectively; and the membrane detergent Triton X-100 (0.1%). Thirty microliters of 
homogenate was then added to 720 µl pre-warmed (37°C) Tris-HCl buffer (100 mM) 
which contained Coenzyme A (0.5 mM) and cofactors NAD
+
 (1 mM) and thiamine 
pyrophosphate (1 mM). The decarboxylation reaction was initiated by the addition of 
30 µl pyruvate (1 mM) as follows:  
 
pyruvate + CoA + NAD+
        PDCa          
→         acetyl-CoA + NADH + H+  
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The reaction was terminated in sequential aliquots after 1, 2 and 3 minutes by adding 
210 µl of the reaction mix to 40 µl perchloric acid (0.5 M). Aliquots were 
subsequently neutralised with 10 µl potassium bicarbonate (2.2 M) and centrifuged 
for three minutes at 20,000G to pellet muscle cell debris. Supernatants were removed 
and stored at -80°C for the determination of the reaction product, acetyl-CoA, using 
a similar radioenzymatic assay as described above for acetylcarnitine.  Ten to twenty 
microliters of neutralised supernatant was made up to a volume of 120 µl in distilled 
water and the assay commenced with the addition of NEM (see Acetylcarnitine 
Assay), with acetyl-CoA concentrations interpolated from linear standard curve of 
known acetyl-CoA concentrations (0-150 pmols) with a typical R
2
>0.999 (Figure 
2.4). PDCa was then calculated as the linear (R
2
>0.99) increase in acetyl-CoA 
concentrations over time (rate of acetyl-CoA production) and corrected for the 
protein content of the muscle homogenate (see Protein content), expressed as nmol 
acetyl-CoA per mg protein per minute. 
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Figure 2.4 Acetyl-CoA assay standard curve. Representative example of the linear 
response of the acetyl-CoA assay to increasing concentrations (0-150 pmols) of 
exogenous acetyl-CoA standard. 
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Protein assay of muscle homogenates 
PDCa values measured in skeletal muscle were normalised to the protein content of 
the homogenate as determined by the Bradford protein assay (Bradford, 1976). Four 
microliters of muscle homogenate, diluted in 996 µl distilled water was added to 250 
µl BioRad reagent (Coomassie Brilliant Blue dye G-520; BioRad laboratories) and 
vortexed well. After a five minute incubation samples were aliquoted (250 µl) in 
triplicate into a 96 well plate and the absorbance was read at 595 nm. Protein content 
was determined from a bovine serum albumin standard curve (0 – 30 mg/ml), also 
aliquoted in triplicate (Figure 2.5). 
 
Calculation of non-mitochondrial ATP production  
In Chapter 4 and Chapter 5, non-mitochondrial ATP production during a given 
exercise bout was estimated based on the theoretical ATP resynthesis from skeletal 
muscle ATP breakdown, PCr degradation and lactate accumulation, given by the 
equation: 
 
Non-mitochondrial ATP production = 2∙∆[ATP] +[PCr]+1.5∙∆[lactate] 
 
It should be noted that this will always represent an underestimate of the ATP 
delivery from non-mitochondrial sources in non-occluded muscle, as it does not 
consider the glycolytic ATP delivery accounted for by lactate efflux. It also ignores 
ATP turnover associated with the accumulation of intermediary metabolites, for 
example, glycerol-3-phopshate or pyruvate (Spriet et al., 1987). However, this 
calculation provides a relative index that is reflective of the overall reliance on non-
mitochondrial ATP delivery and thus, the matching of oxidative ATP production to 
total ATP demand.  
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Figure 2.5 Protein assay standard curve. Representative example of the linear 
increase in absorbance in response to increasing protein concentrations over a range 
of 0 – 30 mg/ml BSA.  
 
 
 
 
 
 75 
 
2.4 Statistical analyses 
For the studies in this thesis, all time-dependent variables were compared using two-
way analysis of variance (ANOVA) to identify main effects of time or treatment. 
Significant main effects were isolated post-hoc using a student’s t-test with a 
Bonferoni stepwise correction for multiple comparisons. Time-independent variables 
in Chapter 3, including urinary carnitine excretion and area under the curve values, 
were compared using one-way ANOVA with Tukey post-hoc testing. Single 
comparisons, such as delta metabolite values between bouts in Chapter 4, were 
performed using a paired Student’s t-test. Area under the analyte x time curve 
analysis, performed for Chapter 3, employed curve integration using the trapezium 
rule. Correlation analysis in Chapter 3 was performed using the Pearson product-
moment correlation coefficient. All statistical tests were performed using GraphPad 
Prism V6 (GraphPad Software Inc; La Jolla, CA, USA) and an alpha level of P<0.05 
was deemed accepted as statistically significant. All data in text, tables and figures 
are presented as mean ± standard error of the mean (SE). 
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CHAPTER 3: ACUTE EFFECTS OF CARBOHYDRATE 
AND WHEY PROTEIN INGESTION ON WHOLE 
BODY L-CARNITINE RETENTION, ABSORPTION 
AND NET MUSCLE BALANCE 
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3.1 Introduction 
Whole body carnitine stores in healthy, non-vegetarian humans equate to 
approximately 20g, with the vast majority (~95%) of this located in skeletal muscle 
(Brass, 1995). As outlined in the General Introduction, manipulation of the skeletal 
muscle carnitine stores may represent an appealing intervention for both athletic and 
clinical populations, but strategies to sustainably increase muscle carnitine content 
still require optimisation. Compartmental analysis of [
3
H]-carnitine kinetics in 
humans suggests that the skeletal muscle carnitine reserve is a relatively stable pool, 
with a predicted turnover time of approximately 190 hours (Rebouche and Engel, 
1984). As skeletal muscle lacks the requisite γ-butyrobetaine hydroxylase enzyme 
for the terminal step of endogenous carnitine synthesis (Rebouche & Seim, 1998), 
muscle carnitine stores are restricted to the extraction of carnitine from the 
extracellular fluid, an active transport process thought to be facilitated by the 
sodium-dependent novel organic cation transporter OCTN2 (Tamai et al., 1998). 
Moreover, muscle carnitine uptake occurs against a considerable (>100-fold) 
concentration gradient and thus any meaningful increase in the rate of muscle 
carnitine accretion requires a targeted up-regulation of muscle carnitine transport. 
Simultaneous elevation of plasma carnitine and serum insulin concentrations has 
proven to be an effective strategy to increase muscle carnitine uptake in healthy 
subjects and would appear to be driven by the insulin-mediated up-regulation of 
OCTN2 (Stephens et al., 2005; see General Introduction). However, the limitations 
of the current carnitine loading regime, in particular the requirement for a large 
carbohydrate load, warrant the investigation into alternative oral formulations that 
can stimulate similarly high insulin responses, but utilise lower carbohydrate loads. 
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The potential for non-glucose substances to stimulate insulin release was initially 
recognised by Cochrane and colleagues (1956) following studies on cases of 
pathological hypoglycaemia. Floyd et al. (1966) later demonstrated that the 
intravenous infusion of essential amino acids, either individually or in combination 
with one another, resulted in a marked stimulation of insulin release. It was 
subsequently observed that the addition of protein to a carbohydrate meal could have 
a synergistic effect on insulin secretion (Rabinowitz et al., 1966; Pallotta & 
Kennedy, 1968). In-vitro studies in pancreatic beta cells have partially elucidated the 
mechanisms behind the insulinotropic properties of amino acids. For example 
leucine and phenylalanine, which would appear to be particularly potent insulin 
secretagogues (van Loon et al., 2000), are thought to simulate beta cell respiration 
both through allosteric activation of glutamate dehydrogenase and by acting as a fuel 
for the enzyme (Sener & Malaisse, 1981). Given the large rise in plasma availability 
of leucine, phenylalanine and other amino acids following protein feeding (Nilsson 
et al., 2007), it would seem likely that the insulin response to protein ingestion is 
secondary to such effects of individual amino acids. A number of studies have 
focused on manipulating the insulinotropic properties of amino acids and protein to 
optimise post-exercise glycogen synthesis (Ivy et al., 2002) or protein anabolism 
(Rasmussen et al., 2000). Of particular interest is a study from Steenge et al. (2000), 
which demonstrated that the combination of 50 g whey protein and 47 g 
carbohydrate was as effective as 96 g carbohydrate in stimulating an insulin-
mediated ~25% increase in whole-body creatine retention. Similarly to carnitine, 
creatine is co-transported into muscle in a sodium-dependent manner and it is 
thought that the insulin-mediated increase in muscle uptake of both compounds is 
related to the stimulation of N
+
/K
+
-ATPase driven sodium efflux. Based on the 
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findings of Steenge and colleagues (2000), whey protein would appear to be an 
attractive candidate to reduce the amount of carbohydrate needed to stimulate muscle 
carnitine uptake.  
 
Strategies to optimise insulin-stimulated muscle carnitine uptake are dependent upon 
adequate L-carnitine absorption in order to maximise muscle carnitine delivery. 
However, the effects of whey protein ingestion on the intestinal absorption of L-
carnitine have not before been tested and it has been speculated that amino acids 
could actually impair L-carnitine absorption (Taylor, 2001). Whilst the 
bioavailability of carnitine from a non-vegetarian diet, providing 2-12 µmol·kg
-
1
·day
-1
 (Rebouche & Engel, 1984; Rebouche, 1992) ranges from 45-85% (Rebouche 
& Chenard, 1991), oral bolus doses of L-carnitine are absorbed with a much lower 
efficiency. For example, Harper et al. (1988) demonstrated that 16% of a 2 g oral 
bolus dose and only 5% of a 6 g dose were absorbed in healthy, non-vegetarian 
volunteers. The finding that L-carnitine bioavailability may be inversely related to 
dose size probably reflects the intestinal transport kinetics of L-carnitine. Studies in 
human intestine mucosa have characterised the intestinal absorption of L-carnitine as 
a predominantly active, sodium-dependent, saturable transport process with a Km for 
carnitine of approximately 560 µM (Hamilton et al., 1986). This would imply that 
postprandial carnitine absorption from the jejunal lumen of healthy humans, where 
fasting carnitine concentrations (~26 µM) can increase by up to 10-fold following a 
standard meal containing approximately 50 mg carnitine (Li et al., 1992), is 
predominantly facilitated by active transport. In contrast, a large component of the 
absorption of a 50 mg·kg
-1
 oral bolus of L-carnitine (approximately 4000 mg), which 
has been shown to elevate intrajejunal total carnitine concentrations to almost 25,000 
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µM, can likely be attributed to passive diffusion (Li et al., 1992). The active 
component of intestinal carnitine transport was initially ascribed to the novel sodium 
dependant cation transporter OCTN2 (Duran et al., 2002). However, the discovery 
that the OCTN2-deficient juvenile visceral steatotic mouse still retains 
approximately 50% of gut carnitine transport capacity would suggest the existence of 
additional transport mechanisms (Yokogawa et al., 1999). For example, the amino 
acid transporter ATB
0,+
, which is strongly expressed in the intestinal tract (Hatanaka 
et al., 2004) has been shown to transport carnitine in a Na
+
- and Cl
-
-dependent 
manner (Nakanishi et al., 2001). Because ATB
0,+
 is energised by the transmembrane 
gradients of both Na
+
 and Cl
-
, it exhibits a much higher transport capacity for 
carnitine than OCTN2. As such, intestinal carnitine transport by OCTN2, which has 
a reported Km for carnitine of 4.3 µM (Tamai et al., 1998), will become saturated at a 
much lower carnitine concentration than transport by ATB
0,+
 (Km=1000-2000 µM; 
Nakanishi et al., 2010). Given these characterisitics, it seems likely that the 
contribution from ATB
0,+
 to intestinal carnitine transport would be of greater 
importance following oral bolus L-carnitine ingestion, when intestinal carnitine 
concentrations are rapidly elevated above normal postprandial levels. However, the 
study from Nakanishi et al. (2001) also demonstrated that transport of L-carnitine by 
ATB
0,+ 
was strongly inhibited by several amino acids, including leucine and 
phenylalanine, both of which are highly enriched in whey protein. Given the already 
low bioavailability of bolus doses of L-carnitine, any feeding strategy that has the 
potential to further compromise carnitine absorption may not represent an 
appropriate means of increasing skeletal muscle carnitine content and requires 
careful investigation.  
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A further consideration when designing strategies to optimise muscle carnitine 
uptake is the renal handling of bolus doses of L-carnitine. In healthy persons, the 
renal reabsorption of carnitine is a very efficient process and around 95% of 
carnitine is conserved during glomerular filtration when plasma carnitine 
concentrations are in their normal range (Rebouche & Engel, 1984). The reported Km 
values for the renal tubular reabsorption of carnitine, which would also appear to be 
facilitated by OCTN2 in the brush border membrane (Tamai et al., 1998), range 
between 20 µM and 55 µM (Rebouche & Mack, 1984). This is equivalent to the 
normal physiological range of plasma carnitine concentrations and implies that any 
marked elevation of the plasma carnitine pool, as occurs with oral dosing or 
intravenous administration, results in a rapid saturation of renal reabsorption with 
renal clearance rates increased to match the filtered load (Stephens et al., 2006b). By 
means of example, 70-80% of an intravenous bolus dose of L-carnitine is recovered 
in the urine within 24 hours (Harper et al., 1988). No detectable degradation of 
intravenously-delivered carnitine occurs prior to its excretion (Rebouche & Engel, 
1984) and, as such, the urinary excretion of carnitine has previously been used as an 
indirect means to estimate whole-body carnitine retention (Stephens et al., 2007b). 
However, any potential impact of co-ingested macronutrients on L-carnitine 
absorption could invalidate the use of urinary carnitine excretion, in isolation, as a 
marker of muscle carnitine uptake. With this in mind, a more direct estimate of acute 
muscle carnitine accretion may be necessary to evaluate the efficacy of prospective 
chronic L-carnitine feeding regimens.  
 
To investigate whether, following acute L-carnitine ingestion, an orally administered 
carbohydrate and protein solution (PRO) could increase muscle carnitine accretion 
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two separate acute studies were performed. Initially, the impact of PRO on whole-
body carnitine retention was investigated by measuring plasma total carnitine and 
urinary carnitine responses (study A). Based on the results of study A, a protocol 
was subsequently developed to more directly estimate the rate of muscle carnitine 
accretion stimulated by PRO, using an arteriovenous forearm balance model with an 
isotopically labelled L-carnitine tracer (study B). In both studies, the responses to 
PRO were compared to those of flavoured water and carbohydrate alone. This 
combination of net muscle carnitine balance and urinary carnitine excretion thus 
provided an indirect index of carnitine absorption for comparison across trials. In 
study A it was hypothesised that 40 g whey protein plus 40 g carbohydrate (PRO) 
would reduce urinary carnitine excretion, relative to a flavoured water control (CON) 
and to the same extent as an isocaloric carbohydrate solution (CHO). This was 
secondary to the hypothesis that PRO and CHO would stimulate similar serum 
insulin responses compared to CON. In study B, it was further hypothesised that 
PRO would increase muscle carnitine uptake and promote a positive net carnitine 
balance, comparable to CHO, whilst CON would promote a net zero balance.  
 
3.2 Methods 
Volunteers  
Fifteen healthy, non-vegetarian male volunteers were recruited to participate in these 
studies. Eight participated in study A (age 23.2 ± 3.7 years; BMI 24.2 ± 2.4 kg∙m-2) 
and seven in study B (24.2 ± 5.0 yrs, 23.3 ± 3.1 kg·m
-2
). Both protocols were 
approved by the University of Nottingham Medical School Ethics Committee. Prior 
to the study, each participant attended a routine medical screening (see General 
Methods) and written consent was obtained.  
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Experimental Protocol 
Study A. Volunteers completed three randomised laboratory visits having fasted from 
10.00 pm the previous evening. The experimental protocol for study visits is 
illustrated schematically in Figure 3.1. Upon arrival (approximately 9.00 am) 
volunteers laid semi-supine on a bed with one hand placed inside an air-warming 
unit heated to ~55°C. A cannula was inserted into a dorsal vein of the heated hand, 
allowing arterialized-venous blood sampling (Gallen & Macdonald, 1990). 
Volunteers ingested a 200 ml beverage of flavoured water containing 4.5 g L-
carnitine tartrate (3g L-Carnitine; Lonza Ltd, Basel, Switzerland) at t=0 hours, then 
were given a  700 ml treatment drink (see beverage composition) at t=1, 2.5 and 4 
hours  to consume over 5 minutes. After a six hour sample collection period (see 
sample collection and analysis), the cannula was removed and volunteers were fed a 
standardised meal.  
 
Study B. Shown in Figure 3.2, the protocol for study B was consistent with that for 
the initial three hours of study A. In addition to the procedures described above, a 
second cannula was placed into a deep-lying antecubital vein of the contralateral 
arm, for the sampling of venous blood draining from the forearm tissue (Andres et 
al., 1954). The 200 ml beverage at t=0 hours additionally contained 1% [methyl-
2
H3]-L-carnitine hydrochloride (Cambridge Isotope Laboratories Inc., Andover, MA) 
and volunteers were given a single 500 ml treatment drink at t=1 hour, with the 
sampling period lasting three hours. Brachial artery blood flow of the non-heated 
arm was also determined using Doppler ultrasound (Aplio SSA-770A, Toshiba 
Medical Systems) with a 12MHz transducer.  The brachial artery (10 cm proximal to 
the antecubital fossa) was imaged in two-dimensions and the arterial luminal 
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diameter was determined using online video callipers with images synchronised to 
the cardiac cycle using a three-lead ECG. Blood velocity was determined at the same 
anatomical location using pulsed-wave Doppler (variable frequency) and the signal 
was integrated using the online software to give time-averaged velocity values. 
 
Beverage Composition 
The composition of the beverages was as follows: flavoured water (<1 g 
carbohydrate; CON), 80 g carbohydrate polymer (Vitargo orange flavour, Swecarb 
AB, Stockholm, Sweden; CHO) and 40 g of the carbohydrate polymer plus 40 g 
whey protein (PRO-10.com, Birmingham, UK; PRO). All drinks were orange 
flavoured and were mixed thoroughly in water one hour prior to consumption. The 
selected carbohydrate was a high-molecular weight glucose polymer and was 
identical to that which had been used to successfully increase muscle carnitine 
content in previous studies (Wall et al., 2011; Stephens et al., 2013), but therefore 
differed to the type of carbohydrate used by Stephens et al. (2007b) to acutely 
increase whole-body carnitine retention, which contained only simple sugars (low 
molecular weight). The calorie content of the PRO drink was matched to this and 
halved the amount of carbohydrate ingested. 
 
 
 
 85 
 
 
Figure 3.1 Schematic showing the protocol for study 1A.  
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Figure 3.2 Schematic showing the protocol for study 1B. 
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Sample collection and analysis 
Blood samples were drawn every 20 minutes in study A and every 10 minutes in 
study B for the determination of serum insulin and plasma free and total carnitine 
concentrations. A total blood volume of 285 ml (95 ml per visit) and 420 ml (140 ml 
per visit) was sampled for study A and B, respectively. Urine was collected during 
all study visits and also for the 18 hour post-visit period in study A and analysed for 
total carnitine content. Following plasma sample purification with strong cation 
exchange solid phase extraction (SPE), 
2
H3-L-carnitine enrichment in study B was 
measured using liquid chromatography mass spectrometry (see General Methods).  
 
Calculations  
Six hour or 24 hour urinary total carnitine excretion (UTC) in milligrams was 
calculated as: 
 
𝑈𝑇𝐶 =
𝐶𝑈 ∙ 𝑉𝑈 ∙ 𝑀
1000
 
 
where CU is the average total carnitine concentration in the urine (in µmol·L
-1
), VU is 
the total volume  of urine passed over the collection period (in L) and M is the 
molecular weight of carnitine (161.2 g·mol
-1
). Mean brachial artery luminal diameter 
(DM) was calculated as: 
 
𝐷𝑀 = (
1
3⁄ ∙ 𝐷𝑃𝑆) + (
2
3⁄ ∙ 𝐷𝐸𝐷) 
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where DPS and DED are the average values from triplicate measures made at peak 
vascular systole and end diastole, respectively. Mean brachial artery blood flow 
(BAF) is subsequently given by the equation: 
 
𝐵𝐴𝐹 = 𝑣 ∙ 𝜋 (
𝐷𝑀
2⁄ )
2
 
 
where v is the time averaged blood velocity. For the calculation of net carnitine 
balance and carnitine rate of disappearance, brachial artery blood flow was converted 
to forearm plasma flow (F) by the equation: 
 
𝐹 = 𝐵𝐴𝐹 ∙ (1 − 𝐻) 
 
where H is the haematocrit fraction in whole blood for each volunteer. Net carnitine 
balance (NCB) was calculated from the arterialised-venous (AC) – venous (VC) 
difference in plasma carnitine concentration determined biochemically using the 
Fick principle and is given as: 
 
𝑁𝐶𝐵 = 𝐹 ∙ (𝐴𝐶 − 𝑉𝐶) 
 
Plasma carnitine fractional extraction (FEC) was also calculated, to provide a flow-
independent marker of muscle carnitine uptake, by the following equation: 
 
𝐹𝐸𝐶 = (𝐴𝐶 − 𝑉𝐶) 𝐴𝐶 × 100⁄  
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The rate of carnitine disappearance (Rd) and, therefore, forearm carnitine uptake was 
determined from standard equations based on the steady-state tracer enrichment 
values (TTR) converted to molar percent excess values for arterialised-venous 
(MPEA) and venous (MPEV) plasma carnitine concentrations: 
 
𝑀𝑃𝐸 = 𝑇𝑇𝑅 (1 + 𝑇𝑇𝑅)⁄  
 
𝑅𝑑 = [(𝑀𝑃𝐸𝐴 × 𝐴𝐶) − (𝑀𝑃𝐸𝑉 × 𝑉𝐶)] ∙
𝐹
𝑀𝑃𝐸𝐴
 
 
Statistics 
Time dependent variables (serum insulin, plasma carnitine, plasma flow, net 
carnitine balance, rate of disappearance and carnitine extraction) were analysed with 
a two way (drink × time) repeated measures analysis of variance (ANOVA) with 
significant main effects isolated post-hoc using a paired t-test with Bonferoni 
stepwise correction for multiple comparisons. Areas under the curve above baseline 
(AUC) were calculated for the same variables using the trapezium rule and were 
compared, along with urinary carnitine excretion, using a one way ANOVA with 
Tukey post-hoc for multiple comparisons. Pearson moment correlations were also 
performed between urinary carnitine excretion, plasma carnitine AUC and serum 
insulin AUC. In study B, time dependent variables (measured every 10 minutes) are 
averaged over 20 minute periods. 
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3.3 Results 
Serum Insulin  
In study A, serum insulin concentrations were similar between trials at baseline (5 ± 
1, 4 ± 0 and 3 ± 0 mU∙L-1 for CON, CHO and PRO, respectively) and did not change 
throughout the CON trial (displayed in Figure 3.3A). Serum insulin concentration 
rose rapidly following the ingestion of each beverage during CHO and PRO, peaking 
at t=80, 180 and 260 minutes. Peak insulin concentration following the first drink 
was no different between CHO (78 ± 19 mU∙L-1) and PRO (78 ± 25 mU∙L-1) but 
remained elevated during CHO at t=120 min compared to PRO (P<0.0001). Peak 
responses during CHO were also greater than PRO following the second (95 ± 16 vs 
51 ± 6 mU∙L-1; P<0.0001) and third (66 ± 8 vs 39 ± 10 mU∙L-1; P<0.01) drinks such 
that the area under the insulin x time curve AUC above baseline during CHO (12.6 ± 
2.0 U∙L-1∙min) was 59% (P<0.05) greater than PRO (7.9 ± 1.2 U∙L-1∙min). For study 
B, serum insulin rose from similar baseline concentrations (7 ± 2, 5 ± 1 and 6 ± 1 
mU∙L-1 for CON, CHO and PRO, respectively) following CHO and PRO ingestion, 
peaking at t=100 minutes (64 ± 10 and 72 ± 10 mU∙L-1, respectively) and remained 
elevated above CON for the rest of the visit (Figure 3.3B). Serum insulin was 
greater in CHO compared to PRO at t=140 minutes (42 ± 13 and 24 ± 4 mU∙L-1, 
respectively; P<0.05) but AUC above baseline was no different between trials (4.5 ± 
0.8 and 3.8 ± 0.6 U∙L-1∙min, respectively; P=0.7). 
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Figure 3.3 Serum insulin responses following ingestion of 3 g L-carnitine (t=0) and 
3 x 700 ml (A) or 1 x 500 ml drink (B; arrows) containing flavoured water (CON; 
squares), 80 g carbohydrate (CHO; circles) or 40 g carbohydrate + 40 g whey protein 
(PRO; triangles). Values are mean ± SE, n=8 (A) or 7 (B). ‡ P<0.05, ‡‡ P<0.01, ‡‡‡ 
P<0.001 for CHO vs PRO.
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Plasma carnitine 
Plasma total carnitine concentrations during both studies are displayed in Figure 3.4. 
Basal plasma total carnitine (TC) concentrations were similar across visits in study A 
(41 ± 4, 42 ± 4 and 44 ± 4) and study B (46 ± 3, 45 ± 3 and 46 ± 3 µmol∙L-1) for 
CON, CHO and PRO, respectively and were no different over the first hour of either 
study. In study A, Plasma TC following CON ingestion increased to 65 ± 3 µmol∙L-1 
at t=100 minutes and peaked at 66 ± 3 µmol∙L-1 at t=180 minutes, before slowly 
declining throughout the rest of the trial but still remaining elevated above baseline 
at t=360 minutes. The rise in plasma TC in CHO was initially slower, such that CON 
was greater (P<0.05) than CHO from t=80 to 120 minutes, but more prolonged, such 
that plasma TC peaked in CHO (70 ± 3 µmol∙L-1) at a later time of t=260 minutes 
and was elevated above CON (P<0.05) from t=240 to 360 minutes. Plasma TC in 
PRO increased more rapidly than CON or CHO and was elevated above CON 
(P<0.05) from t=100 to 260 minutes and above CHO (P<0.05) from t=80 to 200 
minutes. After peaking (82 ± 5 µmol∙L-1) at t=140 minutes, plasma TC in PRO 
declined towards CON values and was lower than CHO (P<0.01) from t=320 to 360 
minutes. The six hour plasma TC AUC during PRO (7.5 ± 0.9 mmol∙L-1·min) was 
25% (P<0.01) and 15% (P=0.05) greater than CON (6.0 ± 0.8 mmol∙L-1·min) and 
CHO (6.5 ± 0.7 mmol∙L-1·min), respectively, which were no different with respect to 
each other. Study B plasma TC responses during were overall similar to those 
described for study A, with PRO producing greater increases than CHO or CON 
(P<0.001). Plasma TC during CHO was also supressed relative to CON at t=160 
(P<0.05). Plasma TC AUC during PRO (3.5 ± 0.5) was 67% and 84% greater than 
CON (2.1 ± 0.2; P<0.05) and CHO (1.9 ± 0.3 mmol∙L-1·min; P<0.01), respectively.   
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Figure 3.4 Plasma total carnitine responses following ingestion of 3 g L-carnitine 
(t=0) and 3 x 700 ml (A) or 1 x 500 ml drink (B; arrows) of either CON (squares), 
CHO (circles) or PRO (triangles). Values are mean ± SE for n=8 (A) or 7 (B). * 
P<0.05 for CHO vs CON; † P<0.05, ††† P<0.001 for PRO vs CON; ‡‡‡ P<0.001 
for CHO vs PRO. 
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Urinary carnitine 
As shown by Figure 3.5A, six hour urinary TC excretion during study A was 71% 
and 23% greater following PRO (183 ± 14; P<0.001) and CHO (149 ± 15; P<0.05) 
than CON (107 ± 10 mg) and tended to be greater in PRO than CHO (P=0.06). After 
24 hours, PRO (322 ± 33) remained 34% greater (P<0.01) than CON (240 ± 25) 
whilst CHO (333 ± 32 mg) was 39% greater, though not significantly (P=0.12 vs 
CON), and was no different to PRO. In study B, three hour urinary TC excretion in 
study B tended to be greater in PRO (92 ± 28) than CHO (45 ± 13; P=0.14) and 
CON (46 ± 5 mg; P=0.05), which were no different (Figure 3.5B)  
 
Plasma flow 
Plasma flow during study B (Figure 3.6) was similar at baseline for CON, CHO and 
PRO (40 ± 7, 47 ± 10 and 44 ± 9 ml·min
-1
, respectively) and did not change over the 
first hour. A main trial effect (P<0.05) was observed such that plasma flow was 
greater in CHO and PRO than CON from t=120 and t=140 minutes, respectively, for 
the remainder of the visit. Plasma flow AUC above the averaged pre-drink baseline 
was greater in CHO (0.5 ± 0.6; P<0.05) and tended to be greater in PRO (0.4 ± 0.6; 
P=0.05) than CON (-0.5 ± 0.2 L·min). 
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Figure 3.5 (A) Six (solid bars) and 24 (dotted bars) hour urinary total carnitine 
excretion following ingestion of 3 g L-carnitine and 3 x 700 ml drink of either CON, 
CHO or PRO. (B) Three hour urinary total carnitine excretion following ingestion of 
3 g L-carnitine and 1 x 500 ml of either CON, CHO or PRO.  Values are mean ± SE 
for n=8 (A) or 7 (B). * P<0.05 for CHO vs CON; † P<0.05, ††† P<0.001 for PRO vs 
CON. Main effect (P<0.05) of trial in study B, PRO vs CON (P=0.05) and vs CHO 
(P=0.14). 
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Figure 3.6 Plasma flow responses following ingestion of 3 g L-carnitine (t=0) and 1 
x 500 ml drink (arrow) of either CON (squares), CHO (circles) or PRO (triangles). 
Values are mean ± SE for n=7. * P<0.05 , ** P<0.01 for CHO vs CON; † P<0.05 
for CHO vs PRO. 
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Net forearm carnitine balance and extraction 
Net carnitine balance (NCB) across the forearm in study B is shown in Figure 3.7A 
and was unchanged over the one hour following L-carnitine ingestion. However, 
there was a main effect of time (P<0.05) such that NCB at t=120 minutes was greater 
(P<0.05) in CHO (170 ± 74) than CON (-18 ± 37) and PRO (-91 ± 104 nmol·min
-1
). 
NCB in PRO was also lower than CHO at t=100 (P<0.05) and t=180 (P<0.01) 
minutes. Net carnitine extraction was increased (P<0.05) in CHO compared to PRO 
at t=100, 120 and 180 minutes and tended to be increased (P=0.09) above CON at 
t=120 minutes.   
 
Carnitine MPE and disappearance rate 
Arterialised-venous plasma [methyl-
2
H3]-L-carnitine enrichment (MPE) reached a 
steady state after t=80 minutes in all trials, with a similar enrichment attained in 
CON and CHO (~0.14%), but a slightly higher enrichment in PRO of ~0.2% (Figure 
3.8). There was no difference between the arterialised-venous and venous MPE 
values during the CON or PRO trials, but there was a main effect (MPEA vs MPEV, 
P<0.05) during CHO, with MPEA tending to be greater (P=0.06) than MPEV at t=100 
mins in CHO. Rd for plasma carnitine was no difference to zero in either CON or 
PRO, but was significantly greater than zero during CHO at t=100 mins (P<0.05) 
and tended to be greater than CON (main effect P=0.12). Rd at t=100, which 
coincided with peak serum insulin concentration in CHO, was 5-fold greater during 
CHO (520 ± 148) compared to CON (102 ± 189 µmol·min
-1
), though this did not 
reach statistical significance (Figure 3.7B).  
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Figure 3.7 Net carnitine balance (A) and rate of carnitine disappearance (B) 
following ingestion of 3 g L-carnitine (1% 
2
H3-L-carnitine) at t=0 and 1 x 500 ml 
drink (arrow) of either CON (squares), CHO (circles) or PRO (triangles). Values are 
mean ± SE for n=7 except PRO in B (n=6). * P<0.05 for CHO vs CON; ‡ P<0.05, 
‡‡ P<0.001, ‡‡‡ P<0.001 for CHO vs PRO. 
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Figure 3.8 [methyl-
2
H3]-L-carnitine enrichment in arterialised-venous (solid line) and venous (dashed line) blood samples (MPE) following 
ingestion of 3 g L-carnitine (1% 
2
H3-L-carnitine) and 1 x 500 ml drink of either CON, CHO or PRO. * P<0.05 for main effect of AV difference 
in CHO.    
CON CHO PRO 
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Correlation analyses 
For study A there was a strong, positive correlation (R
2
=0.81; P<0.01) between six 
hour urinary carnitine excretion and plasma TC AUC during CON and a moderate, 
positive correlation (R
2
=0.56; P<0.05) during PRO. No correlation was found 
between these variables during CHO. Additionally, there were strong negative 
correlations between six hour urinary excretion and serum insulin AUC during CHO 
(R
2
=0.72; P<0.05) and PRO (R
2
=0.74; P<0.05). 
 
3.4 Discussion 
It was previously shown that, following acute oral L-carnitine feeding, repeated 
ingestion of a carbohydrate drink (CHO) resulted in a lower urinary carnitine 
excretion compared to ingestion of a flavoured water control (Stephens et al., 
2006c). Based on the assumption that L-carnitine absorption would be similar and 
maximal during both visits, these findings were taken to indicate that the 
carbohydrate facilitated an insulin-mediated increase in muscle carnitine uptake, 
leading to greater whole-body carnitine retention. In study A of the current 
investigation, it was thus hypothesised that a protein-carbohydrate (PRO) blend 
could promote a similar increase in whole-body carnitine retention, secondary to the 
hypothesis that PRO would stimulate a comparable serum insulin response to CHO. 
Contrary to this hypothesis, urinary carnitine excretion was increased following 
CHO and PRO compared to CON, suggesting differential L-carnitine absorption 
across trials and thus invalidating the use of urinary and plasma carnitine 
concentrations in the relative determination of whole-body carnitine retention. Study 
B was subsequently conducted to circumvent the effect of potential alterations in L-
carnitine absorption on the inference of muscle carnitine accretion, using parallel 
 101 
 
measures of net forearm carnitine balance with plasma carnitine concentrations and 
urinary carnitine excretion over a tightly controlled three hour period. This 
demonstrated a clear stimulation of net muscle carnitine uptake following CHO, but 
not PRO, despite similar serum insulin responses. Thus is can be concluded that 80 g 
carbohydrate is able to promote a positive net muscle carnitine balance. Furthermore, 
it would appear that the addition of 40 g protein to 40g carbohydrate antagonises this 
insulin-mediated muscle carnitine accretion. Collectively, these studies also indicate 
that CHO and PRO treatment drinks, both containing a high-molecular weight 
glucose polymer, were able to increase the systemic availability of L-carnitine, 
presumably due to altered intestinal absorption. 
 
Carbohydrate promotes net muscle carnitine uptake  
Studies from this lab have previously shown that acutely elevating plasma carnitine 
via intravenous infusion has no impact on muscle carnitine content (Stephens et al., 
2005). Furthermore, acute (Soop et al., 1988) or chronic (Wachter et al., 2002) oral 
dosing of L-carnitine does not appear to effect net leg carnitine balance or muscle 
carnitine accretion, respectively. In agreement with these data and consistent with 
the high concentration gradient between the plasma and tissues, 3 g L-carnitine had 
no detectable impact on NCB in the CON trial of study B. In support of this, there 
was a strong positive correlation between plasma carnitine AUC and urinary 
carnitine excretion during CON in study A, which most likely reflects the near 
saturation of renal carnitine reabsorption above basal plasma carnitine concentrations 
(Harper et al., 1988). In contrast, CHO feeding facilitated a positive NCB across the 
forearm compared to CON and no correlation with urinary carnitine excretion, 
providing further support for the ingestion of L-carnitine in a carbohydrate beverage 
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as a means to promote an insulin-mediated increase in muscle carnitine content 
(Wall et al., 2011).  
 
In a prior study from Stephens et al. (2007b), carbohydrate feeding (4 x 90 g) 
following L-carnitine ingestion supressed 24 hour urinary carnitine excretion, both 
acutely and sustainably over a two week period. Moreover, plasma carnitine was also 
numerically lower (though not significantly) throughout the CHO trial and was 
negatively related to the serum insulin response.. Consistent with this, plasma 
carnitine in study A was supressed following the first CHO drink relative to CON 
and this coincided with the first peak in CHO serum insulin concentrations. 
However, despite repeated elevation of serum insulin following the second and third 
drinks in CHO, plasma carnitine concentrations continued to rise such that they were 
actually greater than CON during the final two hours of the visit. This posed the  
question as to whether the suppression of plasma total carnitine following CHO 
ingestion in the previous trial (Stephens et al., 2007b) and following the first CHO 
drink of the current study (A) was indeed due to insulin-stimulated muscle carnitine 
transport or rather, due to a slower L-carnitine absorption from the gut. Indeed, the 
delayed peak in plasma TC concentration during CHO in the current trial could 
reflect an impairment of L-carnitine absorption. However, six hour urinary carnitine 
excretion during CHO exceeded that of CON and appeared to be greater over the 
entire 24 hour period following L-carnitine ingestion. This would imply that total 
systemic L-carnitine availability during CHO was at least as high as during CON and 
argues against a role for CHO in impairing L-carnitine absorption. Moreover, should 
carbohydrate per se have slowed L-carnitine absorption, plasma TC responses during 
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PRO (40 g CHO) would also be expected to reflect this, which was not the case 
(discussed later). 
 
If it assumed that the majority of the measured carnitine extraction from the plasma 
occurred into the forearm musculature (>90% of whole body carnitine stores exist in 
skeletal muscle) it is possible to estimate whole body rates of insulin-stimulated 
muscle carnitine accretion in study B. Insulin was elevated from 80 minutes to 180 
minutes, over which period the mean area under the NCB x time curve was 7.9 
µmols greater in CHO than CON. Assuming a forearm muscle mass of 
approximately 0.6 kg (Andres et al., 1954; Allwood et al., 1959) and a whole body 
muscle mass of 30 kg, this equates to a whole body muscle carnitine uptake of 63 mg 
greater than CON. This is in excellent agreement with the estimate of 60 mg 
carnitine retention calculated from differences in urinary carnitine excretion in a 
previous study (Stephens et al., 2007b). Extended to a chronic feeding scenario, this 
would equate to a daily increase in muscle carnitine content of 57 µmol·kg dw
-1
, 
which would be expected to increase muscle total carnitine content (~22 mmol·kg 
dw
-1
) stores by 22% over 12 weeks. Again, this extrapolation is almost identical to 
the 21% increase in muscle carnitine content reported by (Stephens et al., 2013) and 
provides indirect validation for the values of net carnitine balance determined here. 
In further agreement with our baseline NCB data, one previous study measuring leg 
carnitine balance found no evidence of net carnitine uptake or efflux at rest (Soop et 
al., 1988). 
 
Net balance models normally preclude definitive conclusions on whether a positive 
net balance is due to increased substrate uptake, reduced substrate efflux, or a 
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combination of the two. The use of a [methyl-
2
H3]-L-carnitine tracer in the current 
study enabled a more direct estimation of muscle carnitine uptake. The average rate 
of forearm carnitine disappearance throughout the CON trial was ~63 nmol·min
-1
, 
which equates to 6.3 µmol·kg·hr
-1
. In good agreement with this, compartmental 
modelling of intravenously administered L-[methyl-
3
H]carnitine kinetics estimated 
basal rates of muscle carnitine uptake to be 11.6 µmol·kg·hr
-1 
(Rebouche et al., 
1984). In general, Rd data was highly variable between individuals and despite a 5-
fold greater Rd observed in CHO over CON, differences did not reach statistical 
significance when compared across trials. Interestingly however, peak Rd during 
CHO coincided with peak serum insulin concentrations (t=100 minutes).  
Furthermore, venous tracer dilution (MPEA-V) was only observed during CHO, 
consistent with the proposed mechanism of action that skeletal muscle carnitine 
uptake can be augmented via an insulin-mediated increase in OCTN2 activity. It 
could also be argued that the increase in NCB during CHO above CON was due to a 
nutrient-mediated increase in tissue perfusion, as forearm plasma flow was greater 
following CHO compared to CON ingestion. However, carnitine fractional 
extraction, which does not depend on plasma flow, was also elevated following 
CHO. Furthermore, whilst plasma flow was similarly elevated above CON following 
PRO, no change in NCB or fractional extraction was observed with PRO. Taken 
together, the increase in NCB observed with CHO cannot be explained, at least not 
exclusively, by an increased carnitine delivery to the muscle.  
 
Protein antagonises insulin-mediated net muscle carnitine uptake  
A principle aim of the current study was to determine whether the insulin response to 
40 g carbohydrate plus 40 g protein (PRO) would be sufficient to promote the same 
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increase in whole-body carnitine retention as that observed with CHO alone. The 
relationship between serum insulin concentration and muscle carnitine uptake is not 
unambiguous, but based on previous studies from our group it seems likely that a 
serum insulin threshold for stimulating muscle carnitine uptake exists somewhere 
between 50 and 70 mU∙L-1 (Stephens et al., 2007a; Stephens et al., 2007b). Over the 
six hour study visit, the serum insulin response during PRO was lower than CHO, 
largely as a result of diminished serum insulin concentrations following the second 
and third drinks. The blunted insulin response observed after repeated PRO ingestion 
could perhaps be related to the fact that subjects had been fasting for ~10 hours prior 
to ingesting the first drink. Although the overall insulin response to PRO was lower 
than to CHO, peak serum insulin concentrations following the first drink were 
comparable and hence it seems reasonable to expect that the insulin response to PRO 
would be sufficient to increase muscle carnitine uptake above CON.  
 
As discussed for CHO, it was impossible to discern from study A whether whole-
body carnitine retention following PRO was enhanced over CON. However, study B 
demonstrated that whilst CHO was able to promote a positive net carnitine balance, 
PRO appeared to have no effect on muscle NCB. This was surprising as the serum 
insulin AUC in study B was no different between CHO and PRO. Indeed, the initial 
insulin response between 60-120 minutes, the time period over which CHO 
promoted a positive NCB, was almost identical between CHO and PRO. This would 
suggest that the insulin-mediated increase in NCB promoted by CHO was somehow 
inhibited by PRO. This is supported by the finding that the rate of carnitine 
disappearance following PRO was not significantly different to zero. This would 
appear to be the first study has to report evidence of an inhibitory effect of whey 
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protein or amino acids on muscle carnitine accumulation and the prospective 
mechanism is unclear. However, it would seem likely that the absence of a positive 
NCB following PRO be due to an inhibition of OCTN2-mediated carnitine uptake, 
as no alternative mechanisms appear operative to facilitate skeletal muscle carnitine 
accumulation. This is supported by the finding that defects within the OCTN2 gene 
in patients suffering from primary carnitine deficiency can reduce skeletal muscle 
carnitine concentrations to less than 1% of normal values (Treem et al., 1988). 
Transport of carnitine by OCTN2 is known to be inhibited by several xenobiotics 
including steroidal, zwitterionic and organic cationic compounds, as well as carnitine 
derivatives such as D-carnitine and acylcarnitines of various chain lengths (Ohashi et 
al., 1999; Wu et al., 1999; Tamai et al., 2000). In contrast, endogenous compounds, 
including the amino acids leucine, lysine and arginine, do not appear to influence 
basal OCTN2-mediated carnitine transport (Ohashi et al., 1999; Kobayashi et al., 
2005), at least at the concentrations tested (500 µM). However, this does not 
necessarily rule out a role for amino acids in antagonising the insulin-stimulated up-
regulation of OCTN2 carnitine transport. Similarly to carnitine, the sodium-
dependent co-transport of amino acids in skeletal muscle occurs against a steep 
transport gradient and is augmented by hyperinsulinemia (Shotwell et al., 1983). 
Moreover, Bonadonna et al. (1993) demonstrated that the insulin-mediated increase 
in forearm amino acid uptake is associated with a reversal in net forearm potassium 
balance, implicating the stimulation of Na
+
/K
+
-ATPase activity as a putative 
mechanism. Based on values reported for OCTN2 (Tamai et al., 2000) and the Na
+
-
dependent amino acid transport systems (Jacquez, 1973; Chen & Russell, 1989), 
transport of both carnitine and amino acids would appear to share an affinity for 
sodium in the same order of magnitude (1-5 mM).  Whether the extracellular amino 
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acid concentrations following PRO were sufficient to effectively out-compete 
OCTN2 for sodium is unknown, but seems plausible given that plasma amino acid 
availability was likely several-fold higher than that of carnitine.  
 
It cannot be discounted that our measurement of net carnitine balance in PRO was 
violated by the very rapid rise in plasma carnitine concentrations, providing a non-
steady state condition during the period of greatest serum insulin concentrations. 
However, correcting the venous carnitine concentrations for the expected transit time 
through the forearm (Cobelli et al., 1989; Tessari et al., 1991) did not influence the 
relative differences in net carnitine balance or Rd between trials. Indeed, when using 
an arteriovenous difference model, rapid increases in plasma substrate concentrations 
between two time points are more likely to lead to an overestimation of substrate 
uptake over that period.  
 
Effects of macronutrient co-ingestion on L-carnitine absorption 
The plasma total carnitine pool following L-carnitine ingestion can be considered as 
a function of intestinal absorption and carnitine clearance, with the latter influenced 
by urinary carnitine excretion and tissue carnitine uptake (likely primarily into 
muscle). The reported Km for intestinal carnitine transport is approximately 560 
µmol∙L-1 (Hamilton et al., 1986) and it has been demonstrated that the absolute 
bioavailability of a 6 g oral bolus (~300 mg) of L-carnitine is no greater than that of 
a 2 g bolus (~320 mg; Harper et al., 1988). Thus it was expected that a 3 g dose of L-
carnitine, which would likely increase jejunal carnitine concentrations to 
approximately 19,000 µmol∙L-1 (Li et al., 1992), would saturate intestinal active 
carnitine transport and thus evoke maximal and equivalent carnitine absorption 
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during all trials. However, the divergent responses in plasma carnitine and urinary 
carnitine excretion, when considered together with the calculated differences in net 
forearm carnitine balance indicate that carnitine absorption was not comparable 
across CON, CHO and PRO.  
 
Plasma carnitine responses in CON were very similar between study A and B, 
increasing from an average basal value of 43 µmol∙L-1 to a three hour peak of 67 
µmol∙L-1. Urinary carnitine excretion after three (study B), six and 24 hours in CON 
represented 1.5, 3.6 and 8.0% of the oral dose, respectively. This is in very good 
agreement with other studies that have reported 24 hour urinary carnitine excretions 
of 7-8% from a similar oral bolus (Harper et al., 1988; Stephens et al., 2007b). 
Consistent with the dose-dependent renal elimination rates of intravenously 
administered boluses of L-carnitine (Harper et al., 1988), we also observed a strong 
positive correlation between plasma carnitine AUC and six hour urinary carnitine 
excretion. This also likely reflects the rapid saturation of tubular reabsorption 
following elevation of plasma carnitine concentration. Based on an approximate 
bioavailability of 16% for oral L-carnitine of this dose size (Harper et al., 1988) it 
can be predicted that around 480 mg of L-carnitine would have been absorbed in the 
CON trial, with half of this excreted in the urine within 24 hours. Carbohydrate 
feeding in study A increased 24 hour urinary carnitine excretion to 11% of the 
ingested L-carnitine dose, such that it was 93 mg greater than in CON. Based on the 
greater NCB found with CHO in study B, it can be assumed that muscle carnitine 
uptake would also have been greater in CHO over the six hour study A. Thus, 
increased urinary carnitine excretion following CHO, in the face of greater muscle 
carnitine uptake, relative to CON, would imply that intestinal carnitine absorption 
 109 
 
was greater with CHO. Our calculation of insulin-stimulated whole-body muscle 
carnitine retention (63 mg) would suggest that at least 150 mg more carnitine was 
absorbed during CHO than CON trials. This figure likely represents a conservative 
estimate, given that CHO was fed more frequently in study A and thus insulin-
stimulated muscle carnitine uptake may have been even greater.   
 
Why contrasting results on urinary carnitine excretion were evident in the previous 
acute carbohydrate-L-carnitine feeding study (Stephens et al., 2007b) may be due to 
modifications of the treatment drinks consumed. The main difference between this 
study and the aforementioned study is that the current study utilised Vitargo, a very 
high-molecular weight carbohydrate (500,000-700,000 g·mol
-1
) compared to the 
lower molecular weight glucose-syrup (~500 g mol
-1
) used previously. Vitargo has 
previously been shown to increase gastric emptying by 120% (Leiper et al., 2000) in 
the 10 minute post-ingestion period, as well as both increase and accelerate the post-
ingestion rises in blood glucose and serum insulin (Stephens et al., 2008), compared 
to a low molecular weight solution. Secondly, the Vitargo solution has a very low 
osmolality (<50 mOsmol·L
-1
), which could also be expected to increase fluid 
absorption in the duodenum segment relative to a glucose-syrup formulation (Gisolfi 
et al., 1998). A greater gastric emptying following both CHO and PRO would be 
expected to increase L-carnitine delivery to the small intestine which, along with a 
potentially greater fluid absorption, could be expected to increase L-carnitine 
absorption by facilitating greater passive diffusion (Li et al., 1992).  Thus, the 
sustained elevation of plasma carnitine concentrations in CHO relative to CON in 
study A could reflect a progressive increase in L-carnitine absorption following 
repeated CHO ingestion. It should also be noted that macronutrient availability per 
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se could modulate intestinal transport activity for L-carnitine, by increasing total 
solute flux over that observed with CON (Gisolfi et al., 1998).  
 
The addition of whey protein appeared to further influence the pharmacokinetics of 
L-carnitine. Across both studies, the average rate of increase in plasma carnitine 
concentration over the first hour following PRO ingestion was approximately 0.5 
µmol·L
-1
·min
-1
, which was around 3-fold faster than following CON or CHO 
ingestion (~0.17 µmol·L
-1
·min
-1
 for both). Peak plasma carnitine concentration 
during PRO was also 20-30% greater than CON or CHO trials, and occurred 
consistently earlier. As discussed above, it is possible that the inclusion of a high-
molecular weight carbohydrate in PRO promoted an increased rate of gastric 
emptying, which could potentially explain differences between CON and PRO 
plasma TC concentrations. The question remains as to whether the differences in 
plasma and urinary TC concentrations between PRO and CHO can be explained 
purely by the additional differences in tissue uptake. Based on an average plasma 
volume of 3.25 L, the plasma carnitine compartment at three hours was increased by 
79 and 32 µmols (13 and 5 mg) above baseline in CHO and PRO trials, respectively. 
Urinary carnitine excretion was 45 mg and 92 mg, respectively. Thus it follows that 
the estimated difference in whole body muscle carnitine uptake (~ 92 mg) more than 
compensates for the difference in plasma and urinary carnitine values. It should be 
noted that measurements of net carnitine balance were particularly variable during 
the PRO trial and, as such, these extrapolations should be viewed with caution. 
Indeed, if the differences in plasma carnitine concentrations between CHO and PRO 
were purely due to a greater muscle carnitine uptake in CHO, one might expect the 
arteriovenous difference in CHO to be far greater than what was observed here. 
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Independent effects of whey protein ingestion without carbohydrate on L-carnitine 
absorption cannot therefore be ruled out, and would be plausible given the primary 
sources of dietary carnitine (red meat, fish, dairy products) are foodstuffs rich in 
amino acids. Why then, the uptake of carnitine by skeletal muscle would be inhibited 
by compounds it is habitually co-ingested with is somewhat perplexing. Perhaps this 
may serve to preserve plasma carnitine concentrations during postprandial periods, 
when serum insulin concentrations would be elevated, which would in fact be 
entirely consistent with the stability and slow turnover of the muscle carnitine pool. 
 
Conclusions 
The novel application of an arteriovenous forearm balance model with oral 
2
H3-L-
carnitine tracer methodology is this study confirmed the efficacy of a carbohydrate 
beverage in promoting muscle carnitine accretion when co-ingested with an L-
carnitine bolus. A relatively large bolus of whey protein (40 g), with 40 g 
carbohydrate, appeared to blunt this stimulation of net muscle carnitine uptake, 
despite stimulating comparable insulin secretion and intestinal carnitine absorption 
to 80 g carbohydrate alone. These studies also suggest, for the first time, that 
macronutrients co-ingested with L-carnitine may alter its pharmacokinetic properties 
which should facilitate further developments of strategies used to increase skeletal 
muscle carnitine content.  
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CHAPTER 4: SKELETAL MUSCLE CARNITINE 
METABOLISM, PDC FLUX AND NON-
MITOCHONDRIAL ATP PRODUCTION DURING 
SINGLE-LEG KNEE EXTENSION AND REPEATED-
BOUT CYCLING EXERCISE  
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4.1 Introduction 
Skeletal muscle acetylcarnitine concentrations reflect the balance between pyruvate-
derived acetyl-group production from the PDC and condensation with oxaloacetate 
by citrate synthase. Therefore, the accumulation of acetylcarnitine during exercise 
can be considered as being indicative of an imbalance between PDC flux and TCA 
cycle flux. As discussed in the General Introduction, acetylcarnitine accumulation 
is readily observable during the first 5 - 10 minutes of submaximal exercise above a 
relative intensity of approximately 50% VO2max, with acetylcarnitine concentrations 
reportedly stabilising as the exercise continues (Sahlin et al., 1990; Constantin-
Teodosiu et al., 1992). This plateau in acetylcarnitine concentrations would suggest 
that a steady-state is reached, at which point PDC and TCA cycle fluxes can be 
assumed to be well matched. In a previous study from our lab, it was demonstrated 
that increasing skeletal muscle total carnitine content over a 24 week period was 
associated with a suppression of PDC flux during 30 minutes of cycling exercise at 
50% VO2max, as evidenced by a lower rate of glycogen utilisation, PDCa and 
acetylcarnitine accumulation (Wall et al., 2011). These findings were consistent with 
the role of carnitine in CPT1-mediated fat oxidation under conditions when PDC 
flux is relatively moderate and not limiting to TCA cycle flux. Intriguingly, when the 
exercise was continued for 30 minutes at 80% VO2max, the increase in muscle 
carnitine availability facilitated a greater PDC flux, as reflected by an increase in 
PDCa and acetylcarnitine accumulation. Moreover, this carnitine-mediated increase 
in PDC flux was associated with a reduced reliance on non-mitochondrial ATP 
production, resulting from a lower rate of PCr degradation and a diversion of 
glycogenolysis away from lactate accumulation. These findings would suggest that 
carnitine availability is somehow limiting to PDC flux during continuous high 
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intensity exercise. Moreover, a sparing of PCr and lower muscle lactate 
accumulation at the same absolute workload implies that the increase in PDC flux 
was able to facilitate a greater contribution from oxidative ATP production, which 
also suggests that PDC flux could be limiting to TCA cycle flux under these exercise 
conditions.  
 
In contrast to the proposition that PDC flux may limit TCA cycle flux during 
exercise, Gibala and colleagues (1998) have reported that estimations of TCA cycle 
flux actually exceed PDC flux. Based on values of leg oxygen uptake, it was 
determined that TCA cycle flux was approximately 30% greater than PDCa at a 
workload of 60% Wmax and remained 10% greater at 100% Wmax. Thus, if 
acetylcarnitine does reflect the imbalance between PDC and TCA flux during 5-10 
min of exercise, then under these conditions one might expect its accumulation to be 
negligible. However, neither acetylcarnitine nor glycolytic flux were determined in 
this study and hence inferences about intermediary skeletal muscle metabolism 
upstream of the TCA cycle cannot be made. Moreover, this study utilised a single-
leg knee extension model where, unlike two-legged cycling, mitochondrial ATP 
production would not appear to be limited by muscle oxygen delivery (Andersen & 
Saltin, 1985; Boushel et al., 2011). Previously, Jorn Helge and colleagues from the 
University of Copenhagen have performed a study to interrogate leg substrate 
metabolism during single-leg knee extension at 55% and 85% Wmax (Stallknecht et 
al., 2007). They kindly allowed us to perform further analysis on the muscle samples 
obtained which provided an opportunity to further investigate skeletal muscle 
acetylcarnitine metabolism as an indication of the integration between PDC and 
TCA cycle fluxes, in a single-leg model using comparable relative workloads to 
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those previously employed by Wall et al. (2011) for two-legged cycling (i.e. 50% 
and 80% Wmax).  
 
Another scenario that can provide valuable insight into the matching of PDC and 
TCA cycle fluxes is during two repeated bouts of high-intensity, submaximal 
exercise, where the workload can be maintained constant across both bouts. Under 
these conditions, it is proposed that oxidative ATP delivery and thus, TCA cycle 
flux, will be greater in the second bout of exercise (Bangsbo et al., 2001), possibly as 
a result of a greater PDC flux during this second bout (Putman et al., 1995). Indeed, 
a study from Bangsbo and colleagues (2001) found that leg VO2, an indication of 
TCA cycle flux, during two 3 minute bouts of single-leg knee extension exercise at 
100% Wmax (~66 watts) was greater during the second bout, whilst reciprocally, the 
average rate of non-mitochondrial ATP production was approximately 33% lower. 
During a single high-intensity, three minute exercise bout, it is unlikely that 
acetylcarnitine concentrations would reach a steady-state and thus the imbalance 
between PDC flux and TCA cycle flux would be exemplified (Timmons et al., 
1998b). Furthermore, if reliance on non-mitochondrial ATP production is indeed 
lessened during a subsequent exercise bout, one would expect acetylcarnitine 
accumulation to also be lower compared to the initial exercise bout. Indeed, although 
acetylcarnitine accumulation or PDCa were not determined in the study by Bangsbo 
et al. (2001), PDCa has been demonstrated to be maximal after 3 min of contraction 
in this model (Bangsbo et al., 2002). However, as discussed above, it is possible that 
the restrictions to oxidative ATP production differ between the single-leg knee 
extension and two-legged cycling exercise models and no study has previously 
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determined acetylcarnitine metabolism and non-mitochondrial ATP delivery during 
repeated bouts of two-legged cycling exercise at this fixed workload (100% Wmax). 
 
The overall aim of the current studies was to assess acetylcarnitine accumulation and 
non-mitochondrial ATP delivery during exercise paradigms where TCA cycle flux is 
reportedly higher than PDC flux, thus further characterising the balance between 
PDC flux and oxidative ATP production. This is important if L-carnitine 
supplementation is to be used to enhance athletic performance or improve the 
efficacy of exercise prescription in populations where oxidative ATP production may 
be impaired (see General Introduction).  In study A it was hypothesised that, in 
line with the reported excess of TCA flux relative to PDC flux (Gibala et al., 1998) 
and in contrast to two-legged cycling (Wall et al., 2011), acetylcarnitine 
accumulation and non-mitochondrial ATP production during single-legged knee 
extension would be negligible at both 55% and 85% Wmax. In study B, it was 
proposed that acetylcarnitine accumulation and non-mitochondrial ATP production 
would both decline during a second bout of high-intensity two-legged cycling 
exercise, when TCA cycle flux is purportedly accelerated (Bangsbo et al., 2001) 
relative to a first bout at the same fixed workload (100% Wmax). 
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4.2 Methods 
4.2.1 Study A 
Volunteers 
Following a routine screening and written consent (see General Methods), ten 
healthy male volunteers (age 26 ± 2 years, BMI 24.5 ± 0.8 kg·m
-2
, VO2max 50 ± 2 
ml·kg-1·min-1) completed the exercise protocol approved by the Ethics Committee for 
Medical Research in Copenhagen (Stallknecht et al., 2007). A complete data set of 
muscle biopsies was available for a subset of eight of these volunteers. 
 
Experimental protocol 
Volunteers completed the single experimental visit following a 12 hour (overnight) 
fast and having abstained from vigorous physical activity, caffeine or alcohol for 2 
days prior to the visit. Following a 30 minute rest period, volunteers completed two 
30 minute single-leg knee extension exercise bouts at 55 and 85% of their previously 
determined maximal kicking power (Wmax; Anderson and Saltin, 1985), separated by 
a 30 minute rest interval (Figure 4.1). The second exercise bout was performed on 
the contralateral leg to the first bout, with the order of the legs determined by 
randomisation. In accordance with the objectives of the larger trial that this study 
formed a part of, a third exercise bout was completed at 25% Wmax prior to the 
exercise at 55% Wmax, using the same leg as was recruited for the exercise at 85% 
Wmax. Furthermore, the exercise at 55% Wmax was continued for an extra 90 minutes 
following the initial 30 minute bout. This meant that following the initial exercise 
bout at 25% Wmax, there was a three hour recovery period before the commencement  
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Fidure 4.1 Schematic outlining the protocol for Study 2A. Volunteers completed two single-leg knee extension exercise bouts at 55 and 85% 
Wmax, respectively,  separated by a 30 minute recovery period. Muscle biopsies (arrows) were obtained after 30 minutes of each exercise bout. 
Dotted lines indicate extension of the 55% Wmax exercise bout (see text for details).  
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of the final exercise bout at 85% Wmax with the ipsilateral leg and thus it was 
assumed that any influence of the initial low-intensity exercise bout on skeletal 
muscle metabolism during this latter bout  would be minimal.  
 
Sample collection and analysis 
Muscle biopsies were obtained immediately before and after each exercise bout and 
frozen rapidly (10-15 seconds) in liquid nitrogen for the determination of ATP, 
phosphocreatine, lactate, glycogen, carnitine and acetylcarnitine concentrations (see 
General Methods). Data collection for study A was completed at the University of 
Copenhagen (Stallknecht et al., 2007) and metabolite analysis was carried out at the 
University of Nottingham. 
 
4.2.2 Study B 
Volunteers 
Seven healthy, non-vegetarian male volunteers (mean ± SD age 23 ± 4 years; BMI 
23.6 ± 2.0 kg·m
-2
; VO2max 48.0 ± 6.0 ml·kg
-1
·min
-1
) were recruited to participate in 
study B, which was approved by the University of Nottingham Medical School 
Ethics Committee. Prior to the study, each participant attended a routine medical 
screening (see General Methods). 
 
Experimental protocol 
Volunteers attended the lab 2-3 times prior to the main experimental visit to 
determine the exercise workload (Wmax) corresponding to the attainment of maximal 
oxygen uptake (see General Methods) and to ensure that they were fully 
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familiarised with the exercise protocol. On the day of the main experimental visit, 
volunteers arrived at the laboratory at approximately 8.30 am following an overnight 
fast and having abstained from alcohol, caffeine or strenuous exercise for 48 hours. 
Following a 30 minute period of supine rest, a muscle biopsy was obtained from one 
leg and volunteers completed a brief warm-up period (3 minutes at 25% Wmax) on 
the cycle ergometer. It has previously been shown that neither acetyl-CoA nor 
acetylcarnitine concentrations are altered by either one minute of cycling at 35% 
VO2max (Howlett et al., 1998) or three minutes at 30% VO2max (Constantin-Teodosiu 
et al., 1991). Volunteers subsequently cycled for three minutes at their pre-
determined 100% Wmax workload and, upon cessation of exercise, a second biopsy 
was immediately obtained from the same leg as the first. Volunteers then rested for 
five minutes before completing a second three minute bout of exercise at the same 
absolute workload, with further biopsies obtained from the contralateral leg 
immediately before and after the second bout (Figure 4.2). The order of the biopsies 
was randomised between legs, but the biopsied leg was kept consistent within bouts.  
 
Sampling and analysis 
Muscle biopsies were rapidly (~10 seconds) frozen in liquid nitrogen-cooled 
isopentane and a portion (approximately 50 mg ww) was freeze-dried for the 
determination of metabolites. A second portion (10-20 mg ww) was used for the 
determination of PDC activation status. 
 
Statistics 
Muscle metabolite concentrations for both studies were compared using a two-way 
ANOVA (intensity or bout x time) and any significant main effects were isolated 
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Figure 4.2 Schematic outlining the protocol for study 2B. Volunteers completed two 3 minute bouts of cycle ergometer exercise at 100% 
VO2max, separated by a five minute passive recovery period. Muscle biopsies (arrows) were obtained before and after each exercise bout. 
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post-hoc using paired t-tests with Bonferoni stepwise correction for multiple 
comparisons. Delta values for metabolites (PCr degradation, lactate accumulation, 
glycogen utilisation, acetylcarnitine accumulation or non-mitochondrial ATP 
production) were compared between exercise intensities using paired t-tests. Data are 
presented as mean ± standard error. 
 
4.3 Results 
4.3.1 Study A 
Skeletal muscle ATP, PCr, lactate and glycogen 
The concentrations of muscle metabolites before and after each exercise bout are 
shown in Table 4.1. Resting levels of ATP and PCr were no different between legs 
and remained unchanged throughout exercise. Lactate was also unchanged during 
exercise at 55% Wmax and although it increased slightly during exercise at 85% Wmax 
(P<0.05), lactate accumulation was no different between the two exercise workloads 
(2.6 ± 0.9 and 6.2 ± 2.2 mmol·kg dw
-1
 for 55 and 85%, respectively). Muscle 
glycogen utilisation was not significant during exercise at 55% Wmax and as such, the 
pre-exercise glycogen content for each leg was similar. As shown in Figure 4.3 
however, muscle glycogenolysis at 85% Wmax was 3-fold greater than at 55% Wmax 
(116.7 ± 41.2 vs 39.3 ± 13.9 mmol·kg dw
-1
, respectively; P<0.01). The total non-
mitochondrial ATP production during each exercise bout is shown in Figure 4.4 and 
was similar between exercise at 55% and 85% Wmax (0.9 ± 5.9 and 15.0 ± 5.0 
mmol·kg dw
-1
, respectively; P=0.13).   
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Table 4.1 Skeletal muscle metabolite concentrations  before and after two 30 minute bouts of single-leg knee extension exercise at 55 or 85% 
Wmax. Data are presented as mean ± SE for 8 subjects in mmol·kg dw
-1
. 
a 
Main effect of time, 
b 
main effect of intensity, 
c 
interaction effect for 2-
Way ANOVA. * P<0.05, ** P<0.01, ***P<0.001 vs PRE of same bout; † P<0.05 vs POST 55% Wmax. 
 
55% Wmax  85% Wmax 
PRE POST  PRE POST 
ATP 26.3 ± 0.8 26.6 ± 1.0  26.1 ± 0.6 26.3 ± 0.7 
PCr 83.7 ± 2.3 86.1 ± 2.1  85.7 ± 2.4 79.5 ± 3.9 
Lactate
a
   4.1 ± 0.4   6.7 ± 1.5    4.2 ± 0.6   10.4 ± 1.8* 
Glycogen
a,c
 403 ± 34 363 ± 37  423 ± 39      308 ± 29*** 
Carnitine
a,b
 18.9 ± 1.0   14.6 ± 1.2*  17.3 ± 1.0      10.6 ± 1.0**† 
Acetylcarnitine
a
   0.8 ± 0.2     6.1 ± 1.9*    2.3 ± 0.8      8.1 ± 1.8** 
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Figure 4.3 Skeletal muscle glycogen utilisation (Δ glycogen) during 30 minutes of 
single-leg knee extension exercise at 55% (black bar) or 85% (white bar) Wmax. Data 
are presented as mean ± SE for 8 subjects in mmol·kg dw
-1
. **P<0.01 vs 55% Wmax 
for paired t-test analysis. 
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Figure 4.4 Net skeletal muscle ATP production from non-mitochondrial sources 
(black bars), comprising ATP (striped bars), PCr (white bars) and lactate (dotted 
bars) during 30 minutes of single-leg knee extension exercise at 55% or 85% Wmax. 
Data are presented as mean ± SE for 8 subjects in mmol·kg dw
-1
. Total non-
mitochondrial ATP production was no different between workloads (P=0.13; paired 
t-test). Negative values imply net ATP or PCr resynthesis from oxidative 
metabolism. 
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Skeletal muscle carnitine metabolism 
Free carnitine concentrations declined from similar resting values by approximately 
23% (P<0.05) and 39% (P<0.01) during exercise at 55% and 85% Wmax, 
respectively. Although post-exercise free carnitine availability was lower (P<0.05) 
following exercise at 85% Wmax compared to 55% Wmax (Table 4.1), the absolute 
decline in free carnitine availability during exercise was no different between 
workloads (4.3 ± 1.5 and 6.8 ± 2.4 mmol·kg dw
-1
 at 55 and 85%, respectively; 
P=0.23). Reciprocally, acetylcarnitine concentrations increased during both exercise 
workloads, with acetylcarnitine accumulation equivocal between exercise at 55% 
and 85% Wmax (5.3 ± 1.9 and 5.8 ± 2.0 mmol·kg dw
-1
, respectively; P=0.80; Figure 
4.5).
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Figure 4.5 Skeletal muscle acetylcarnitine accumulation (Δ acetylcarnitine) during 
30 minutes of single-leg knee extension exercise at 55% (black bar) or 85% (white 
bar) Wmax. Data are presented as mean ± SE for 8 subjects in mmol·kg dw
-1
. 
Acetylcarnitine accumulation was no different between workloads (P=0.80; paired t-
test). 
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4.3.2 Study B 
Skeletal muscle ATP and PCr  
Skeletal muscle metabolite concentrations before and after each exercise bout are 
shown in Table 4.2. ATP concentrations tended to decrease 11% (P=0.09) during 
the first bout of exercise and declined (P<0.05) by a similar amount (16%) in the 
second bout of exercise. During bout one, PCr decreased to 64% of its resting value 
and was completely resynthesized over the recovery period such that the pre-exercise 
values were identical for each bout. During bout two, PCr declined (P<0.001) to 
26% of the pre-bout value with PCr degradation being 2-fold greater (P<0.05) during 
bout two (60.9 ± 7.7 mmol·kg dw
-1
) compared to bout one (29.3 ± 9.0 mmol·kg    
dw
-1
; Figure 4.6). 
 
Lactate accumulation and glycogenolysis 
There were main effects of exercise (P<0.01) and bout (P<0.001) on muscle lactate 
concentration, with lactate increasing significantly (P<0.05) during bout one and 
tending (P=0.05) to remain elevated at the start of bout 2. Lactate increased (P<0.05) 
by a similar amount during bout two such that there was no difference in lactate 
accumulation between bouts (50.3 ± 19.8 and 59.3 ± 4.9 mmol·kg dw
-1
 for bouts 1 
and 2, respectively; Figure 4.7). Glycogen content declined during both exercise 
bouts (main effect of exercise P<0.001), although glycogenolysis tended (P=0.11) to 
be 2.1-fold greater during bout two (99.4 ± 17.9 mmol·kg dw
-1
) compared to bout 
one (54.4 ± 13.7 mmol·kg dw
-1
;
 
Figure 4.8).  
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Table 4.2 Skeletal muscle metabolite concentrations before and after two 3 minute bouts of cycling exercise at 100% Wmax separated by 5 
minutes of passive recovery. Data are presented as mean ± SE for 7 subjects in mmol·kg dw
-1
. 
a 
Main effect of time, 
b 
main effect of bout, 
c 
interaction effect for 2-Way ANOVA. * P<0.05, ** P<0.01, ***P<0.001 vs PRE of same bout; † P<0.05, †† P<0.01 vs POST bout one. 
 
Bout 1  Bout 2 
PRE POST  PRE POST 
ATP
a
 27.9 ± 1.2 24.8 ± 1.4  26.3 ± 1.5 22.2 ± 1.7* 
PCr
a,b,c
 82.4 ± 3.6   53.1 ± 9.5*
 
   82.1 ± 2.9†        21.1 ± 6.2***†† 
Lactate
a,b
   6.5 ± 1.5    56.8 ± 18.9*    44.3 ± 12.3   103.6 ± 13.1*† 
Glycogen
a,b
 403.8 ± 43.3 351.9 ± 48.2  373.2 ± 55.8    265.0 ± 54.9**† 
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Figure 4.6 Skeletal muscle phosphocreatine degradation (Δ PCr) during two 3 
minute bouts of cycling exercise at 100% Wmax separated by 5 minutes of passive 
recovery. Data are presented as mean ± SE for 7 subjects in mmol·kg dw
-1
. * P<0.05 
versus bout one (paired t-test). 
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Figure 4.7 Skeletal muscle lactate accumulation (Δ lactate) during two 3 minute 
bouts of cycling exercise at 100% Wmax separated by 5 minutes of passive recovery. 
Data are presented as mean ± SE for 7 subjects in mmol·kg dw
-1
. Lactate 
accumulation degradation was not significantly different between the two exercise 
bouts (P=0.68 for paired t-test). 
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Figure 4.8 Skeletal muscle glycogen utilisation (Δ glycogen) during two 3 minute 
bouts of cycling exercise at 100% Wmax separated by 5 minutes of passive recovery. 
Data are presented as mean ± SE for 7 subjects in mmol·kg dw
-1
. Glycogen 
degradation was not significantly different between the two exercise bouts (P=0.11 
for paired t-test). 
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Skeletal muscle carnitine metabolism 
Resting acetylcarnitine concentration was 4.0 ± 1.4 mmol·kg dw
-1
, increasing to 9.3 
± 2.0 and 12.5 ± 1.0 mmol·kg dw
-1 
following bout one and bout two, respectively 
(main effect of exercise; P<0.001; Figure 4.9). Acetylcarnitine was unchanged 
during the recovery period such that concentrations before the start of bout two (8.3 
± 2.1 mmol·kg dw
-1
) tended to be 2.1-fold greater than at rest (P=0.10) whilst the 
absolute accumulation was similar between bout one and bout two (5.3 ± 2.1 vs 4.2 ± 
1.5 mmol·kg dw
-1
). Free carnitine concentration was 15.9 ± 1.1 mmol·kg dw
-1 
at rest 
and mirrored the changes in acetylcarnitine, with free carnitine tending to decline 
during bout one (33%; P=0.12) and bout two (41%; P=0.13). Free carnitine 
remained unchanged during the recovery period (Figure 4.9). 
 
Pyruvate dehydrogenase complex activation status 
Shown in Figure 4.10, PDCa tended to increase 3.2-fold (P=0.06) during bout one, 
from a resting value of 3.6 ± 0.9 to 11.5 ± 2.6 nmol·mg protein
-1
·min
-1
, before 
returning to basal values prior to the start of bout two (4.4 ± 1.0 nmol·mg protein
-
1
·min
-1
). During bout two, PDCa increased 5-fold (P<0.05) to a value of 15.5 ± 3.1 
nmol·mg protein
-1
·min
-1
. 
 
Non-mitochondrial ATP production 
The calculated non-mitochondrial ATP production was not significantly different 
(P=0.29) between bouts, despite a 42% increase in the second bout (110.9 ± 40.3 vs 
158.0 ± 14.4 mmol ATP·kg dw
-1
 for bouts one and two, respectively; Figure 4.11). 
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Figure 4.9 Skeletal muscle free carnitine (white circles) and acetylcarnitine (black 
circles) concentrations before and after two 3 minute bouts of cycling exercise at 
100% Wmax separated by 5 minutes of passive recovery. Data are presented as mean 
± SE for 7 subjects in mmol·kg dw
-1
. Main effects of exercise (P<0.001) and bout 
(P<0.01) for two-way ANOVA were observed for both free carnitine and 
acetylcarnitine concentrations. 
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Figure 4.10 Activation status of the pyruvate dehydrogenase complex in skeletal 
muscle before and after two 3 minute bouts of cycling exercise at 100% Wmax 
separated by 5 minutes of passive recovery. Black bars show bout 1 response; white 
bars show bout 2 response. Data are presented as mean ± SE for 7 subjects in nmol 
acetyl-CoA·mg protein
-1
·min
-1
. Main effects of exercise (P<0.001) for two-way 
ANOVA. * P<0.05 vs pre-bout value. 
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Figure 4.11 Skeletal muscle ATP production from non-mitochondrial sources, 
comprising ATP (striped bars), PCr (white bars) and lactate (dotted bars) during two 
3 minute bouts of cycling exercise at 100% Wmax, separated by 5 minutes of passive 
recovery. Data are mean ± SE for 7 subjects. *P<0.05 vs bout 1 for PCr. Total non-
mitochondrial ATP production was not significantly different between the two 
exercise bouts (P=0.29 for paired t-test).  
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4.4 Discussion 
The current studies were performed to provide further insight into the interplay 
between PDC and TCA cycle fluxes by determining acetylcarnitine accumulation 
and non-mitochondrial ATP production under different exercise conditions, where 
the demand and capacity for oxidative ATP production may vary. The results 
demonstrate that acetylcarnitine accumulation and non-mitochondrial ATP 
production during single-leg knee extension exercise are considerably lower than the 
equivalent values reported for two-legged cycling exercise at comparable relative 
workloads. Secondly, non-mitochondrial ATP production is increased during a 
second bout of high-intensity cycling exercise in the face of similar acetylcarnitine 
accumulation which, in contrast to repeated bouts of single-leg knee extension 
exercise, would suggest that both PDC and TCA cycle flux decline during a second 
bout when the workload is fixed. The rates of acetylcarnitine accumulation and non-
mitochondrial ATP production across these various exercise paradigms are 
illustrative of the relative matching between glycolytic, PDC and TCA cycle fluxes 
and, as will be discussed, are consistent with the proposal that free carnitine 
availability can dictate PDC flux and hence influence oxidative ATP provision 
during high-intensity exercise. 
 
Single-leg knee extension at 55 and 85% Wmax 
During two-legged cycling, Wall et al. (2011) reported a near doubling of 
acetylcarnitine accumulation when the exercise intensity was increased from 50% to 
80% VO2max. As a consequence of this elevation in skeletal muscle acetylcarnitine 
content (~17 mmol·kg dw
-1
 at 80% VO2max), free carnitine availability was reduced 
to an extent that it likely became limiting to further increases in PDC flux, as 
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evidenced by the near doubling of non-mitochondrial ATP production at 80% 
compared to 50% VO2max. In accordance with this, increasing skeletal muscle 
carnitine availability enhances PDC flux and reduces reliance on non-mitochondrial 
ATP production during exercise at 80% VO2max (Wall et al., 2011). In contrast, in 
study A, acetylcarnitine accumulation was similar at 55% and 85% Wmax and thus 
acetylcarnitine content following the latter bout was only 8.1 mmol·kg dw
-1
, less 
than half that measured by Wall and colleagues (2011). Although glycogen 
utilisation was 3-fold greater at 85% Wmax
 
compared to 55% Wmax, lactate 
accumulation remained relatively low (only 6.2 mmol·kg dw
-1
) and PCr degradation 
was similarly negligible. As a result, reliance on non-mitochondrial ATP production 
at 85% Wmax was substantially lower than the values reported by Wall et al. (2011) 
at 80% VO2max, suggesting a better matching of glycolytic, PDC and TCA cycle 
fluxes during single-leg knee extension exercise compared to two-legged cycling. 
These findings are consistent with the greater oxygen uptake per unit of muscle mass 
recruited during single-leg knee extension exercise (Boushel & Saltin, 2013) as well 
perhaps, as the lower catecholamine response and hence lower adrenergic 
stimulation of vasoconstriction and glycolysis (Greenhaff et al., 1991), compared to 
two-legged cycling. Indeed, it has previously been argued that TCA cycle flux 
exceeds PDC flux during moderate to intense knee extension exercise (Gibala et al., 
1998) and thus, acetylcarnitine accumulation under these conditions would be 
somewhat paradoxical.  
 
Although the calculation of TCA cycle flux by Gibala and colleagues assumed that 
mitochondrial ATP production was supported entirely by carbohydrate oxidation, the 
discrepancy between PDC and TCA cycle fluxes would actually suggest additional 
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acetyl-group provision independent from the PDC, likely from non-carbohydrate 
substrates.  Indeed, the absolute rates of leg fat oxidation observed during study A 
were substantial and actually increased from 55% to 85% Wmax (see Appendix 3.2). 
In this respect, another consequence of extensive acetylation of the total carnitine 
pool during high-intensity exercise (70% in the study by Wall et al., 2011) is the 
expected restriction on CPT-mediated fatty acid oxidation (Stephens et al., 2013). 
Thus, the lower acetylcarnitine accumulation in study A is a likely mechanism to 
explain why fat oxidation is preserved at higher relative exercise intensities during 
single-leg knee extension (Helge et al., 2007) compared to two-legged cycling. 
Nevertheless, it is difficult to relate acetylcarnitine accumulation to an increase in 
PDC flux when the rate of β-oxidation is increasing in parallel. However, it is known 
that carbohydrate oxidation is more rapidly activated than fat oxidation at the onset 
of exercise and thus PDC flux likely delivers the majority of mitochondrial acetyl-
groups during the initial minutes of exercise. As such, the 5-6 mmol·kg dw
-1
 
acetylcarnitine accumulation that occurred in both bouts of study B could still reflect 
an imbalance between PDC flux and TCA cycle flux during this initial period, while 
leg oxygen uptake and TCA cycle flux were still rising. If it is assumed that 
measurements made after 30 minutes of exercise represent the steady-state 
acetylcarnitine concentration, under these conditions it would seem equally 
appropriate to view acetylcarnitine accumulation as simply the expansion of the 
mitochondrial acetyl-group pool associated with the moderate increase in PDC flux. 
Moreover, when a significant proportion of acetyl-groups entering the TCA cycle are 
provided from the β-oxidation of fatty acids, TCA cycle flux is unlikely to be limited 
by PDC flux. On the contrary, the refinement of PDC flux to acetyl-group demand 
when glycolytic flux is relatively low is illustrated by the finding that the 
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augmentation of fat oxidation in response to skeletal muscle carnitine loading 
(Stephens et al., 2013) was previously associated with an approximately 30% 
reduction in both PDCa and acetylcarnitine accumulation (Wall et al., 2011). 
 
Repeated bouts of high-intensity cycling exercise  
The rate of acetylcarnitine accumulation of 1.8 mmol·kg dw
-1
·min
-1
 during bout one 
of study B was similar to that generally reported over the initial minutes of cycling 
exercise at intensities between 75-90% VO2max (~2.2 mmol·kg dw
-1
·min
-1
; see figure 
1.5 in General Introduction) and coincided with a 3.2-fold increase in the 
activation of the PDC. During the five minute passive recovery period, 
acetylcarnitine concentrations remained relatively stable whilst PDCa returned to 
resting values. Based on the findings of Bangsbo and colleagues (2001), it was 
hypothesised that acetylcarnitine accumulation would be lower during a second bout 
of exercise. However, acetylcarnitine concentrations in the subsequent bout actually 
increased by a comparable amount (from an elevated pre-bout value), such that the 
post-exercise free carnitine concentration was approximately 34% lower compared 
to the first bout. Therefore, given the apparently lower rate of mitochondrial ATP 
provision in the face of similar acetylcarnitine accumulation, PDC flux was 
presumably lower during the second bout of exercise. Thus it can be proposed that, 
despite a similar PDC activation, the continued decline of free carnitine availability 
during the second bout of exercise restricted PDC flux and consequently limited the 
contribution from the TCA cycle to total ATP production.  
 
Previous studies have suggested that during repeated bouts of high-intensity 
exercise, non-mitochondrial ATP delivery is reduced (Putman et al., 1995; Bangsbo 
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et al., 2001) and VO2 kinetics are accelerated in the second bout relative to the first 
(Putman et al., 1995; Bangsbo et al., 2001; Campbell-O'Sullivan et al., 2002). For 
example, during two 3 minute bouts of single-leg knee extension exercise at 100% 
thigh VO2peak, Bangsbo and colleagues (2001) reported that the combined ATP 
production from PCr degradation and lactate accumulation decreased from 175 
mmol ATP·kg dw
-1 
during the first bout, to 135 mmol ATP·kg dw
-1 
in the second 
bout. In contrast, in study B non-mitochondrial ATP production was no lower during 
the second bout of exercise and, if anything, averaged 42% higher values. The latter 
was primarily accounted for by an approximately 2-fold greater PCr degradation 
during the second bout of exercise relative to the first. PCr resynthesis relies heavily 
on oxidative ATP provision via the mitochondrial creatine kinase shuttle (Perry et 
al., 2012) and thus the extent of PCr degradation, which has been shown to reach a 
steady-state within two minutes of high-intensity exercise (Karlsson & Saltin, 1970), 
can be considered a very sensitive marker of mitochondrial ATP delivery. In 
addition to the increase in PCr degradation, muscle glycogen utilisation tended to be 
2.1-fold greater during the second exercise bout. If it is assumed firstly, that the total 
ATP demand of contraction was similar for each bout (the external workload was 
fixed) and secondly, that the intensity and duration of the exercise precluded any 
significant contribution from fat oxidation (see General Introduction), this increase 
in glycogen utilisation would suggest a greater reliance on anaerobic glycolysis. 
Whilst muscle lactate accumulation was no greater during the second bout, the rate 
of muscle lactate efflux was not determined and so it is plausible that total lactate 
production increased in parallel with glycogen utilisation. Thus although the 
difference in non-mitochondrial ATP production between bouts was not significant 
in study B, the increased PCr degradation and glycogen utilisation strongly suggest 
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that mitochondrial ATP provision was compromised during the second exercise 
bout.  
 
The opposing results obtained from study B and the study from Bangsbo and 
colleagues (2001), which both used a protocol involving two 3 minute exercise bouts 
at 100% Wmax separated by a similar recovery period, are probably attributable to the 
previously discussed differences between single-leg knee extension and two-legged 
cycling exercise.  In particular, the restricted blood flow per unit muscle mass during 
exercise involving a large muscle mass, such as cycling, is likely to limit oxidative 
ATP delivery to a greater extent than during exercise involving a smaller mass 
(Boushel et al., 2011). Therefore pulmonary oxygen kinetics, which are known to be 
accelerated during a second exercise bout (Campbell-O'Sullivan et al., 2002), may 
be a more primary determinant of mitochondrial ATP production during single-leg 
knee extension exercise. Nevertheless, previous studies using two-legged cycling 
protocols have reported a reduced reliance on non-mitochondrial ATP production 
during a second exercise bout. For example, Putman et al. (1995) provided evidence 
to suggest that PDC flux and mitochondrial ATP production increased progressively 
over three 30 second maximal effort cycle sprints. However, the total work 
performed (and thus contraction intensity) declined by 17% and 24% in the second 
and third bout, respectively, relative to the first. Moreover, the protocol employed by 
Putman and colleagues (1995) did not enable complete PCr resynthesis between 
exercise bouts resulting in a 12% and 19% reduction in pre-bout PCr availability 
before the second and third bout, respectively. Thus the demand and capacity for 
non-mitochondrial ATP production would have been reduced progressively over 
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each sprint, whilst it was maintained constant by the fixed workload and complete 
PCr resynthesis in the current study B.  
 
It should be noted that most previous protocols investigating skeletal muscle 
metabolism during repeated bout exercise do not include a warm-up period. In the 
current study we chose to include a warm-up period to better reflect the nature of a 
practical exercise session. It has previously been demonstrated that a 10 minute 
exercise bout at 55% VO2max accelerates oxygen uptake kinetics and reduces non-
mitochondrial ATP production by 89% over the first minute of a subsequent bout at 
75% VO2max, compared to when no prior low-intensity exercise is performed 
(Campbell-O'Sullivan et al., 2002). Thus it is possible that previous reports of 
increased oxidative ATP delivery during repeated exercise bouts are attributable to 
the “warm-up” effect of the first exercise bout. Conversely, the current protocol 
removed this effect by ensuring that subjects were already warmed-up prior to the 
start of the first bout and thus enabled us to investigate the true differences between 
first and second bouts. Interestingly, in the study by Campbell-O'Sullivan et al. 
(2002) non-mitochondrial ATP production for the remaining nine minutes of the 
bout at 75% VO2max was actually 96% greater in the prior-exercise condition such 
that, if anything, it was 11% greater over the entire 10 minute bout. Thus, whilst 
prior exercise appeared to accelerate PDC and TCA cycle flux at the start of a 
second bout, it did not ultimately favourably impact upon the total oxidative ATP 
production over the entire bout.  
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Conclusions 
In conclusion, these studies principally emphasise the differences between the 
metabolic responses to single-leg knee extension exercise and two-legged cycling 
exercise, but also demonstrate the consistency in the relationship between 
acetylcarnitine metabolism and oxidative ATP provision across both exercise 
modalities. During single-leg knee extension, the ATP demand of contraction can be 
met almost entirely by mitochondrial ATP delivery up to a workload of at least 85% 
Wmax and thus muscle PCr degradation and lactate accumulation are much lower 
than during two-legged cycling at comparable relative intensities. Similarly, the 
relatively low levels of acetylcarnitine accumulation likely reflect the moderate 
increase in PDC flux during the initial minutes of exercise and the subsequently mild 
expansion of the mitochondrial acetyl-group pool. In comparison, during a single 
three minute bout of high-intensity cycling exercise, which elicits a substantially 
higher ATP demand, non-mitochondrial ATP production provides a much greater 
proportion of total ATP production. In this situation, acetylcarnitine accumulation 
reflects an immediate imbalance of PDC and TCA cycle flux, as it would appear no 
other pathways can significantly contribute to the mitochondrial acetyl-group pool. 
This situation is exacerbated further in a second bout of exercise, where 
acetylcarnitine accumulation continues to the extent that free carnitine availability 
would appear to become limiting to PDC flux and reliance on non-mitochondrial 
ATP production must increase. In this respect, increasing free carnitine availability 
to enhance PDC flux may represent a targetable approach to improve exercise 
performance during repeated bouts of high-intensity submaximal cycling. 
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CHAPTER 5: MANIPULATING SKELETAL MUSCLE 
CARNITINE CONTENT: METABOLIC ADAPTATIONS 
TO SUBMAXIMAL HIGH-INTENSITY 
INTERMITTENT EXERCISE TRAINING AND 
CONSEQUENCES FOR EXERCISE PERFORMANCE 
 146 
 
5.1 Introduction 
The transfer of pyruvate-derived acetyl-groups to free carnitine prevents excessive 
acetyl-CoA accumulation and thus maintains a viable mitochondrial pool of CoASH 
in the face of accelerated flux through PDC, for example during high-intensity 
cycling exercise. The utility of this acetylation of the free carnitine pool during 
exercise is exemplified by the study of Wall et al. (2011), in which an increase in 
muscle total carnitine content was associated with increased PDCa and 
acetylcarnitine accumulation during continuous exercise at 80% VO2max and a 
subsequent decrease in PCr degradation and lactate accumulation. As highlighted by 
the findings in Chapter 4, this carnitine-mediated enhancement of PDC flux and 
subsequent reduction in non-mitochondrial ATP production could become 
particularly pertinent during a second bout of exercise, where PDC flux would 
appear to decline in concert with free carnitine availability. Assuming that, under 
these conditions, a similar alteration of metabolic flux is obtainable following 
skeletal muscle carnitine loading, it is plausible that this could influence the 
adaptations to a chronic period of exercise training. For example, Wall et al. (2011) 
found that in addition to the metabolic alterations noted above, subjects were able to 
complete more work in an all-out work performance test in the carnitine-loaded 
state. If reproduced over multiple training sessions, this enhanced work output could 
reasonably be expected to provide a greater stimulus for metabolic and/or functional 
adaptations to the exercise. 
 
Exercise training is known to elicit improvements in exercise performance and 
capacity, which at the whole body level is reflected by increases in maximal power 
output, VO2max and exercise endurance (Holloszy et al., 1977).  The metabolic 
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adaptations that underpin these functional improvements are also well characterised, 
such as an increased reliance on oxidative ATP delivery and reciprocal reductions in 
phosphocreatine degradation, lactate accumulation and glycogen utilisation 
(Vollaard et al., 2009). A lower requirement for non-mitochondrial ATP production 
would suggest a better matching of mitochondrial, PDC and glycolytic fluxes during 
exercise. In agreement with this, Vollaard et al. (2009) found that the accumulation 
of both lactate and acetylcarnitine within skeletal muscle during a 10 minute exercise 
bout at 70% VO2max was reduced following their six week endurance training 
protocol. In another study, PDC activation and acetylcarnitine accumulation during 
15 minutes of exercise at ~80% VO2max were reduced following seven weeks of 
exercise training (Leblanc et al., 2004). It seems intuitive to expect that similar 
adaptations to training are manifest during more intense exercise, where there is a 
greater mismatch between glycolytic and mitochondrial substrate fluxes. Indeed, the 
recently popularised HIT (high-intensity interval training) type exercise paradigm 
has been shown to elicit many adaptations classically thought to be primarily 
associated with endurance-type training (ET) paradigms. For example, Burgomaster 
et al. (2008) demonstrated that both HIT and ET facilitated comparable reductions in 
PCr degradation and glycogen utilisation during exercise following training, despite 
marked differences in the overall training volume completed. Although studies 
utilising HIT have typically employed maximal sprint efforts, it has also been shown 
that training sessions consisting of 8-12 one minute bouts of cycling exercise at 
100% Wmax (submaximal) are sufficient to induce robust increases in markers of 
skeletal muscle oxidative capacity over a two week period, as well as enhance 
exercise performance (50 and 750 kJ time trial) and resting muscle glycogen content  
(Little et al., 2010).  Hence this type of submaximal HIT paradigm has been 
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proposed as a viable time-efficient strategy to improve health and fitness (Gillen & 
Gibala, 2013) in an increasingly sedentary population, when a “lack of time” is 
frequently cited as one of the major perceived barriers to physical activity (Trost et 
al., 2002).  
 
The overall premise of the current study is that the previously reported effects of 
skeletal muscle carnitine loading will alter the metabolic and functional adaptations 
to a 24 week period of submaximal HIT. At present, daily L-carnitine and 
carbohydrate feeding is the only known efficacious dietary strategy to increase the 
muscle carnitine stores over a 12-24 week period (Wall et al., 2011). As discussed in 
the General Introduction, the carbohydrate load associated with the current L-
carnitine supplementation protocol may have a negative impact upon body 
composition (Wall et al., 2011), hence the efforts to reduce the carbohydrate 
requirement of L-carnitine supplementation in Chapter 3 of this thesis.  However, it 
would appear that replacement of some of this carbohydrate with whey protein may 
interfere with the insulin-mediated stimulation of muscle carnitine accretion (see 
Chapter 3) and thus, the previously validated use of a twice-daily L-carnitine and 
carbohydrate formulation likely still represents the most appropriate approach to 
increase muscle carnitine content in healthy volunteers. It is therefore also important 
to assess whether the differential treatment effects on body fat mass observed by 
Wall et al. (2011) are abated in the current intervention, as periods of structured 
exercise training are known to impact positively upon body composition (Nordby et 
al., 2012).  It was hypothesised that manipulation of muscle carnitine content with 
daily L-carnitine and carbohydrate feeding would alter metabolic flux during 
repeated bouts of exercise at 100% Wmax (reduced PCr degradation and lactate 
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accumulation), particularly during a second bout, when PDC flux would appear to 
decline. Secondly, it was proposed that any carnitine-mediated reduction in non-
mitochondrial ATP production during exercise would enable a greater amount of 
work to be completed over progressive training sessions and thus augment the 
training-induced gains in exercise capacity (VO2max, Wattmax and cycling efficiency), 
performance (work output) and body composition. 
 
5.2 Methods 
Volunteers 
Fourteen healthy, non-vegetarian male volunteers (mean ± SE age 23.2 ± 1.1 years; 
BMI 24.4 ± 0.9 kg·m
-2
; VO2max 41.6 ± 2.1 ml·kg
-1
·min
-1
) were recruited to 
participate in this study, which was approved by the University of Nottingham 
Medical School Ethics Committee. Prior to the study, each participant gave informed 
consent to take part and attended a routine medical screening (see General 
Methods). 
 
Experimental protocol 
The overall study protocol is depicted in Figure 5.1. Prior to the baseline study visit, 
volunteers completed a VO2max assessment, confirmation visit and were familiarised 
with the exercise protocol (see General Methods). On the study day (Figure 5.2), 
volunteers arrived at approximately 8.30 am following an overnight fast and 
underwent a full body DEXA scan to determine total body, fat and lean mass and a 
blood sample was taken for the determination of plasma total carnitine concentration. 
A resting muscle biopsy was obtained and the proceeding acute exercise protocol 
was identical to that described in study 2B (See Chapter 4). This study day was 
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repeated following 24 weeks of exercise training and supplementation (see below), 
with VO2max and Wmax re-assessed after 4, 8, 12, 18 and 24 weeks to monitor 
improvements in fitness. Mechanical cycling efficiency at Wmax was also determined 
at 0, 12 and 24 weeks (see General Methods). Plasma carnitine was measured every 
six weeks to assess systemic carnitine availability and confirm compliance to the 
supplementation protocol. In addition, a resting biopsy and DEXA scan were 
obtained at 12 weeks to monitor any progressive impact of the intervention on total 
muscle carnitine and body composition, respectively.  
 
Training protocol 
Volunteers trained three times per week (normally Monday, Wednesday and Friday) 
over a 24 week period and were required to complete >85% of all training sessions 
for inclusion in the final data set. All training sessions were supervised and involved 
a three minute warm-up at 25% Wmax followed by 3 x 3 minute exercise bouts at 
100% Wmax and a fourth bout to exhaustion, each separated by five minute passive 
recovery periods. During the final bout of each training session, volunteers received 
standardised verbal encouragement to exercise as long as they could (typically less 
than six minutes). The absolute training workload was adjusted, in line with the 
reassessment of Wmax at regular intervals (see Figure 5.1), to maintain a constant 
relative intensity of 100% Wmax. Additionally, when volunteers were able to exercise 
for six minutes in the final bout during more than two consecutive training sessions, 
the workload was increased by a further 1% for the subsequent training session. Thus 
the training paradigm was designed to maximise work output, in every progressive 
training session. 
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Figure 5.1 Schematic showing the experimental study protocol. Fourteen healthy, male volunteers were randomised into either CON (n=7) or 
CARN (n=7). *The first three exercise bouts lasted three minutes, the fourth bout was open-ended to allow exercise until exhaustion but 
generally lasted 0-6 minutes. † The dotted arrow indicates that only a DEXA scan and resting biopsy was obtained at 12 weeks.  
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Figure 5.2 Schematic showing the protocol for study visits, completed at 0 and 24 weeks.  
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Supplementation protocol 
Volunteers were assigned to receive twice-daily beverages of either carbohydrate 
alone (80 g maltodextrin; Maldex 180, SYRAL Belgium) or 80 g carbohydrate plus 
3 g L-carnitine tartrate (1.5 g L-carnitine; Nutramet, UK) in a randomised, double-
blinded fashion. The exact formulation utilised by Wall et al. (2011) was not 
available for use in the current study, but the quantities of L-carnitine and 
carbohydrate provided by Nutramet were identical to those used previously.  Drinks 
were made up in 500 ml cold water from sachets of powder and were matched for 
flavour, appearance and carbohydrate type. Volunteers were instructed to consume 
one beverage first thing in the morning, and the second beverage four hours later to 
maximise the time period over which plasma carnitine and serum insulin 
concentrations were simultaneously elevated (Wall et al., 2011 and Chapter 3).  
 
Sampling and analysis 
Plasma from samples taken at 0, 6, 12, 18 and 24 weeks were analysed for total 
carnitine. Skeletal muscle free, acetyl, acyl and total carnitine, as well as ATP, PCr, 
lactate, glycogen and PDCa were determined in biopsy samples at 0 and 24 weeks. 
Skeletal muscle total carnitine was additionally determined at 12 weeks (see 
General Methods).  
 
Statistics 
Data were compared using two-way ANOVA for the effect of training (exercise x 
time) for each group and treatment (group x time) for each biopsy condition with 
Bonferoni-corrected t-test post-hoc analysis (see General Methods). Data are 
presented as mean ± SE. 
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5.3 Results 
5.3.1 Plasma and muscle total carnitine  
Plasma total carnitine concentrations at baseline were similar between CON and 
CHO (42.8 ± 2.4 and 40.8 ± 1.4 µmol·L
-1
) and remained stable in CON throughout 
the 24 week intervention period. However, following six weeks, plasma carnitine 
concentrations in CARN were elevated above both CON and baseline, remaining 
approximately 24% greater than CON for the duration of the intervention (Figure 
5.3). Skeletal muscle total carnitine content, shown in Figure 5.4, was no different 
between groups at baseline but an interaction effect (group x time; P<0.05) occurred, 
such that total carnitine was decreased after 12 weeks (P<0.05 vs 0 weeks) in CON, 
but not CARN. After 24 weeks, total carnitine content in CON was no different from 
12 weeks or 0 weeks, whilst the change from baseline in muscle carnitine was 
significantly greater in CARN compared to CON (1.5 ± 0.7 vs -0.9 ± 0.6 mmol·kg 
dw
-1
; P<0.05).  
 
5.3.2 Skeletal muscle metabolites 
Carnitine metabolism and PDCa 
The effect of training on skeletal muscle free carnitine concentrations during 
exercise is shown in Figure 5.5 for both CON and CARN. In the CON group, 
training appeared to attenuate the exercise-induced decline in free carnitine, but only 
during bout two (ΔFC = 4.5 ± 1.4 and 1.4 ± 1.3 mmol·kg dw-1 at 0 and 24 weeks, 
respectively; P=0.09). As such, CON free carnitine at the end of bout two tended to 
be 40% higher at 24 weeks compared to baseline (P=0.07). 
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Figure 5.3 Plasma total carnitine concentrations at 0, 6, 12, 18 and 24 weeks of 
exercise training, receiving twice daily drinks of either 80 g carbohydrate (CON; 
black circles) or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN; white 
circles). Values are mean ± SE for 7 subjects. 2-way ANOVA (group x time): 
††P<0.01, ††† P<0.001 vs 0 weeks; ‡ P<0.05, ‡‡ P<0.01 vs CON. 
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Figure 5.4 Skeletal muscle total carnitine content at 0, 12 and 24 weeks of exercise 
training, receiving twice daily drinks of either 80 g carbohydrate (CON; black bars) 
or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN; white bars). Values are 
mean ± SE for 7 subjects. 2-way ANOVA (group x time): †P<0.05 vs 0 weeks.  
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In the CARN group, resting free carnitine availability was 31% greater than CON 
(P<0.05) after 24 weeks and, in contrast to CON, the decline in free carnitine during 
bout one was reduced with training (ΔFC = 5.2 ± 1.4 and 1.9 ± 1.1 mmol·kg dw-1 at 
0 and 24 weeks, respectively for CARN; P<0.05). This resulted in a 39% greater free 
carnitine content at the end of bout one in CARN compared to CON (P<0.05), which 
also represented a 35% increase from baseline (P<0.05). Free carnitine availability 
prior to the onset of the second bout remained 45% greater in CARN than CON 
(P<0.05) at 24 weeks, but was no different at the end of the second bout. Although 
not significant, the bout two decline in free carnitine at 24 weeks was 3.9-fold 
greater in CARN than CON (P=0.12). The changes in acetylcarnitine accumulation 
with training in CON mirrored the preservation of free carnitine observed in bout 
two, with acetylcarnitine concentrations tending to be 36% lower (P=0.06) at the end 
of bout two compared to baseline (see Table 5.1). Although no significant 
differences were observed between CON and CARN acetylcarnitine concentrations 
during exercise at either time-point, bout one acetylcarnitine accumulation was 
quantitatively 2.9-fold lower after training in CARN, compared to baseline (ΔAC = 
4.0 ± 1.8 and 1.2 ± 0.6 mmol·kg dw
-1 
at 0 and 24 weeks, respectively; P=0.18). 
Conversely, in bout two the percentage of the carnitine pool that was acetylated only 
increased in CARN (P<0.05) and not CON (P=0.9) at 24 weeks. There was no 
difference in PDCa between CON and CARN at either time-point and PDCa was not 
influenced by training in either group (Figure 5.6).  
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Figure 5.5 Skeletal muscle concentrations of free carnitine before and after two 3 
minute bouts of exercise at 100% Wmax, at baseline (left) and following 24 weeks  of 
exercise training (right) receiving twice daily drinks of either 80 g carbohydrate 
(CON; black circles) or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN; 
white circles). Values are mean ± SE for 7 subjects. 2-way ANOVA (exercise x 
time): †P<0.05 vs 0 weeks; (time x group): ‡P<0.05 vs CON. 
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Figure 5.6 Activation status of the pyruvate dehydrogenase complex before and after 
two 3 minute bouts of exercise at 100% Wmax, at baseline (left) and following 24 
weeks  of exercise training (right) receiving twice daily drinks of either 80 g 
carbohydrate (CON; black circles) or 80 g carbohydrate plus 1.5 g L-carnitine 
tartrate (CARN; white circles). Values are mean ± SE for 7 subjects expressed as a 
rate of acetyl-CoA production in nmol·mg protein
-1
·min
-1
.  
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Skeletal muscle ATP and PCr 
ATP concentrations during bout one were not influenced by training or 
supplementation, although the decline in ATP tended to be less after training across 
both groups (main effect of time P=0.08). ATP content at the end of bout two was no 
different after training in CON (P=0.16) but was 20% greater in CARN (P<0.05) 
compared to baseline. Resting skeletal muscle PCr concentrations were similar 
before and after training in both CON and CARN (Table 5.1). PCr degradation 
during bout one tended (P=0.07) to be reduced by training across both groups 
(Figure 5.7) but the post-bout PCr concentration was only increased in CARN 
(P<0.05), not CON (P=0.37), at 24 weeks compared to baseline.  In bout two, PCr 
degradation tended to be lower at 24 weeks in both CON (P=0.07) and CARN 
(P=0.09) compared to baseline such that the post-bout PCr concentrations were 
similarly increased above baseline in both groups (P<0.05). Once corrected for 
workload, bout one PCr degradation tended to be reduced at 24 weeks in CARN 
(P=0.08) but not CON (P=0.60), whilst bout two PCr degradation was lower in both 
groups (P<0.05), compared to 0 weeks (see Appendix 3.3).  
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Table 5.1 Skeletal muscle metabolites before and following 2 x 3 min bouts of exercise at 100% Wmax, before and after 24 weeks of exercise 
training receiving twice daily drinks of either 80 g carbohydrate (CON) or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN). Values are 
mean ± SE for 7 subjects. 2-way ANOVA (exercise x time): *P<0.05, *P<0.01, **P<0.001 vs PRE value of same bout; †P<0.05 vs 0 weeks. 
  BOUT ONE  BOUT TWO 
  PRE POST  PRE POST 
  CON CARN CON CARN  CON CARN CON CARN 
0 
ATP 25.6 ± 1.3 24.9 ± 0.9 23.5 ± 1.1 22.1 ± 1.7  24.2 ± 2.0 21.7 ± 1.4 20.0 ± 1.8 19.7 ± 1.2 
PCr 72.3 ± 4.0 74.7 ± 3.4   55.4 ± 7.2*   50.1 ± 7.7*  74.1 ± 3.9 73.4 ± 5.1     25.8 ± 7.3***     23.4 ± 3.6*** 
Lactate   4.5 ± 0.6   7.2 ± 1.7    39.0 ± 10.9*  51.2 ± 20.7**  15.8 ± 2.1 19.6 ± 7.3   91.3 ± 15.4***     83.9 ± 8.2*** 
Glycogen 378 ± 28 413 ± 20 318 ± 21 347 ± 15  399 ± 23 375 ± 31     243 ± 13**    264 ± 24** 
Acetylcarnitine   2.8 ± 0.7   2.3 ± 0.9   5.7 ± 1.2 6.4 ± 1.6    5.0 ± 1.0   5.3 ± 2.0    9.0  ± 0.6*    9.8 ± 1.1* 
24 
ATP 23.6 ± 1.5 24.0 ± 1.0 25.0 ± 1.1 24.2 ± 1.6  23.6 ± 1.1 23.8 ± 1.1 22.8 ± 1.1  23.6 ± 1.6
†
 
PCr 73.9 ± 3.8 78.1 ± 3.2 65.5 ± 5.7 70.8 ± 5.3
†
  77.6 ± 1.9 78.5 ± 4.1   49.1 ± 7.2***
†
    48.9 ± 9.2***
†
 
Lactate   8.0 ± 2.4   6.7 ± 1.5 23.0 ± 7.3 16.7 ± 6.1
†
  23.0 ± 3.1 20.0 ± 4.5    50.2 ± 9.7*
†
     53.6 ± 11.7*
†
 
Glycogen     567 ± 33
†††
     570 ± 46
†††
     501 ± 32
†††
 536 ± 40
†††
   516 ± 48
†
     532 ± 44
†††
     462 ± 55
†††
    479 ± 55
†††
 
Acetylcarnitine   2.9 ± 0.7   2.8 ± 0.7   4.9 ± 1.2 4.0 ± 0.7    4.2 ± 0.6   3.9 ± 0.9   5.7 ± 0.9   7.7 ± 1.9 
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Figure 5.7 Muscle phosphocreatine degradation during two 3 minute bouts of 
exercise at 100% Wmax, before and after 24 weeks of exercise training receiving 
twice daily drinks of either 80 g carbohydrate (CON; black bars) or 80 g 
carbohydrate plus 1.5 g L-carnitine tartrate (CARN; white bars). Values are mean ± 
SE for 7 subjects. 2-way ANOVA (time x group): ††P<0.01 vs 0 weeks. 
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Muscle lactate accumulation and glycogen utilisation 
Muscle lactate concentrations were no different between CON and CARN at any 
time-point (Table 5.1). However, muscle lactate accumulation (Figure 5.8) during 
bout one tended to be 77% lower at 24 weeks in CARN (P=0.08) compared to 0 
weeks, but showed no tendency to change in CON (P=0.39). These differences 
remained after correcting for workload, with bout one lactate accumulation tending 
to be lower in CARN (P=0.05) but not CON (P=0.35) after training. As such, the 
post-bout lactate tended to be lower in CARN (P=0.06) but not CON (P=0.57), 
compared to baseline. Conversely, lactate accumulation during bout two was 64% 
lower after training in CON (P<0.05), but not significantly different in CARN, 
despite a 48% reduction (P=0.14), although the latter tended towards significance 
after correcting for workload (P=0.08 for CARN, 24 vs 0 weeks; see Appendix 3.4).  
 
The resting muscle glycogen content was increased at 24 weeks by 50% (P<0.01) 
and 38% (P<0.05) in CON and CARN, respectively, compared to 0 weeks. 
Glycogen utilisation during bout one was not influenced by training in either group 
(Figure 5.9) and accordingly, the post-bout muscle glycogen content was greater at 
24 weeks in both groups (P<0.01) compared to baseline. During bout two, muscle 
glycogen utilisation at 24 weeks was 65 and 53% lower in CON and CARN, 
respectively, though this difference was only significant for CON (P<0.05). 
Nevertheless, the muscle glycogen remaining after bout two was 90 and 81% greater 
in CON and CARN, respectively, at 24 weeks compared to baseline (P<0.01). 
Workload correction had no impact on the pattern of glycogen utilisation in either 
group. 
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Figure 5.8 Muscle lactate accumulation during two 3 minute bouts of exercise at 
100% Wmax, before and after 24 weeks of exercise training receiving twice daily 
drinks of either 80 g carbohydrate (CON; black bars) or 80 g carbohydrate plus 1.5 g 
L-carnitine tartrate (CARN; white bars). Values are mean ± SE for 7 subjects. 2-way 
ANOVA (time x group): †P<0.05 vs 0 weeks. 
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Figure 5.9 Muscle glycogen degradation during two 3 minute bouts of exercise at 
100% Wmax, before and after 24 weeks of exercise training receiving twice daily 
drinks of either 80 g carbohydrate (CON; black bars) or 80 g carbohydrate plus 1.5 g 
L-carnitine tartrate (CARN; white bars). Values are mean ± SE for 7 subjects. 2-way 
ANOVA (time x group): *P<0.05 vs 0 weeks. 
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Non-mitochondrial ATP production 
The calculated ATP production from non-mitochondrial sources was similar at 
baseline between CON and CARN in bout one (72.9 ± 23.1 and 96.2 ± 38.8 
mmol·kg dw
-1
, respectively) and bout two (169.9 ± 30.9 and 150.3 ± 15.2 mmol·kg 
dw
-1
, respectively).  Following 24 weeks of exercise training, non-mitochondrial 
ATP production during bout one had fallen by 61 and 77% in CON and CARN, 
respectively (Figure 5.10A), though this reduction only tended to be significant in 
CARN (P=0.07) and not CON (P=0.32). In bout two, training reduced non-
mitochondrial ATP production in both CON (P<0.01) and CARN (P<0.05) by a 
similar amount (Figure 5.10B). All differences in non-mitochondrial ATP 
production persisted after correction for workload. 
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Figure 5.10 Non-mitochondrial ATP production determined from the change in 
muscle ATP (black bars), PCr (white bars) and lactate (spotted bars) during a first 
(A) and second (B) 3 minute bout of exercise at 100% Wmax, before and after 24 
weeks of exercise training receiving twice daily drinks of either 80 g carbohydrate 
(CON; black bars) or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN; white 
bars). Values are mean ± SE for 7 subjects. †P<0.05, ††P<0.01 vs 0 weeks for total 
non-mitochondrial ATP production. 
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5.3.3 Whole body adaptations 
VO2max and Wattmax 
Baseline VO2max was 3.12 ± 0.29 and 3.16 ± 0.24 L·min
-1
 in CON and CARN, 
respectively and was increased in both groups (P<0.01) after 8 weeks of training, to 
3.36 ± 0.34 and 3.39 ± 0.20 L·min
-1
, respectively. No further increases in VO2max 
occurred after 8 weeks, although values remained elevated above baseline in both 
CON (3.34 ± 0.31, 3.41 ± 0.32 and 3.47 ± 0.30 L·min
-1
, P<0.01) and CARN (3.40 ± 
0.20, 3.34 ± 0.18 and 3.40 ± 0.16, P<0.001) at 12, 18 and 24 weeks, respectively. 
When normalised to body weight, the improvement in VO2max did not reach 
significance until 24 weeks, increasing from 41.3 ± 3.1 to 45.2 ± 3.2 ml·kg-1·min-1 in 
CON and from 42.0 ± 2.9 to 44.5 ± 2.1 ml·kg-1·min-1 in CON (P<0.05). The 
percentage change from baseline in absolute VO2max was no different between CON 
and CARN at any time point over the 24 week training period (Figure 5.11). Wmax 
was similar at baseline in CON and CARN (206 ± 24 and 208 ± 24 watts, 
respectively) and was increased by a similar amount in both groups at 8 weeks (233 
± 25 and 235 ± 20 watts, respectively), with no further increases occurring at 12 (232 
± 24 and 239 ± 20), 18 (239 ± 26 and 238 ± 18) or 24 weeks (232 ± 23 and 243 ± 18 
watts, respectively). Normalising Wmax to body weight or lean mass did not influence  
statistical differences with respect to either training or group. 
 
Mechanical efficiency 
Mechanical efficiency at Wmax was no different between groups at baseline (19.2 ± 
0.7 and 19.3 ± 0.9% in CON and CARN, respectively) and was unchanged over 24 
weeks in CON (Figure 5.12). However, mechanical efficiency in CARN increased 
to 20.8 ± 0.8% after 12 weeks (P<0.05) and remained elevated after 24 weeks (21.2  
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Figure 5.11 Percentage change in maximal oxygen uptake (VO2max) at baseline and 
at 4, 8, 12, 18 and 24 weeks exercise training, receiving twice daily drinks of either 
80 g carbohydrate (CON; black circles) or 80 g carbohydrate plus 1.5 g L-carnitine 
tartrate (CARN; white circles). Values are mean ± SE for 7 subjects. 2-way ANOVA 
(time x group): †P<0.05, ††P<0.01, †††P<0.001 vs 0 weeks. 
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± 0.6%; P<0.01), such that the change from baseline at 24 weeks was greater in 
CARN than CON (1.9 ± 0.8 and -0.2 ± 0.7%, respectively; P<0.05).   
 
Work output 
The work completed during the training sessions increased from baseline values of 
153 ± 24 and 166 ± 18 kJ to 8 week values of 189 ± 24 and 196 ± 20 kJ in CON 
(P<0.01) and CARN (P<0.05), respectively.  Work output remained elevated in 
CON (187 ± 27, 191 ± 24 and 195 ± 25 kJ) and CARN (202 ± 19, 192 ± 18 and 196 
± 19 kJ) at 12, 18 and 24 weeks, respectively but no further increases occurred after 
8 weeks in either group. The percentage improvement from baseline is shown in 
Figure 5.13 and was no different between CON and CARN at any time point. 
 
Body composition 
Total body mass was no different between CON and CARN at baseline (75.2 ± 3.6 
and 76.3 ± 5.9 kg, respectively), 12 weeks (75.9 ± 3.3 and 77.8 ± 6.1 kg, 
respectively) or 24 weeks (76.7 ± 3.4 and 77.6 ± 5.9 kg, respectively). Lean body 
mass was similar in CON and CARN at baseline (55.3 ± 3.6 and 55.8 ± 3.4 kg, 
respectively) and increased by a small amount in CON at 12 (56.0 ± 3.8 kg; P=0.09) 
and 24 (56.5 ± 3.4 kg; P<0.01) weeks. The 1.2 kg increase in lean body mass over 
24 weeks in CON was primarily due to a 0.9 kg increase (P<0.05) in lean trunk 
mass. Lean body mass in CARN did not change significantly after either 12 (56.0 ± 
3.4 kg; P=0.34) or 24 (56.5 ± 3.4 kg; P=0.12) weeks, although the overall change in 
lean mass at 24 weeks was no different between groups (Δlean mass = 1.2 ± 0.3 vs 
0.7 ± 0.2 kg in CON and CARN, respectively; P=0.15). Fat mass was similar  
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Figure 5.12 Mechanical efficiency at Wmax, determined as the percentage of VO2 
accounted for by mechanical work (see General Methods), at baseline and at 12, 
and 24 weeks exercise training, receiving twice daily drinks of either 80 g 
carbohydrate (CON; black bars) or 80 g carbohydrate plus 1.5 g L-carnitine tartrate 
(CARN; white bars). Values are mean ± SE for 7 subjects. 2-way ANOVA (time x 
group): †P<0.05, ††P<0.01, vs 0 weeks. 
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Figure 5.13 Work completed during training sessions at baseline and at 4, 8, 12, 18 
and 24 weeks exercise training, receiving twice daily drinks of either 80 g 
carbohydrate (CON; black circles) or 80 g carbohydrate plus 1.5 g L-carnitine 
tartrate (CARN; white circles). Values are mean ± SE for 7 subjects. 2-way ANOVA 
(time x group): †P<0.05, ††P<0.01, †††P<0.001 vs 0 weeks. 
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Figure 5.14 Total lean (black bars) and fat (white bars) mass at 0, 12 and 24 weeks 
of exercise training, receiving twice daily drinks of either 80 g carbohydrate (CON) 
or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN). Values are mean ± SE 
for 7 subjects. 2-way ANOVA (time x group): ††P<0.01 vs 0 weeks. 
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between groups and did not change over 12 or 24 weeks in either CON or CARN 
(Figure 5.14). 
 
5.4 Discussion 
The present study investigated the influence of a proven carnitine loading strategy on 
skeletal muscle carnitine stores during a chronic period of intense exercise training 
and evaluated its impact upon the metabolic and functional adaptations to this type 
of training paradigm. These data clearly demonstrate that daily L-carnitine and 
carbohydrate feeding completely prevented the 12% decline in skeletal muscle 
carnitine content associated with a 12 week period of submaximal HIT in healthy, 
untrained volunteers. This preservation of total muscle carnitine content enabled the 
better maintenance of free carnitine availability during repeated bouts of high-
intensity exercise, following 24 weeks of submaximal HIT. Interestingly, a trend 
towards a training-induced reduction in non-mitochondrial ATP production during 
an initial three minute bout of exercise at 100% Wmax was evident in CARN but not 
CON, which is consistent with carnitines role in the matching of glycolytic and 
mitochondrial fluxes. However, neither PCr degradation nor lactate accumulation 
was different between groups in the first or second exercise bout following 
submaximal HIT. Moreover, in line with this apparent inability of carnitine 
supplementation to influence substrate metabolism during repeated bouts of exercise 
beyond submaximal HIT alone, the gains in VO2max, Wmax and work performance 
were similar between groups. Taken together this would suggest that high-intensity 
repeated-bout exercise training per se, results in a better matching of PDC and TCA 
cycle flux during multiple bouts of exercise such that carnitine availability is not 
limiting to oxidative ATP production. Nevertheless, mechanical efficiency during 
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exercise at 100% Wmax was enhanced in the CARN group over 12 and 24 weeks of 
training, but not in CON.  
 
Muscle total carnitine content 
Limited data exist on the plasticity of the muscle carnitine stores during chronic 
periods of exercise training. Endurance-trained individuals purportedly have 
augmented levels of muscle total carnitine (Arenas et al., 1991), although the same 
study reported a somewhat paradoxical 6% reduction in muscle total carnitine in the 
same group of athletes following 120 days of structured endurance training. Two 
other studies have previously determined skeletal muscle carnitine concentrations 
following shorter controlled periods of structured exercise training. Following six 
weeks endurance training (45 minutes cycling at 70% VO2max, 4 times per week), the 
sum of the free and acetylcarnitine values reported by Vollaard et al. (2009) was 
11% lower than at baseline. The equivelent values reported by Leblanc et al. (2004) 
declined by approximately 19% over a seven week training period (60 minutes 
cycling at 75% VO2max, 5 times per week). Although direct statistical comparisons 
were not made in either study, these data would suggest that several weeks of 
exercise training could facilitate a decline in muscle carnitine content. In agreement 
with this, the current data demonstrate that in previously untrained volunteers, 
intense repeated-bout exercise training is associated with a 12% reduction in muscle 
total carnitine content over a 12 week period. However, this decline appeared to be 
transient, as muscle carnitine content was somewhat restored following 24 weeks of 
continued training. One possible explanation for this measured decline could relate 
to changes in whole-body lean mass, which increased linearly in the CON group 
over the duration of the 24 week intervention. An increase in lean mass, comprising 
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presumably of mainly skeletal muscle, would require an increase in whole-body 
carnitine retention (or endogenous synthesis) and muscle carnitine uptake to 
maintain skeletal muscle carnitine concentrations at the same level. Thus the 
reduction in muscle carnitine concentrations at 12 weeks may simply reflect the 
relatively slow transport of carnitine into skeletal muscle (Rebouche & Engel, 1984) 
in the face of a greater whole-body skeletal muscle mass. However, the gains in lean 
mass in the CON group were relatively modest (~1.3%) and are therefore perhaps 
insufficient to entirely explain the 12% reduction in muscle carnitine content. The 
decline in muscle carnitine content could also be related to alterations in fibre-type 
composition, as the stimulus provided from our exercise training intervention could 
conceivably result in a shift towards a more oxidative muscle phenotype in these 
previously untrained volunteers (Buller et al., 1960; Yan et al., 2011). Indeed, 
studies in rats have suggested that the total muscle carnitine content of the oxidative 
soleus muscle is somewhat lower that than of gastrocnemius muscle (mixed fibre 
type) or the primarily glycolytic muscles, extensor digitorum longus and tibialis 
anterior (Porter, 2012). Although human data would not appear to support the 
existence of fibre-type differences in total carnitine content (Constantin-Teodosiu et 
al., 1996), the influence of training on this relationship has not previously been 
tested. Finally, given the improved matching of PDC and TCA cycle fluxes 
following training, evidenced by lower acetylcarnitine accumulation at the same 
absolute workload (Vollaard et al., 2009), it could be argued that this type of training 
reduces the dependence on free carnitine availability during high-intensity exercise. 
Thus the decline in skeletal muscle carnitine content from 0 -12 weeks in the CON 
group could reflect an adaptation to a lower carnitine requirement over the period 
when gains in exercise performance (and thus presumably metabolic adaptations) 
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were greatest. Importantly, and consistent with the increase in muscle total carnitine 
content observed following 12 (Stephens et al., 2013) and 24 (Wall et al., 2011) 
weeks of L-carnitine and carbohydrate feeding, this same feeding strategy was able 
to prevent the decline in muscle carnitine content in the current study. As a result, 
the change in muscle carnitine from baseline to 24 weeks was greater in the CARN 
group than in the CON group, thus providing the opportunity to assess whether the 
manipulation of muscle carnitine availability could have influenced the adaptations 
to the repeated bout exercise training paradigm. 
 
Metabolic adaptations to training and carnitine 
Consistent with the previously reported impact of high-intensity repeated bout 
exercise upon mitochondrial oxidative capacity (Little et al., 2010), reliance on non-
mitochondrial ATP delivery was reduced at 24 weeks in the current study, regardless 
of group. This training effect is particularly notable when it is considered that both 
groups were exercising at an approximately 15% greater absolute workload during 
the post-training biopsy visit. Moreover, the reductions in bout one non-
mitochondrial ATP delivery at 24 weeks were only significant in the CARN treated 
group. Although not statistically different to CON values, bout one post-exercise PCr 
and lactate concentrations were only significantly elevated and supressed, 
respectively, at 24 weeks in the CARN group. That carnitine may have been able to 
accentuate the sparing of non-mitochondrial ATP delivery following 24 weeks is 
consistent with the 35% reduction in non-mitochondrial ATP production following 
24 weeks of skeletal muscle carnitine loading demonstrated by Wall et al. (2011) and 
implies that oxidative ATP provision during the first exercise bout was increased to a 
greater extent following training in CARN versus CON. Interestingly, the carnitine-
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mediated reduction in non-mitochondrial ATP delivery in the study by Wall et al. 
(2011) was paralleled by increases in PDCa and acetylcarnitine accumulation, 
whereas we observed no difference, or even lower PDCa and carnitine acetylation 
following training in the CARN group. Thus it could be speculated that during a 
single bout of high-intensity exercise, the combination of training and increased 
muscle carnitine availability facilitated an appropriately greater delivery of 
mitochondrial acetyl-groups, thus better matching glycolytic and TCA cycle fluxes 
whilst at the same time improving the matching between the PDC and TCA cycle 
fluxes.  
 
It was originally hypothesised that the impact of increasing skeletal muscle carnitine 
might be greater during a second bout of exercise, when PDC flux would appear to 
decline. The reliance on non-mitochondrial ATP production during bout two was 
robustly reduced with training in both groups, although it remained substantially 
greater than during bout one. In the CON group, acetylcarnitine accumulation at 24 
weeks was similar across both bouts which, as discussed in Chapter 4, would 
suggest PDC flux still declined during the second bout. In contrast, bout two 
carnitine acetylation was significantly greater than bout one in the CARN group after 
24 weeks, which would be indicative of a better maintenance of PDC flux and was 
consistent with our hypothesis that increasing free carnitine availability at the onset 
of a second bout could avert the decline in PDC flux during repeated bouts. Unlike in 
bout one however, this apparent acceleration of acetyl-group delivery did not seem 
to translate into any further enhancement of oxidative ATP provision beyond 
training alone, as the decrement in non-mitochondrial ATP production at 24 weeks 
was equal between groups. The potency of the training response in both groups is 
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underlined by the observation that bout two non-mitochondrial ATP production at 24 
weeks was very similar to that measured during bout one at baseline. Nevertheless, 
the finding that oxidative ATP production still declines in a second bout of exercise 
in the face of an enhanced PDC flux would perhaps suggest that acetyl-group 
delivery is limiting to oxidative ATP production during a first, but not a second bout 
of high-intensity exercise.  
 
Impact on whole-body adaptations 
The mean increase in VO2max at 24 weeks was 0.36 and 0.24 L·min
-1 
for the CON 
and CARN groups, respectively, whilst the change in Wmax was 26 and 30 watts, 
respectively, which represented a 15 and 20% increase from baseline. However, 
neither the relative nor absolute improvements in VO2max or Wmax appeared to be 
influenced by CARN treatment.  It was originally hypothesised that, consistent with 
the findings from Wall et al. (2011), CARN would enable a greater amount of work 
to be completed during training sessions and thus potentially augment the training 
stimulus to increase VO2max and Wmax. In this respect, given that no effect of CARN 
treatment was apparent on metabolism during the second bout of exercise, or work 
output during training sessions, it is perhaps unsurprising that no differences 
between groups were observed in the gains in VO2max or Wmax, particularly as 
skeletal muscle carnitine loading per se would not appear to influence VO2max (Wall 
et al., 2011). Interestingly however, a significant interaction effect was observed for 
mechanical efficiency, suggesting that the relative oxygen cost of work at Wmax was 
reduced over time in CARN, but not CON. Data from another study recently 
completed in our lab demonstrate that this same L-carnitine and carbohydrate 
feeding protocol, in the absence of exercise training, does not appear to impact upon 
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mechanical efficiency during exercise at Wmax (see Appendix 3.5). This would 
suggest that the increase in mechanical efficiency at Wmax observed in the current 
study is a result of manipulating free carnitine availability during training, rather 
than an acute effect of skeletal muscle carnitine loading per se. Moreover, given that 
the exercise training was performed at the same workload as that for which 
mechanical efficiency was determined, albeit under different exercise conditions 
(repeated bout vs continuous incremental protocol), it is quite possible that this effect 
would have been similarly manifest during training sessions. Taken together with the 
findings reported above, it therefore seems highly likely that daily L-carnitine and 
carbohydrate feeding would have altered metabolic flux during the training sessions, 
which raises the question as to why no apparent impact was observed upon work 
output and the associated markers of exercise performance.  
 
As we did not investigate skeletal muscle metabolism during exercise after 12 weeks 
of the intervention, it is impossible to ascertain over what time period the differential 
effects discussed above were occurring. However, given that skeletal muscle 
carnitine content was reduced after 12 weeks in CON, and differences in mechanical 
efficiency were already manifest at this point, it seems likely that at least some 
effects of L-carnitine feeding would have been present for the latter 12 weeks of the 
intervention. Given that no impact of CARN on non-oxidative ATP delivery was 
observed during the second exercise bout, it would also seem unlikely that any 
further impact would be manifest during subsequent exercise bouts, particularly as 
free carnitine concentrations were no different between groups following the second 
bout at 24 weeks. In this regard, it seems likely that the metabolic effect of 
manipulating free carnitine availability would not have been of sufficient magnitude 
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to influence work output during the fourth exercise bout in training sessions. Lastly, 
it should also be acknowledged that as work output remained equivalent between 
groups, the apparent enhancement of oxidative ATP production with CARN could 
possibly be expected to dampen the training stimulus, as reductions in both the 
myocellular oxygen tension and PCr/Cr ratio have been identified as metabolic 
events that may regulate various signalling processes leading to skeletal muscle 
adaptation in response to exercise (Egan & Zierath, 2013).  
 
Conclusions 
In conclusion, this study demonstrates that daily L-carnitine and carbohydrate 
feeding can be used to manipulate the skeletal muscle carnitine stores during a 
chronic period of intense exercise training, when total muscle carnitine content 
would otherwise seem to decline. However, the consequent elevation of muscle free 
carnitine availability during repeated-bout exercise training does not ultimately 
appear to influence the training-induced increase in oxidative ATP provision across 
repeated bouts of high-intensity cycling exercise, despite the potential preservation 
of PDC flux during a second bout of exercise. Finally, and likely as a result of this 
latter finding, neither work output, VO2max or body fat were differentially altered by 
carnitine treatment. Nevertheless, these data provide further evidence for the acetyl-
group buffering role of carnitine in the facilitation of PDC flux in human skeletal 
muscle and suggest that oxidative ATP production during single high-intensity 
exercise efforts can be enhanced with L-carnitine and carbohydrate feeding over a 
chronic period of submaximal HIT.  
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CHAPTER 6: GENERAL DISCUSSION 
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6.1 Overview of findings 
The overall aim of this thesis was to further investigate the role of carnitine during 
high-intensity submaximal exercise and to test the hypothesis that increasing skeletal 
muscle carnitine content in healthy human volunteers could augment the adaptations 
to a chronic period of submaximal high-intensity intermittent training (HIT). Initially 
this attempted to identify an L-carnitine feeding strategy that did not rely on the high 
carbohydrate load previously used by our group to increase carnitine content. 
Thereafter, it identified an exercise paradigm during which muscle carnitine 
availability might influence PDC flux and non-mitochondrial ATP production and 
that when implemented in a training program would potentially induce greater gains 
than classical endurance exercise training at an intensity where we also know 
carnitine availability to be limiting (e.g. 30 min at 80% VO2max; Wall et al., 2011). 
 
Through the novel application of a 
2
H3-carnitine tracer with a forearm carnitine 
balance model and parallel estimations of whole-body carnitine retention, a 
carbohydrate formulation was demonstrated to have greater potential for increasing 
muscle carnitine accretion compared to a whey protein-carbohydrate formulation, 
which appeared to antagonise the insulin-mediated stimulation of muscle carnitine 
uptake (Chapter 3). The potential inhibitory action of amino acids on muscle 
carnitine transport is a novel finding and may have important implications with 
respect to our understanding of the chronic regulation of skeletal muscle carnitine 
content.  
 
The acute exercise studies in Chapter 4 demonstrated that acetylcarnitine 
accumulation and the reliance on non-mitochondrial ATP production during 
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moderate and high-intensity single-leg knee extension is minimal compared to 
previously reported values during two-legged cycling, suggesting that PDC flux is 
probably not limiting to oxidative ATP production under these exercise conditions. 
Conversely, non-mitochondrial ATP production during repeated bouts of high-
intensity, fixed-workload cycling was found to increase in a second bout in the face 
of similar acetylcarnitine accumulation, suggesting that PDC flux declines during 
this second bout. This was in contrast to previous studies of maximal sprint efforts, 
or single-leg knee extension, where PDC flux is thought to increase with progressive 
bouts. 
  
Drawing on these initial findings, the final study of this thesis (Chapter 5) assessed 
whether increasing skeletal muscle carnitine content by daily L-carnitine and 
carbohydrate feeding could prevent this decline in PDC flux during repeated bouts of 
exercise and thus increase work output and concomitantly enhance the adaptations to 
a 24 week period of submaximal high-intensity interval training (HIT). L-carnitine 
supplementation was successful in manipulating skeletal muscle carnitine 
availability and appeared to preserve PDC flux across repeated bouts of exercise, but 
did not ultimately influence non-mitochondrial ATP production following 
submaximal HIT. In line with this latter observation, L-carnitine did not potentiate 
any of the functional adaptations induced by submaximal HIT alone. Collectively, 
these data further underline the importance of the acetyl-group buffering role of 
carnitine in skeletal muscle PDC flux during exercise and should aid the 
development of nutritional strategies to improve exercise performance in both 
athletic and clinical populations. 
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6.2 Implications for skeletal muscle carnitine accumulation  
Whey protein inhibits insulin-stimulated muscle carnitine transport 
As mentioned in the General Introduction and Chapter 3, the factors that regulate 
skeletal muscle carnitine content are poorly understood, but would appear to be 
highly dependent on the functionality of OCTN2 (Treem et al., 1988). Insulin is 
known to increase muscle carnitine transport by OCTN2 (Stephens et al., 2006b) and 
the finding in Chapter 3 that carbohydrate ingestion is able to promote a positive 
forearm carnitine balance is consistent with this. Moreover, these data provide the 
most direct estimate to date of insulin-stimulated muscle carnitine uptake in vivo and 
confirm the expected rates of muscle carnitine accumulation based on previous acute 
(Stephens et al., 2007b) and chronic (Stephens et al., 2013) feeding studies from this 
lab. A key question to arise from Chapter 3 is why a large oral bolus of whey 
protein might inhibit insulin-stimulated muscle carnitine transport, given that dietary 
L-carnitine is typically sourced from amino acid-rich foods (Mitchell, 1978). In view 
of the fact that plasma carnitine availability is unaltered by a standard mixed meal 
(containing approximately 350 µmols carnitine; Li et al., 1992), it is questionable as 
to whether carnitine transport into muscle would be appreciably different between 
basal and postprandial periods and indeed, plasma carnitine concentrations would 
appear to be far more tightly regulated than the reportedly slow turnover of the 
muscle carnitine stores (Rebouche & Engel, 1984). Nevertheless, following whey-
protein and carbohydrate co-ingestion, plasma carnitine availability and serum 
insulin concentrations were sufficiently elevated to levels that were able to promote 
muscle carnitine uptake following carbohydrate ingestion alone. Whether these 
findings infer a direct influence of amino acid availability on OCTN2 activity or an 
indirect effect mediated, for example, by sodium-amino acid co-transport requires 
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further investigation. One further possible mechanism could involve the inhibition of 
OCTN2 by acylcarnitines (Ohashi et al., 1999), as total plasma acylcarnitine 
concentrations during the PRO trial were raised throughout the period when serum 
insulin was elevated (see Appendix 3.1). The reason for the greater plasma 
acylcarnitines during PRO is unclear, although acylcarnitines are known to 
accumulate in response to excessive amino acid oxidation, either as direct by-
products of amino acid catabolism (e.g. propionylcarnitine, isovalerylcarnitine) or as 
a result of incomplete β-oxidation (Stephens et al., 2014). Cell-based studies to 
investigate the rate of intracellular carnitine accumulation in the presence of variable 
insulin, amino acid and acylcarnitine concentrations would be a useful approach to 
address this mechanism.  
 
Regulation of muscle carnitine content: Diet and exercise 
Another novel finding from this thesis relating to muscle carnitine transport was the 
observation that total muscle carnitine content declined over 12 weeks of 
submaximal HIT and daily carbohydrate feeding in the control group. Although it 
has previously been speculated that high-intensity exercise training could lead to a 
reduction in the muscle carnitine stores (Arenas et al., 1991 and Chapter 5), it 
cannot be excluded that the increase in daily carbohydrate load, rather than the 
submaximal HIT, was responsible for the decline in muscle total carnitine content. 
Interestingly, in two previous prolonged studies from our lab, total muscle carnitine 
content was 6-10% lower (though not statistically significant) following 12 weeks of 
daily carbohydrate feeding in control subjects (Wall et al., 2011; Stephens et al., 
2013). As well, vegetarians, who will typically obtain a relatively large proportion of 
their energy intake from carbohydrates, have lower levels of muscle and plasma 
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carnitine compared to their non-vegetarian counterparts (Stephens et al., 2011). 
Whilst the latter is undoubtedly related to a habitually lower carnitine intake 
(Rebouche, 1992),  L-carnitine infusion studies from our lab have also suggested that 
the stimulatory effect of insulin on muscle carnitine accumulation and OCTN2 
expression is diminished or absent in vegetarian subjects (Stephens et al., 2011). 
Reciprocally a non-vegetarian diet, which is typically associated with an increased 
fat intake, could conceivably promote muscle carnitine accumulation given the 
emerging role of the PPAR nuclear receptors (of which fatty acids are ligands) in the 
regulation of OCTN2 expression and carnitine transport activity (Ringseis et al., 
2007; Maeda et al., 2008; Zhou et al., 2014a; Zhou et al., 2014b). Thus aside from 
the influence of habitual diet on plasma carnitine availability, macronutrient 
availability may also be involved in the chronic (i.e. transcriptional) regulation of 
muscle carnitine transport and accretion.  
 
With respect to the role of submaximal HIT in muscle carnitine content, studies in 
rats have indicated that OCTN2 may be translocated to the sarcolemma membrane in 
response to muscle contraction (Furuichi et al., 2012) and thus it has been speculated 
that regular muscle contraction could actually promote muscle carnitine accretion. 
However, human data does not support a role for exercise in acutely stimulating 
muscle carnitine uptake, with or without oral L-carnitine supplementation to increase 
plasma carnitine availability (Soop et al., 1988). On the contrary, it has been 
suggested that high-intensity exercise could acutely increase muscle carnitine efflux, 
potentially via acetylcarnitine export (Brass, 2004). However, the majority of studies 
that have determined muscle carnitine moieties before and after exercise have been 
unable to detect differences in total carnitine content, suggesting minimal net 
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loss/gain from the skeletal muscle compartment during exercise (Carlin et al., 1986; 
Harris et al., 1987; Constantin-Teodosiu et al., 1992; van Loon et al., 2001; Wall et 
al., 2011). Thus it would perhaps seem more likely that the decline in muscle total 
carnitine content in the control group of Chapter 5 is perhaps related to something 
other than the accumulative effect of repeated acute bouts of intense exercise on 
muscle carnitine efflux per se. Finally, this decline in muscle carnitine content with 
training and/or carbohydrate feeding could also explain why the observed increase in 
muscle carnitine content in the L-carnitine supplemented group was somewhat less 
than projections based on the results from Chapter 3 and on previous research 
(Stephens et al., 2007b; Wall et al., 2011). 
 
Skeletal muscle carnitine loading in clinical populations 
In Chapter 5, the previously reported increase in fat mass in response to 12 weeks 
carbohydrate feeding (Control group; Stephens et al., 2013) appeared to be offset by 
submaximal HIT, consistent with the observed effects of an increase in physical 
activity levels on body composition (Nordby et al., 2012). However, the 
development of an L-carnitine feeding approach that does not rely on such a large 
carbohydrate load (160 g per day) is still desirable if the emerging metabolic benefits 
of skeletal muscle carnitine loading in young, healthy volunteers are to be translated 
to other populations, such as overweight or obese, diabetic, or elderly individuals. 
Despite the finding that 40 g whey protein plus 40 g carbohydrate was unable to 
promote a positive forearm carnitine balance in Chapter 3, the potential for other 
reduced-carbohydrate formulations to increase muscle carnitine accretion cannot be 
disregarded. Indeed, our lab has recently demonstrated that daily L-carnitine feeding 
in a formulation containing 44 g carbohydrate, 14 g protein and 11 g fat was able to 
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increase muscle carnitine content over 24 weeks in older (65-75 years old) adults 
(Chee et al., 2014). Thus the use of a smaller protein load could be efficacious in 
lowering the carbohydrate requirement of carnitine supplementation without 
inhibiting insulin-mediated muscle carnitine transport. Further chronic studies are 
currently in progress in our lab which will address the efficacy of similar feeding 
strategies in overweight and diabetic subjects.  
 
6.3 Oxidative ATP provision declines during high-intensity repeated-bout 
cycling exercise 
An interesting and novel observation in Chapter 4 was the increase in PCr 
degradation during a second bout of cycling exercise at 100% Wmax, data that were 
reproduced and thus validated using the same exercise paradigm in Chapter 5. 
Combining the datasets from Chapter 4 with the baseline (pre-training) data from 
Chapter 5 emphasises this finding and clearly demonstrates that reliance on non-
mitochondrial ATP production is significantly greater, by approximately 70% across 
these 21 subjects, during the second bout of exercise (Figure 6.1). This was related 
to both a 121% increase in PCr degradation and a 54% greater lactate accumulation. 
Given that the mechanical work performed during each bout would have been 
identical, an increased reliance on non-mitochondrial routes of ATP production must 
indicate either a reduction in oxidative ATP production or a lower metabolic 
efficiency of muscle contraction, i.e. a greater ATP demand per unit work. The latter 
could feasibly result from a lowering of muscle pH at the onset of contraction 
through altered Ca
2+
-ATPase kinetics (Wolosker et al., 1997), as muscle lactate was 
greater prior to the start of the second bout (Table 6.1). Alternatively, it is possible 
that muscle temperature, which has been shown to influence whole-body oxygen 
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uptake during cycling exercise (Ferguson et al., 2001), was greater during the second 
exercise bout. However, the impact of either muscle pH or temperature on metabolic 
efficiency would appear to be relatively small during dynamic human skeletal 
muscle contraction (Bangsbo et al., 2001) and probably insufficient to explain the 
70% greater non-mitochondrial ATP production during bout two. Thus it seems 
likely that the increased reliance on PCr degradation and anaerobic glycolysis was a 
direct compensation for the inability to sustain oxidative ATP production in the 
second bout. This is in contrast to single-leg knee extension exercise, as it was 
shown in Chapter 4 that oxidative ATP provision is well matched to the total ATP 
demand during continuous exercise at 55% or 85% Wmax , whilst it has previously 
been shown that oxidative ATP provision is better matched to total ATP demand 
during a second exercise bout at 100% Wmax (Bangsbo et al., 2001). Our findings 
also differ from maximal two-legged cycling conditions, where a progressive decline 
in work output parallels the decline in non-mitochondrial ATP production during 
each bout (Putman et al., 1995). 
 
The progressively greater reliance on non-mitochondrial ATP production is 
consistent with exercise performance during this type of repeated bout paradigm, 
which we found elicited exhaustion in our untrained subjects within 3-4 bouts (9-12 
minutes). If, as previous studies have argued, oxidative ATP provision was indeed 
able to provide an increasingly higher proportion of total ATP production during 
each bout, then reliance on anaerobic glycolysis would reciprocally decrease with 
each bout and exercise performance would be expected to continue until muscle 
glycogen stores were depleted. 
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Figure 6.1 Skeletal muscle ATP production from non-mitochondrial sources, 
comprising ATP (black bars), PCr (white bars) and lactate (dotted bars) during two 3 
minute bouts of cycling exercise at 100% Wmax, separated by 5 minutes of passive 
recovery. Data are mean ± SE for 21 subjects. ****P<0.0001 for PCr; $ P=0.07 for 
lactate; †† P<0.01 for total non-mitochondrial ATP, vs bout one.  
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Table 6.1 Skeletal muscle metabolite concentrations before and after two 3 minute bouts of cycling exercise at 100% Wmax separated by 5 
minutes of passive recovery. Data are presented as mean ± SE for 21 subjects in mmol·kg dw
-1
 except PDCa (nmol·mg protein
-1
·min
-1
). Values 
with different letters are significantly different (P<0.05) from each other following one-way ANOVA with bonferoni post-hoc comparison.   
 
Bout 1  Bout 2 
PRE POST  PRE POST 
ATP 25.8 ± 0.8
a 
23.6 ± 0.8
a 
 24.0 ± 1.0
a
 20.8 ± 0.9
b
 
PCr 76.4 ± 2.2
a
  53.1± 4.8
b 
 75.4 ± 2.6
a
 23.9 ± 3.2
c
 
Lactate   6.1 ± 0.8
a
 48.9 ± 9.6
b 
 26.9 ± 5.2
c 
92.9 ± 7.2
d 
Glycogen 399.3 ± 17.5
a 
337.8 ± 17.2
b 
 382.4 ± 21.2
a 
258.1 ± 19.2
c 
Free Carnitine 15.4 ± 0.6
a 
11.1 ± 0.8
b 
 12.5 ± 0.8
b 
  7.9 ± 0.8
c 
Acetylcarnitine   3.1 ± 0.6
a 
  7.2 ± 1.0
b 
   6.1 ± 1.1
b 
10.4 ± 0.6
c 
PDCa   3.7 ± 0.5
a 
   6.5 ± 1.5
ab 
   3.9 ± 0.8
a 
10.6 ± 1.4
b 
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Indeed, it is generally accepted that muscle glycogen availability is unlikely to 
become limiting to exercise performance during continuous exercise at such 
intensities (see General Introduction and Karlsson and Saltin, 1970). However, 
with our exercise paradigm muscle glycogen utilisation increased by 2-fold in the 
second exercise bout (Table 6.1) to a rate of over 40 mmol·kg dw
-1
·min
-1
, which 
could quite conceivably elicit fatigue within a further two bouts. Such a marked 
increase in glycogenolysis would perhaps suggest an increased recruitment of type II 
muscle fibres in this second exercise bout (Greenhaff et al., 1991; Soderlund et al., 
1992) and would appear to be in contrast with the progressive reduction in muscle 
glycogen utilisation during continuous exercise performance (Karlsson & Saltin, 
1970) or maximal sprint performance (Spriet et al., 1989).  
 
Based on the arguments discussed above and the combined data set from Chapter 4 
and Chapter 5, which clearly demonstrate that non-mitochondrial ATP production 
and glycolytic flux are greater during a second bout of exercise in the face of similar 
acetylcarnitine accumulation, it seems reasonable to conclude that despite a greater 
activation of PDC, oxidative ATP production and thus PDC flux were lower during a 
second exercise bout. In other words, the ratio of acetylcarnitine accumulation to 
glycolytic flux may be considered an informative index of PDC flux in human 
skeletal muscle during high-intensity exercise. Reasons for the discrepancy in these 
findings with those of different exercise models were discussed in Chapter 4, 
though it remains unclear as to what mechanisms are restricting oxidative ATP 
provision during a second bout of high-intensity cycling exercise. Whole body 
oxygen consumption during this type of exercise paradigm would not appear to 
decline during a second bout (see Appendix 3.6) and thus would seem unlikely to be 
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limiting to TCA cycle flux, although this may not necessarily reflect the oxygen 
uptake of the working muscle mass. In Chapter 4 it was postulated that this 
suppression of oxidative ATP production could be related to an inhibition of PDC 
flux, secondary to a reduction in free carnitine availability. Chapter 5 subsequently 
tested the hypothesis that increasing muscle carnitine availability could abate this 
decline in oxidative ATP production, the implications of which will be discussed 
below.  
 
6.4 Adaptations to chronic submaximal HIT and carnitine supplementation 
Submaximal HIT improves matching between glycolytic, PDC and TCA cycle fluxes 
Given the current popularity of the HIT exercise paradigm to increase fitness and 
health in various sedentary populations (Gillen & Gibala, 2013), our submaximal 
HIT intervention was a pertinent and timely approach to investigate carnitine 
metabolism during exercise training.  A particularly novel aspect of our study is its 
24 week duration, as most previous HIT studies have only investigated relatively 
short-term responses (Sloth et al., 2013). Prior studies have demonstrated the ability 
of 2-6 weeks HIT to reduce glycogen utilisation and lactate accumulation with a 
concomitant increase in lipid oxidation during constant load exercise at intensities of 
60 - 90% VO2max (Burgomaster et al., 2006; Burgomaster et al., 2008). Markers of 
oxidative capacity in resting skeletal muscle also reportedly increase in response to 
short-term submaximal HIT (Gibala et al., 2006; Little et al., 2010; Cochran et al., 
2014). However, this is the first study to demonstrate the profound impact of long-
term submaximal HIT upon oxidative ATP production during this type of exercise 
protocol, where the demand for mitochondrial ATP production is stressed near-
maximally. Data from a combined group of 18 subjects to have completed our 
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training intervention demonstrate the marked effect of submaximal HIT on skeletal 
muscle metabolism during two bouts of exercise at 100% Wmax, resulting in 
reductions in non-mitochondrial ATP production of 61 and 52% during the first and 
second bout, respectively (Figure 6.2). Moreover, and consistent with prior reports 
on short-term HIT (Burgomaster et al., 2006), resting muscle glycogen content was 
increased approximately 50% after 24 weeks of submaximal HIT in these 18 
volunteers, whilst net muscle glycogen utilisation throughout both exercise bouts 
was reduced by approximately 40%. In line with the discussion above (see section 
6.3), these training-induced alterations in skeletal muscle substrate availability and 
utilisation are reflective of a better matching between glycolytic and mitochondrial 
fluxes and more than likely facilitated the ~30% increase in work output at 100% 
Wmax. We also noted an ~10% improvement in VO2max, which is in agreement with 
the range (4-13.5%) reported in a recent meta-analysis on the adaptations to HIT 
intervention (Sloth et al., 2013). All together it seems probable that these adaptations 
are indicative of an increased capacity for oxidative ATP production in skeletal 
muscle, particularly given the strong correlation between training-induced 
improvements in whole-body VO2max and skeletal muscle citrate synthase activity 
(Vigelso et al., 2014), a reliable marker of mitochondrial content (Larsen et al., 
2012). Interestingly, most of the measured improvements in Wmax, VO2max and 
exercise performance occurred during the first 8-12 weeks of our intervention and 
therefore it would be also salient to address whether this apparent plateau in 
functional adaptation is related to a “ceiling” in the metabolic adaptations observed 
after 24 weeks of training. Indeed, given that most prior HIT studies have been of a  
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Figure 6.2 Skeletal muscle ATP production from non-mitochondrial sources, 
comprising ATP (black bars), PCr (white bars) and lactate (dotted bars) during two 3 
minute bouts of cycling exercise at 100% Wmax, separated by 5 minutes of passive 
recovery before and after 24 weeks of submaximal HIT. Data are mean ± SE for 18 
subjects. *P<0.05 for ATP; †† P<0.01, †† †P<0.001 for PCr; ‡ P<0.05, ‡‡‡‡ 
P<0.0001 for lactate; $$ P<0.01, $$$$ P<0.0001 for total non-mitochondrial ATP vs 
0 weeks. 
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shorter duration, these findings now question whether continued meaningful 
improvements in exercise capacity are possible with a HIT model, beyond an 8-12 
week period.  Ongoing work will investigate the genomic adaptations that occurred 
in resting muscle biopsy samples over 12 and 24 weeks of intervention. 
 
Manipulating muscle carnitine availability during submaximal HIT 
Despite a robust training-induced reduction in non-mitochondrial ATP production 
across both bouts of our exercise protocol (discussed above), an apparent decline in 
PDC flux during the second exercise bout still persisted following 24 weeks of 
submaximal HIT (see Figure 6.2). Drawing on the findings from Chapter 4 it was 
rationalised that increasing free carnitine availability could maintain PDC flux 
during this second bout of exercise and thus improve work capacity during 
submaximal HIT, leading to greater functional adaptations. Consistent with this 
hypothesis, manipulation of the skeletal muscle carnitine pool with L-carnitine and 
carbohydrate feeding resulted in an increased free carnitine availability during both 
bouts of cycling exercise at 100% Wmax and appeared to preserve PDC flux during 
the second bout. Thus a novel finding to arise from this study was that, despite the 
aforementioned carnitine-mediated preservation of PDC flux, the training-induced 
reduction in PCr utilisation and lactate accumulation – and thus non-mitochondrial 
ATP production - was no different between groups across either exercise bout.  
 
Given the impressive improvement in oxidative ATP delivery in response to 
submaximal HIT discussed above, it is possible that the training-induced 
improvement in the balance of glycolytic, PDC and mitochondrial fluxes during the 
second bout was greater than that which could be expected from manipulating free 
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carnitine availability. Indeed, this tighter matching of metabolic fluxes could lessen 
the dependence on free carnitine availability as demonstrated by the training-induced 
blunting of bout two acetylcarnitine accumulation in the Control group (see Table 
5.1). In this respect, muscle carnitine loading should not be discounted as a potential 
strategy to enhance the efficacy of exercise prescription in patients suffering from 
impairments in oxidative ATP delivery (e.g. peripheral vascular disease), as reliance 
on non-mitochondrial ATP production in these individuals is likely to be even more 
exaggerated (Hands et al., 1986; Bauer et al., 1999).  
 
The reciprocal relationship between carnitine-mediated PDC flux and non-
mitochondrial ATP production demonstrated by Wall et al. (2011) implied that PDC 
flux was limiting TCA cycle flux and oxidative ATP delivery during continuous 
exercise at 80% VO2max. In contrast, here we demonstrate that increasing PDC flux 
in a second bout of high-intensity exercise is not able to reduce the reliance on non-
mitochondrial ATP production. If it is assumed that acetylcarnitine accumulation is 
in equilibrium with acetyl-CoA production (Constantin-Teodosiu et al., 1993), this 
could imply that under these conditions, oxidative ATP production is restricted by 
factors other than acetyl-group delivery, possibly by sites distal to the TCA cycle. 
For example a limitation at the level of the electron transport chain would restrict 
NAD
+
 production, an important cofactor for several enzymes of the TCA cycle, 
which is consistent with the high redox potential that would have been needed to 
drive the greater rate of lactate production during the second exercise bout. 
Moreover, oxygen uptake by the working muscle mass is known to be compromised 
during high-intensity two-legged cycling (Boushel & Saltin, 2013), secondary to the 
high demand on cardiac output and blood flow distribution (Calbet et al., 2007), in 
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addition perhaps, to a sympathetic vasoconstriction-mediated decline in muscle peak 
perfusion (Savard et al., 1989). Whether these limitations are more marked and 
could restrict oxygen supply to the electron transport chain during a second bout of 
exercise is a fascinating supposition but requires further examination. Alternatively, 
if submaximal HIT is considered as a chronic stimulus to improve the matching of 
glycolytic and mitochondrial fluxes and thus lower the requirement for carnitine 
availability, it might be speculated that increasing free carnitine availability under 
these conditions could alter the equilibrium of the CAT reaction. Thus further studies 
attempting to manipulate the skeletal muscle carnitine pool should also determine 
skeletal muscle acetyl-CoA and CoASH content. Finally, as previously discussed it 
is difficult to delineate the independent effects of skeletal muscle carnitine 
availability and submaximal HIT from the chronic interaction of the two. Therefore, 
the impact of skeletal muscle carnitine loading on the acute responses to repeated 
bout exercise in untrained volunteers warrants future investigation.  
 
6.5 Concluding remarks 
Over the past two decades, the skeletal muscle carnitine pool has received attention 
as a dynamic, manipulable component of human skeletal muscle metabolism, being 
one of the most important buffers of the integration of fat and carbohydrate 
metabolism, and glycolytic and oxidative ATP production. Recent advances have 
demonstrated the efficacy of increasing muscle carnitine availability and its utility in 
elucidating the determinants of exercise performance and metabolism, the 
implications of which are under current investigation in our lab with respect to 
ageing, weight loss and type II diabetes. Novel data from the studies in this thesis 
provide valuable information relating to skeletal muscle carnitine transport that can 
  
200 
 
assist in the development of more efficacious strategies to accelerate muscle 
carnitine accumulation and in these investigations. Moreover, these data further 
advance our knowledge of the interplay between carnitine metabolism, PDC flux and 
non-mitochondrial ATP production during high-intensity exercise and challenge the 
current understanding of oxidative ATP delivery during high-intensity repeated bout 
exercise.  
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Appendix 1.1 Example of a healthy volunteers consent form 
Metabolic Physiology Group, 
School of Life Sciences, 
University of Nottingham Medical School, 
Queen’s Medical Centre Nottingham 
 
Title of Project: Effects of six months of L-carnitine and carbohydrate 
feeding on the adaptations to high-intensity exercise training 
 
Name of Investigators: Chris Shannon, Dr Francis Stephens, Professor Paul 
Greenhaff 
Healthy Volunteer’s Consent Form 
 
Please read this form and sign it once the above named or their designated 
representative, has explained fully the aims and procedures of the study to you 
 I voluntarily agree to take part in this study. 
 I confirm that I have been given a full explanation by the above named and that 
I have read and understand the information sheet given to me which is 
attached. 
 I have been given the opportunity to ask questions and discuss the study with 
one of the above investigators or their deputies on all aspects of the study and 
have understood the advice and information given as a result. 
 I agree to the above investigators contacting my general practitioner [and 
teaching or university authority if appropriate] to make known my participation 
in the study where relevant. 
 I agree to comply with the reasonable instructions of the supervising 
investigator and will notify him immediately of any unexpected unusual 
symptoms or deterioration of health. 
 I authorise the investigators to disclose the results of my participation in the 
study but not my name. 
 I understand that information about me recorded during the study will be kept in 
a secure database.  If data is transferred to others it will be made anonymous.  
Data will be kept for 7 years after the results of this study have been published. 
 I authorise the investigators to disclose to me any abnormal test results. (delete 
this if not applicable) 
 I understand that I can ask for further instructions or explanations at any time. 
 I understand that I am free to withdraw from the study at any time, without 
having to give a reason for withdrawing. 
 I confirm that I have disclosed relevant medical information before the study. 
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 I shall receive an inconvenience allowance of £X per study visit (involving 
biopsies), plus an additional £X upon completion of the study. If I withdraw from 
the study for medical reasons not associated with the study a payment will be 
made to me proportional to the length of the period of participation. If I 
withdraw for any other reason or fail to complete any part of the study, the 
payment to be made, if any, shall be at the discretion of the supervising 
investigator.  
 I have not been a subject in any other research study in the last three months 
which involved: taking a drug;  being paid a disturbance allowance; having an 
invasive procedure (eg venepuncture >50ml, endoscopy) or exposure to ionising 
radiation. 
 I understand that I should not take part in any other research study during my 
participation in this study, or within three months of completing this study. 
 
Name: ………………………………………………………………………………………… 
 
Address:   …………………………………………………………………………………….. 
 
Telephone number:  …………………………………………………………………………. 
 
Signature:  ………………………………………….   Date:  ………………………………. 
 
I confirm that I have fully explained the purpose of the study and what is 
involved to: 
…………………………………………………………………………………………………. 
I have given the above named a copy of this form together with the information 
sheet. 
 
Investigators Signature:  ………………………..        Name: ……………………………… 
 
Study Volunteer Number:   ………………………………………………………………….. 
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Appendix 1.2 Example of a healthy volunteer’s health questionnaire 
 
 
Metabolic Physiology Group, 
School of Life Sciences, 
University of Nottingham Medical School, 
Queen’s Medical Centre Nottingham 
 
Title of Project: Effects of six months of L-carnitine and carbohydrate 
feeding on the adaptations to high-intensity exercise training 
 
Name of Investigators: Chris Shannon, Dr Francis Stephens, Professor Paul 
Greenhaff 
Healthy Volunteer’s Questionnaire 
 
Please remember, all information will be treated in the strictest of confidence. 
 
 
NAME_________________________ 
 
 
DATE OF 
BIRTH_________________________ 
 
 
ADDRESS_____________________ 
 
______________________________ 
 
______________________________ 
 
______________________________ 
 
 
PHONE NO____________________ 
 
 
EMAIL________________________ 
 
______________________________ 
 
HEIGHT_______________________ 
 
 
 
WEIGHT_______________________ 
 
 
 
BMI___________________________ 
 
 
 
HR LYING_____________________ 
 
 
 
HR STANDING_________________ 
 
 
BP LYING_____________________
 
 
 
BP STANDING_________________
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Are you a smoker?        YES / NO 
 
 
Are you taking ANY medication?      YES / NO
  
If yes, please give details: 
 
 
 
Do you or have you ever suffered from any of the following? 
 
 Cardiovascular Disease       YES / NO
 Metabolic Diseases e.g. Diabetes     YES / NO
 Epilepsy        YES / NO
 Nervous Disorder       YES / NO 
 Any other CHORNIC medical condition     YES / NO 
  
 If yes to any of the above, please give details: 
 
 
 
Have you ever fainted? E.g. on standing, in warm room, following fasting YES / NO 
 
 
Roughly, how many units of alcohol do you consume per week? _______________units 
 
 
Roughly, how many cups of coffee, tea, or cola do you drink a day? ____________units 
 
 
Are you, or have you ever been a Vegetarian or Vegan?   YES / NO 
 
 If yes, please give details: 
 
 
If you are not a Vegetarian or Vegan, how often do you eat meat or fish?__times/week 
 
 Do you eat red meat? E.g. beef, lamb etc.    YES / NO 
 
 If yes, how often?       ____times/week 
 
 
Have you ever taken any sports nutritional supplements?    YES / NO 
E.g. creatine, amino acids 
 If yes, please give details: 
 
 
How would you assess your present fitness level?        POOR / AVERAGE / HIGH 
 
 
How regularly do you take part in physical activity? Please state the type of activity and 
how often. 
 
_______________________________________________________________________ 
 
Have you taken part, or intend to take part in any other trial within three months  
 
prior to and following this particular study? E.g. other studies, blood donor  YES / NO 
 
 
 If yes, please give details e.g. dates: 
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Appendix 1.3 Healthy volunteer’s DEXA suitability questionnaire 
DEXA Questionnaire 
Please complete the following questions to the best of your ability. If you 
have any questions, please ask the DEXA operator for assistance. 
 Have you had any investigations involving x-rays within the last week? YES/NO 
o If ‘YES’, please give details………………………………………………………. 
…………………………………………………………………………………………… 
 Have you had any investigations involving x-rays within the last month? YES/NO 
o If ‘YES’, please give details………………………………………………………. 
…………………………………………………………………………………………… 
 Have you had any investigations involving x-rays within the last year? YES/NO 
o If ‘YES’, please give details………………………………………………………. 
…………………………………………………………………………………………… 
 Do you have any of the following medical devices in your body? Please tick any 
which apply & describe the device in the adjacent space provided. 
o Ostomy devices (e.g. colostomy bag)………………………………………… 
o Prosthetic devices (e.g. hip or knee replacement)………………………….. 
o Surgical devices (e.g. metal clips, pins, plates)…………………………….. 
o Pacemaker or pacemaker leads……………………………………………… 
o Radioactive implants (i.e. for treatment of cancer)…………………………. 
o Catheters or tubes……………………………………………………………… 
 Are you exposed to ionising radiation as part of your job?  YES/NO 
  
221 
 
 Do your clothes contain any metal such as buttons, zips or clips?  YES/NO 
Any clothes containing metal will need to be removed before you have the 
DEXA scan. Tops and trousers are available to change into, and lockers 
are provided. 
 Are you wearing any jewellery?       YES/NO
           
Any jewellery, including watches and piercings will need to be removed 
before you have the DEXA scan. If you are unable to remove any items, 
please inform the DEXA operator. 
 Do you have any foreign objects in your body? e.g. shrapnel, buckshot YES/NO 
I certify that the information given above is, to the best of my 
knowledge, true and correct. 
Name: ……………………………………………………… 
Signed: ……………………………………………………..  Date: 
……./……../……… 
Witnessed: 
Name: ……………………………………………………… 
Signed: ……………………………………………………  Date: ……./……../…… 
  
  
222 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 2: ANALYTICAL BUFFERS 
  
223 
 
Appendix 2.1 Preparation of [
14
C]-oxaloacetate 
Assays of acetylcarnitine and acetyl-CoA (for PDCa) required the fresh synthesis of 
[
14
C]-oxaloacetate by the transamination of [
14
C]-aspartic acid (40 µM) with α-
ketogluturate (30 mM) in a 0.5 M HEPES buffer (pH 7.4) containing 11 mM EDTA 
(Cooper et al., 1986).  
 
[ C14 ]-aspartate +α-ketogluturate  
𝐺𝑂𝑇
→  [ C14 ]-oxaloacetate +glutamate 
 
The reaction was initiated by the addition of glutamate-oxaloacetate transaminase 
and allowed to proceed for 10 minutes at room temperature. The transamination was 
terminated with 1M PCA, neutralised with 0.6 M KOH and diluted 2.5 times in 
EDTA (11 mM). This solution was prepared immediately before the citrate synthase 
condensation reaction step of the acetyl-CoA assay (as General Methods). 
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Appendix 2.2 Homogenisation buffer for PDCa extraction 
 
Reagent Concentration (mM) 
Sucrose 200 
Potassium chloride 50 
Magnesium chloride hexohydrate 5 
EGTA 5 
Tris 50 
Sodium fluoride 50 
Dichloroacetate 5 
Triton X-100 0.1% 
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Appendix 3.1 Plasma acylcarnitine concentrations following ingestion of 3 g L-
carnitine (t=0) and 1 x 500 ml drink (arrow) of either CON (squares), CHO (circles) 
or PRO (triangles). Values are mean ± SE for n= 7. * P<0.05 for CHO vs CON; †† 
P<0.01, ††† P<0.001 for PRO vs CON; ‡‡ P<0.01 for CHO vs PRO. Supplementary 
data from Chapter 3; Study 1B. 
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Appendix 3.2 Leg thigh fat oxidation during 30 minutes of single-leg knee extension 
exercise at 55 and 85% Wmax. Supplementary data from Chapter 4; Study 2A. 
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Appendix 3.3 Muscle PCr degradation, corrected for work output, during two 3 
minute bouts of exercise at 100% Wmax, before and after 24 weeks of exercise 
training receiving twice daily drinks of either 80 g carbohydrate (CON; black bars) 
or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN; white bars). Values are 
mean ± SE for 7 subjects. 2-way ANOVA (time x group): *P<0.05 vs 0 weeks. 
Supplementary data from Chapter 5; Study 3. 
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Appendix 3.4 Muscle lactate accumulation, corrected for work output, during two 3 
minute bouts of exercise at 100% Wmax, before and after 24 weeks of exercise 
training receiving twice daily drinks of either 80 g carbohydrate (CON; black bars) 
or 80 g carbohydrate plus 1.5 g L-carnitine tartrate (CARN; white bars). Values are 
mean ± SE for 7 subjects. 2-way ANOVA (time x group): *P<0.05 vs 0 weeks. 
Supplementary data from Chapter 5; Study 3. 
 
  
230 
 
 
Appendix 3.5 Cycling efficiency at Wmax, determined as the percentage of VO2 
accounted for by mechanical work (see General Methods), at baseline and 24 weeks 
of twice-daily  80 g carbohydrate (CON; black bars) or 80 g carbohydrate plus 1.5 g 
L-carnitine tartrate (CARN; white bars) supplementation. Values are mean ± SE for 
7 subjects. Supplementary data from Chapter 5; Study 3. 
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Appendix 3.6 Whole body oxygen uptake during two 3 minute exercise bouts at 
100% Wmax separated by 5 minutes of passive recovery and preceded by a 3 minute 
warm-up period at 25% Wmax. Boxes indicate timings of exercise periods. Data are 
minute-averaged values from a single trial. Supplementary data from Chapter 5; 
Study 3. 
 
 
 
